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Abstract 
Clostridium difficile infection (CDI) currently affects around 20,000 people 
each year, in healthcare institutions and in the community, and will often 
follow disruption of the gut microbiome. Current treatment strategies call for 
the use of further antibiotics, of which there is a limited choice. There is a 
need for additional remedial and prophylactic solutions with greater specificity 
and low levels of toxicity and resistance.  
This thesis describes the pathogenesis of CDI, the current treatment 
strategies and navigates the growing body of studies investigating the 
potential use of phage. The project involved extensive screening including 
faecal samples and environmental sources in an attempt to identify novel 
phages of C. difficile and documents efforts to improve the therapeutic 
capacity of a selected phage, ФCD27, by mutagenesis. No exclusively lytic 
phages were isolated or obtained following mutagenesis with ethylmethane 
sulphonate, hydroxylamine or sodium pyrophosphate.  
Batch fermentation models of CDI showed that a prophylactic approach to 
phage therapy of CDI offers a higher efficacy than a remedial regime. A 
continuous model of CDI in a colon model was successfully produced and 
demonstrated variable efficacy rates from no apparent decrease in the burden 
of C. difficile to a reduction to below the limit of detection by culture, with no 
detrimental effect on commensal microbiota. The lysogenic capacity of 
ФCD27 appeared to prevent clearance of C. difficile in the models, but some 
strains containing the prophage exhibited reduced toxin production 
phenotypically. A possible mechanism of this altered phenotype included the 
action of ФCD27 repressor proteins on the promoter regions of C. diffiicle 
toxin genes or regulatory elements, but affinity of a candidate repressor, 
ORF44, to PaLoc constituents was not demonstrated.  
Studies have also demonstrated the ability of ФCD27 to prevent outgrowth of 
germinating C. difficile spores, thus potential as an environmental 
decontaminant.  
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The findings of the project and the future prospects of phage therapy as an 
agent against CDI are discussed. 
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Chapter 1 - Introduction 
1.1. Clostridium difficile infection 
Clostridium difficile is a Gram-positive spore-forming rod, ubiquitous in the 
environment but fastidious in nature, requiring strict anaerobic conditions for 
germination and growth. C. difficile was first described in 1935 as a 
component of neonatal faecal flora (Hall and O'Toole, 1935) and it was not 
until 1978 that two independent groups identified it as a causative agent of 
antibiotic-associated diarrhoea (AAD) (Bartlett et al., 1978; George et al., 
1978). C. difficile infection (CDI) has since been implicated as the most 
common cause of AAD (Rupnik et al., 2009), responsible for up to 30% of 
cases and accounting for 50-75% reports of antibiotic-associated colitis (Kelly 
et al., 1994).  
Despite an encouraging decline in the number of reports in England and 
Wales since 2007, 19,130 cases were reported in 2011, and 77% of these 
were in patients aged 65 years and over (Health Protection Agency 
surveillance data). C. difficile is predominantly transmitted via the faecal-oral 
route and it is estimated that 7-10% of adults are colonised without suffering 
from symptoms (Ryan et al., 2010), but this incidence may be higher in 
hospitals and care institutions where exposure to C. difficile is more likely. 
Colonisation may also result from the ingestion of animal meat (Rodriguez-
Palacios et al., 2007) or contact with new-born mammals, including humans, 
as their gastrointestinal (GI) tract seems to serve as an important reservoir for 
C. difficile without causing symptomatic disease (Mandell et al., 2010, 
Rodriguez-Palacios et al., 2006; Rolfe and Iaconis, 1983).  
There are few data detailing the financial burden of CDI in the UK but 
estimates suggest that it may run into billions of pounds each year (Dubberke 
and Olsen, 2012; Dubberke et al., 2007; Kyne et al., 2002; O'Brien et al., 
2007; Song et al., 2008) 
CDI normally follows a course of broad-spectrum antibiotic therapy due to the 
resulting collateral damage to the enteric microbiotia and the intrinsic 
antibiotic resistance profile typical of C. difficile (Starr et al., 2003). This is 
particularly a problem in patients over the age of 65, as the numbers of 
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protective commensal species including Bifidobacteria spp. generally 
decrease with age regardless of antibiotic treatment (Hopkins and 
MacFarlane, 2002). In this compromised environment, the germination of C. 
difficile spores is permitted and C. difficile binds to intestinal mucus and 
epithelial cells via a mixture of high and low molecular weight surface layer 
proteins (Calabi et al., 2002). During outgrowth, C. difficile produces two 
potent toxins – A and B, which give rise to colitis and pseudomembranous 
colitis (PMC), so called due to the formation and coalescence of neutrophilic, 
fibrinous, mucoid plaques throughout the colon (Mandell et al., 2010). Patients 
experience abdominal cramping and diarrhoea and also suffer a loss of 
intestinal barrier function that can lead to dehydration and malnutrition. In 
severe cases of CDI, patients can progress to toxic megacolon (TM), a 
condition characterised by non-obstructive, radiologically confirmed dilatation 
of the colon greater than 6 cm in diameter with fever, leucocytosis, 
tachycardia or anaemia, sometimes with dehydration and a compromised 
mental state (Jalan et al., 1969). 
Prevention and management of CDI in a hospital environment can be difficult 
with many patients taking broad-spectrum antibiotics and being cared for 
together in wards. With an aging population, CDI is set to become one of the 
biggest challenges of the 21st century. 
1.2. Pathogenesis of C. difficile 
The Pathogenicity Locus (PaLoc) of the C. difficile genome, depicted in Fig. 
1.1, contains genes required for the production and regulation of toxin A 
(tcdA) and toxin B (tcdB), which give rise to the virulent disposition of this 
organism (Voth and Ballard, 2005).  
 
 
Figure 1.1. The pathogenicity locus (PaLoc) of toxigenic C. difficile 
strains. Approximately 20 kb of DNA containing toxin and regulatory 
genes. 
tcdR tcdB tcdE tcdA tcdC 
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Toxin A is a 308 kDa single-chain protein that binds to glycan receptors at the 
apex of the human colonocyte (Stubbe et al., 2000) and is internalised by 
clathrin-mediated endocytosis (Papatheodorou et al., 2010). It is a potent 
enterotoxin that contains four functional domains. The transmembrane 
domain allows the toxin to be transported to the cytoplasm after endosome 
acidification via pore formation (Zeiser et al., 2011), at which point a cysteine 
protease cleaves the N-terminal glucosyltransferase domain (Egerer et al., 
2007). The glucosyltransferase is responsible for the glucosylation and 
subsequent inactivation of Rho, Rac, Cdc42, RhoG and TC10 – small GTP-
binding proteins of the Rho family (Genth et al., 2008). These proteins 
regulate the dynamics of the cellular actin and their dysfunction causes 
collapse of the cytoskeleton and disrupts the integrity of the tight junctions 
between the cells, allowing passage of the toxins through the epithelium 
(Rupnik et al., 2009). Eventually the cells round up and die due to the ability of 
the toxins to activate the pro-apoptotic protein RhoB (Genth et al., 2008). 
Macroscopic plaques comprised of neutrophils and fibrin may also be a 
feature (Gerding et al., 1995) (Fig. 1.2).  
Toxin B is also a glycosylating toxin, acting on the Rho proteins in the same 
manner as toxin A to cause cytotoxicity. It is smaller than toxin A at 270 kDa 
(Qamar et al., 2001) and binds at the basolateral surface of enterocytes 
(Stubbe et al., 2000). Although previously regarded as inferior to toxin A in 
terms of its capacity to induce disease (Lyerly et al., 1985) it is now accepted 
that toxin B is a potent instigator of disease in its own right. Affinity to cardiac 
tissue has been demonstrated (Hamm et al., 2006) and although extracolonic 
manifestations of CDI are rare, there have been cases of C. difficile 
bacteraemia (Lee et al., 2010, Libby and Bearman, 2009) one of whom 
presented with a pericardial effusion (Byl et al., 1996).  
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Figure 1.2. Pseudomembranous colitis showing neutrophilic fibrinous 
plaques. Image from CT evaluation of the colon: inflammatory disease 
(Horton et al., 2000). 
Past failures to demonstrate toxin B’s ability to cause significant intestinal 
damage might have been due to the absence of specific toxin receptors 
(Carter et al., 2010) inherent instability of the toxin (Reineke et al., 2007), 
impure preparations (Krivan and Wilkins, 1987, Sullivan et al., 1982) or self-
aggregative properties (Mandell et al., 2010).  
While the vast majority of toxigenic strains will express both toxin A and B, 
some strains possess just one of these genes. The role of either toxin as the 
dominant virulence factor has been the subject of much debate with both 
A+B- and A-B+ strains implicated as capable pathogens and similarly A+B- 
and A-B+ strains with no apparent virulence capacity (Drudy et al., 2007; 
Kuehne et al., 2010; Lyerly et al., 1985; Lyras et al., 2009; Mitchell et al., 
1986, 1987). In a study using mutated strains of C. difficile, one with toxin A 
production disabled and another with toxin B production disabled, it was 
shown that those producing only toxin B caused death in 16/20 hamsters, 
whereas just 4/20 animals died due to infection with a toxin B deficient strain 
(Carter et al., 2010). It has been proposed that the lack of either toxin 
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prevents an effective immune response to the pathogen (Drudy et al., 2007), 
resulting in increased disease severity.  
A third toxin, referred to as the binary toxin (or CDT) is encoded by three 
genes located at a different chromosomal locus – the CdtLoc. CDT can be 
found in strains that are also positive for toxins A and B (Perelle et al., 1997; 
Stubbs et al., 2000) including the hypervirulent NAP1/027 strain (McDonald et 
al., 2005) but it is estimated that approximately 2% of A-B- strains also 
produce the binary toxin (Geric et al., 2003). The specific binding capacity of 
the toxin is encoded by the cdtB domain, with the cdtA gene responsible for 
the enzymatic activity of the protein (Rupnik et al., 2009). In cell culture, the 
addition of CDT has been shown to result in adenine diphosphate (ADP) 
ribosylation of G-actin causing breakdown of the actin fibres and a loss of cell 
integrity, plus in an ileal loop model it was sufficient to induce fluid 
accumulation and haemorrhage (Geric et al., 2006). In a hamster model 
however, strains of A-B- C. difficile that produced CDT did not cause disease 
(Geric et al., 2006). Its role in CDI pathogenesis remains unclear but in a 
comparison of 30-day fatality rates, patients infected with strains of C. difficile 
that produced binary toxin were more likely to die than those infected with a 
strain that did not produce binary toxin (relative risk 1.8, 95% confidence 
interval 1.2-2.7) (Bacci et al., 2011). 
1.3. The immune response to CDI 
The immune response to C. difficile causes much of the intestinal damage 
characteristic of CDI (Savidge et al., 2003) as it has been shown that disease 
severity in animal models can be significantly lessened by manipulation of the 
immune attack (Anton et al., 2004; Cottrell et al., 2007; Kelly et al., 1994). 
Both toxins A and B have cytotoxic activity, mediated by their 
glucosyltransferase function (Zeiser et al., 2011) and cause massive 
recruitment of neutrophils (Kelly et al., 1994) due to the stimulation of 
inflammatory mediators from colonocytes, mast cells and phagocytes 
including Tumour Necrosis Factor  (TNF ), interleukin (IL) 1  (Jeffrey et al., 
2010) and IL-8 (He et al., 2002). Almost 100-fold increases in IL-8 production 
have been demonstrated following stimulation of human monocytes with just 1 
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nM toxin A, and this up-regulation is largely a result of enhanced IL-8 gene 
transcription (Jefferson et al., 1999). Expression of the pro-inflammatory 
cyclooxygenase-2 plus release of prostaglandin E2 and reactive oxygen 
species are triggered by toxin A (Kim et al., 2005). The NF- B and mitogen-
activated protein (MAP) kinase pathways are also stimulated (Chae et al., 
2006; Chen et al., 2006; Jefferson et al., 1999; Kim et al., 2005; Warny et al., 
2005). Toxin A has also been shown to activate and up-regulate protease-
activated receptor 2 (Cottrell et al., 2007) and corticotropin-releasing hormone 
as promoters of inflammation in ileal loop models. Long-term exposure to 
toxins A and B also leads to apoptosis and necrosis (Huelsenbeck et al., 
2007; Nottrott et al., 2007) and the ensuing leakage of cytoplasmic contents 
results in further enrolment of immune mediators (Genth et al., 2008). This 
inflammatory response is in stark contrast to the minimal reaction to other 
enteric toxins such as those produced by Escherichia coli (Erume et al., 
2012).  
It is well documented that the magnitude of the  immunoglobulin (Ig) A and G 
response to both toxin A and B can be used as a predictor for disease 
outcome, with a strong response lessening the chance of severe disease and 
recurrence (Kelly and Kyne, 2011; Kyne et al., 2001; Leav et al., 2010). 
However, it is important to note that this protective effect is not so evident in 
severely ill patients with multiple co-morbidities (Kelly and Kyne, 2011). 
Specific deficiencies in IgG2 and IgG3 subclasses have also been associated 
with an increased likelihood of CDI recurrence (Katchar et al., 2007). 
The antibody response to toxin antigens has been found to correlate with the 
levels of antibodies to non-toxin antigens, suggesting that a multi-faceted 
approach to immunomodulation may be required to achieve good protection 
(Kelly and Kyne, 2011). In response to C. difficile, antibodies are also 
generated against the surface layer proteins used by C. difficile to bind to 
mucus and intestinal epithelial cells (Calabi et al., 2002). The levels of IgG 
directed against these proteins were found to be similar in asymptomatic 
carriers, CDI patients and control patients, but it is thought that the extent of 
the IgM response (the first antibody class to be produced in response to an 
antigen) may affect the course of disease, a lesser response being associated 
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with a higher chance of recurrence (Drudy et al., 2004). Antibodies to flagellar 
proteins (such as FliC) and surface associated proteins (such as Cwp84) 
have also been detected in patients with CDI, but levels significantly decrease 
following resolution of symptoms (Pechine et al., 2005 b).  
1.4. Diagnosis of CDI 
Due to the fact that patients may be colonised with C. difficile without suffering 
any symptoms of disease, it is essential to consider the results of diagnostic 
tests in light of clinical information. The detection of both toxins A and B (and 
it is important that an assay capable of detecting both of these toxins is used) 
in patients’ stool is a good indicator of disease, but this is not suitable as a 
stand-alone test for CDI. Evidence of the presence of C. difficile should first 
be obtained through the use of an assay to detect glutamate dehydrogenase 
(GDH), which is present in both toxigenic and non-toxigenic C. difficile strains. 
Alternatively, a nucleic acid-based amplification method can be used – 
targeting either the toxin genes or a C. difficile housekeeping gene. Faecal 
lactoferrin, a neutrophil-derived protein, can also serve as a useful marker in 
assessing the extent of intestinal inflammation (Wren et al., 2009).  
In addition to laboratory testing, the identification of multiple plaques or 
pseudomembranes by endoscopy can offer or support a diagnosis when C. 
difficile is suspected (Fekety 1997). 
1.5. Additional risk factors for CDI 
Besides antimicrobial therapy, there are a myriad of documented and 
hypothesised factors thought to contribute to the development of CDI and in a 
recent study of community-acquired cases, approximately one third had not 
received antimicrobial therapy (or been hospitalised) in the 6 months prior to 
CDI development (Wilcox et al., 2008). Increased awareness, frequency of 
testing and surveillance reporting can help to elucidate unconfirmed and 
unknown predispositions to CDI. 
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1.5.1. Patient demographics  
Advanced age is a well-documented risk factor for CDI and recurrent CDI 
(Kim et al., 2010; Loo et al., 2011) and this is most commonly attributed to the 
changes in the gut microbiome including reductions in the numbers of 
Bifidobacteria spp. thought to offer colonisation resistance against C. difficile 
(Hopkins and MacFarlane, 2002). Elderly patients are also more likely to 
receive antimicrobial therapy and suffer the cumulative effects of previous 
courses plus an increased rate of hospitalisation and institutional admission is 
also to be expected, which raises the chance of C. difficile exposure. 
1.5.2. Colonisation with C. difficile NAP1/027 
The hypervirulent C. difficile NAP1/027 emerged in Canada, America and 
Europe in the late 1990s causing numerous outbreaks of severe CDI that 
responded less favourably to first-line treatment (Musher et al., 2005; Pepin et 
al., 2004; Warny et al., 2005). This strain has been shown to produce toxin for 
a longer period relative to other strains (23 days as opposed to 13 days) 
(Freeman et al., 2007), which may be due to an 18 base pair (bp) deletion in 
the tcdC gene responsible for down-regulation of toxin A production (Warny et 
al., 2005). Detection of C. diffiicle NAP1/027 has been shown to be an 
independent risk factor for the development of CDI due to the increased 
virulence of this strain (Loo et al., 2011). It has also been shown that 
colonisation with other strains (including non-toxigenic strains) may offer cross 
protection and enhance colonisation resistance against this pathogen (Loo et 
al., 2011) 
1.5.3. Use of Antacid Medications 
The use of antacid medication including proton pump inhibitors and histamine 
receptor antagonists has also been identified as an independent risk factor for 
the development of CDI (Loo et al., 2011). The reduced acidity of the stomach 
environment may weaken resistance against vegetative C. difficile cells and it 
has been shown that the survival rate of spores was enhanced at pH values 
approaching neutrality (Jump et al., 2007). C. difficile colonisation in the large 
and small intestine has also been shown to be more successful in vivo when 
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gastric acid production is suppressed (Jump et al., 2007; Lewis et al., 1996; 
Verdu et al., 1994; Wilson et al., 1985) 
Antacid treatments have been shown to reduce neutrophilic reactive oxygen 
production leading to decreased bacteriocidal action (Zedtwitz-Liebenstein et 
al., 2002), which may further weaken defence against C. difficile colonisation 
and infection.  
1.5.4. Feeding via a nasogastric (NG) tube 
In addition to an increased need for antimicrobial therapy and long-term 
institutional care, some critically ill patients require nutritional support in the 
form of elemental feeds via a nasogastric tube. These feeds are completely 
absorbed in the small intestine, divesting colonic bacterial populations of the 
starch, dietary fibre, oligosaccharides and other nutritional compounds 
needed to support their growth (O'Keefe, 2010). In this state, numbers of 
Bifidobacteria spp. and butyrate-producers in the lower GI tract are 
suppressed, giving rise to the overgrowth of C. difficile (May et al., 1994). This 
method of feeding also fails to stimulate the production of gastric secretions 
and gut motility, affecting turnover of the microbiota (Kaushik et al., 2005; 
O'Keefe, 2010). In addition, the invasive nature of NG tube insertion can serve 
as an efficient inoculation mechanism straight into the GI tract, plus elemental 
feeds have been used as a culture medium for C. difficile with great success 
(Iizuka et al., 2004). It has been demonstrated that by adding oligosaccharide 
supplements to the feeds, the numbers of intestinal Bifidobacteria spp. were 
boosted and the environment of the GI tracts of these patients were less 
permissive to the germination of C. difficile, causing clinical reduction in 
diarrhoea in NG fed patients with chronic relapsing CDI (Lewis et al., 2005).  
1.5.5. Other intestinal pathogens 
It can be hypothesised that GI disruption due to infection by other pathogens 
could increase the risk of C. difficile colonisation and germination. Salmonella 
spp. infection has been shown to cause changes in the proportions and 
numbers of commensal intestinal bacteria (Santos et al., 2009) and indeed 
CDI progressing to fatal PMC has been described following Salmonella 
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Saintpaul infection in a 20 year old female (Halvorson et al., 2011). 
Uncomplicated cases of colitis associated with co-infections of C. difficile and 
Salmonella spp. or Shigella spp. have also been reported (Grinblat et al., 
2004). 
Gastroenteritis is commonly of viral aetiology, with norovirus being most 
frequently implicated both in the community, in institutions and in hospitals. 
The virus can be transmitted easily from person to person due to the low 
infectious dose and hardy nature of the virus and it has been noted that 
increases in norovirus cases correlate positively with reports of CDI (Lopman 
et al., 2004; Siebenga et al., 2007). During a recent outbreak of norovirus, C. 
difficile toxins were demonstrated in the stool samples of 5/29 affected 
patients and a further 2/29 were C. difficile positive by culture alone (Koo et 
al., 2009). The age range of the patients was not mentioned in this study but 
is of importance here since similar outbreaks in geriatric wards, where 
patients’ microbiota may be more susceptible to colonisation and the 
development of fulminant CDI, may cause a higher proportion of patients to 
be affected.   
1.5.6. Smoking 
Cigarette smoking has also been proposed as a risk factor for CDI, with active 
smokers 75% more likely to develop it relative to people who have never 
smoked (Rogers et al., 2012). This is possibly due to the very act of smoking 
as a route of spore ingestion, since Clostridium spp. are common isolates 
from cigarette samples and it is likely that the spores survive the effect of the 
smoke (Eaton et al., 1995; Sapkota et al., 2010). It may be that this increased 
risk reflects significant differences in the gut microbiome of smokers due 
directly to the effects of tobacco, given that cigarette smoke has been shown 
to decrease the levels of Bifidobacteria spp. (and organic acids) in the cecum 
of rats (Tomoda et al., 2011). Other factors could include the different dietary 
tendencies and higher alcohol consumption reported in studies of smokers 
(Cade and Margetts, 1991) and the anticipated higher risk for hospitalisation 
and antimicrobial therapy. 
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1.6. The genome of C. difficile 
The adaptive and resilient nature of C. difficile strains is further evidenced by 
their genomes, which show a high degree of heterogeneity across all 
functional categories and a core genome of only 16% - predicted to be the 
lowest of any bacterial species known to date (Janvilisri et al., 2009; Scaria et 
al., 2010). Some additional conservation can be observed in strains infecting 
a particular host species, demonstrating their adaptation to survive in different 
environments (Janvilisri et al., 2009). When compared to other sequenced 
Clostridial genomes C. acetobutylicum, C. botulinum, C. perfringens and C. 
tetani, a homology of just 15% is observed, with up to 61% of the predicted 
coding sequences being exclusive to C. difficile (Sebaihia et al., 2006). 
Further details of the relatedness of some Clostridial species to C. difficile can 
be found in 4.2 
The continual evolution of C. diffcile can be seen by comparing sequence 
data from historical strains right up to the hypervirulent NAP1/027 strain and 
includes the acquisition of transcriptional regulators, restriction modification 
genes, a multi-antimicrobial extrusion family drug/sodium antiporter, genes 
permitting the utilisation of different carbohydrate sources and antibiotic 
resistance elements. Antimicrobial resistance patterns are a likely reflection of 
various antibiotic policies of hospitals across the world but now typically 
include tetracycline, erythromycin, bacitracin, beta-lactamase and 
fluoroquinolones, confirmed by antimicrobial assays (Sebaihia et al., 2006; 
Stabler et al., 2009). The hypervirulent strain NAP1/027 also has 14 genes 
that have been disrupted by an insertion and 10 frameshift mutations 
including one that results in a truncated version of tcdC – a negative regulator 
of toxin A production. Variability in the toxin B gene sequence is a feature of 
many strains, but in NAP1/027 it has been shown to correlate with increased 
cytotoxicity in cell cultures (Stabler et al., 2009). Variations in the flagella 
region also seem to confer greater motility – another important virulence 
factor since it allows easier traversal of the mucus layer on its way to gut 
epithelial cells. All of these features are compatible with the increased 
virulence and fatality rate associated with NAP1/027 strain types (Loo et al., 
2011). 
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C. difficile genomes commonly harbour prophages and prophage elements 
(Fortier and Moineau 2007; Goh et al., 2005, 2007; Govind et al., 2006; 
Horgan et al., 2010; Janvilisri et al., 2009; Mahony et al., 1985; Nagy and 
Foldes, 1991; Sebaihia et al., 2006; Sell et al., 1983; Stabler et al., 2009) and 
this may to some extent account for the inexorable uptake of new genetic 
elements driving the progressive nature of this pathogen.  
The importance of re-annotating genome sequences was recently illustrated 
for CD630 (NCTC 11307) (Monot et al., 2011). New database submissions 
over 5 years allowed the function of over 500 previously unclassified genes to 
be assigned, and using updated techniques, 127 new coding sequences were 
identified. This information is imperative to our understanding of C. difficile 
pathogenesis both to support previous findings and to discover new virulence 
mechanisms and potential therapeutic targets. 
1.7. Therapies used for the treatment of CDI 
1.7.1. Current antibiotics 
1.7.1.1. Metronidazole 
Patients presenting with uncomplicated C. difficile for the first time are treated 
with oral metronidazole – a nitroimidazole antibiotic with a high specificity for 
anaerobic bacteria and a range of parasites (Muller, 1983). Upon reduction of 
the nitrile group under anaerobic conditions, cytotoxic intermediate products 
are produced that interact directly with the bacterial DNA to inhibit synthesis 
and cause cell death. The usual dosage for an adult is 400 mg orally every 8 
h for 10-14 days, which has few side effects (Joint_Formulary_Committee, 
2012). Metronidazole treatment of C. difficile carriage in the absence of 
diarrhoea and/or abdominal symptoms is not effective (Johnson et al., 1992). 
Clinical improvement is normally observed within 2 or 3 days following 
treatment initiation, but the frequency of resistant strains, defined as those 
with a minimum inhibitory concentration (MIC) of >16 µg/mL, has increased in 
recent years. Some institutions have reported rates as high as 6.3% (Pelaez 
et al., 2008). The frequency of recurrences following metronidazole therapy 
(not associated with resistance) has also been reported to occur in 10-35% of 
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cases (Barbut et al., 2000; Do et al., 1998; McFarland et al., 2002) and these 
are normally seen within 8 weeks post treatment. 
1.7.1.2. Vancomycin 
Vancomycin is an effective agent in the treatment of CDI but its use is tightly 
restricted to prevent the development of resistance in enteric bacteria, 
particularly in Enterococcus spp. and Staphylococcus spp. (Sujatha and 
Praharaj, 2012). It is reserved for patients who have severe CDI or those who 
have suffered a relapsed or re-infection with C. difficile. 
Vancomycin is a glycopeptide antibiotic that acts primarily by disrupting 
bacterial cell wall synthesis through binding to the D-Ala-D-Ala terminus of the 
peptidoglycan precursors. This prevents the enzymatic cross-linking required 
to complete the cell wall formation (Watanakunakorn, 1984). Oral 
administration allows a greater concentration of the drug to reach the gut and 
the poor absorption efficiency means that the toxicity concerns can be 
minimised. Its spectrum of activity includes both aerobic and anaerobic Gram-
positive bacteria. 
Relapses of CDI are also common following vancomycin treatment (Louie et 
al., 2011) but proposed preventative strategies include tapering the treatment 
frequency after a course of 10-14 days to twice daily dosing, then once daily 
and a ‘pulse’ every other day after symptom resolution (Tedesco, 1982) or by 
giving another antimicrobial such as rifaximin immediately after the treatment 
course (Johnson et al., 2009). The aim here is to eliminate the spores that 
have survived the antimicrobial treatment and are germinating in the 
compromised enteric microbiome. 
Interestingly, genetic elements thought to impart resistance to vancomycin 
(58-77% similar to VanG-type resistance of Enterococci) have been 
demonstrated in C. difficile 630 (Sebaihia et al., 2006). Phenotypic resistance 
however, was not demonstrated by antimicrobial assay and it is not clear if 
these genes are not expressed or are not sufficient to impart resistance to the 
effects of the antibiotic. 
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1.7.1.3. Nitazoxanide 
Nitazoxanide is a synthetic thiazolide compound that interferes with electron 
transfer in anaerobic energy metabolism (Mandell et al., 2010). The few small 
studies that have compared the efficacy of nitazoxanide versus metronidazole 
or vancomycin have suggested a comparable cure rate (Musher et al., 2006 
a, 2006 b, 2009) and it has even achieved clinical responses in cases of initial 
treatment failure following metronidazole therapy (Musher et al., 2007). 
1.7.1.4. Rifaximin 
Rifaximin is a narrow-spectrum rifamycin drug that acts via steric inhibition of 
the beta subunit of the bacterial DNA-dependent ribonucleic acid (RNA) 
polymerase causing abortive transcription (Mandell et al., 2010). Mammalian 
polymerases are unaffected at the concentrations required to prevent 
bacterial DNA replication. Due to the mode of action, high level resistance to 
rifamycins can be achieved by single amino acid substitutions (O'Connor et 
al., 2008) and so it is always preferable to use these agents in combination 
with other drugs. Rifaximin is not active against all clinical strains of C. 
difficile, for example the hypervirulent strain NAP1/027 is resistant, but in 
sensitive isolates it has been shown to be as effective as vancomycin in an 
animal model (Kokkotou et al., 2008). Other studies have demonstrated a 
reduced rate of CDI recurrence when a 2 week course of rifaximin is 
administered after treatment with vancomycin (Johnson et al., 2007). 
1.7.1.5. Rifalazil 
Rifalazin is also a rifamycin known to have activity against a wide range of 
Gram-positive, Gram-negative organisms and Mycobacteria (Luna-Herrera et 
al., 1995). Good activity versus a range of C. difficile strains was recorded, 
plus the authors demonstrated superiority to vancomycin in a hamster model 
of CDI both in terms of symptom resolution and reduction of recurrence rates 
(Anton et al., 2004).  
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1.7.1.6. Tigecycline 
Tigecycline is a third generation tetracycline that reversibly inhibits protein 
synthesis by binding to the 30S ribosomal subunit (Mandell et al., 2010). Its 
use in the treatment of CDI is limited to a handful of cases refractory to 
metronidazole and vancomycin therapy, but has shown promise in these 
patients with 6 out of 6 patients reporting treatment success (Larson et al., 
2011). 
1.7.1.7. Bacitracin 
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis, which 
complexes with cell wall components to impede cell wall formation (Mandell et 
al., 2010). It is active against many Gram-positive bacteria and is often used 
as a topical application (Joint_Formulary_Committee, 2012). Early studies 
have suggested a clinical efficacy equal to that of vancomycin therapy, 
although a high number of patients continued to excrete C. difficile (Dudley et 
al., 1986). More recently, high level resistance has been demonstrated in C. 
difficile strains (Citron et al., 2003), including the NAP1/027 hypervirulent 
strain (Bourgault et al., 2006), thus bacitracin is of diminishing clinical use for 
the treatment of CDI. 
1.7.1.8. Fusidic acid 
Fusidic acid is produced by Fusidium coccineum, and blocks the elongation 
phase of protein synthesis in a select range of anaerobic and aerobic bacteria 
(Mandell et al., 2010). In a small double-blind, randomised controlled trial, 
fusidic acid was shown to be equally as effective as metronidazole in the 
treatment of CDI (Wullt and Odenholt, 2004), but the bacteriostatic nature of 
the drug means that high recurrence rates can be expected. 
1.7.1.9. Teicoplanin 
Derived from Actinoplanes teichomyceticus, teicoplanin is a mixture of 
glycopeptide analogues that inhibit cell wall synthesis in a similar manner to 
vancomycin (Mandell et al., 2010). It has a long half-life and is listed as an 
alternative treatment of CDI and PMC in the British National Formulary 
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(Joint_Formulary_Committee, 2012). In a study of 47 patients allocated to 
vancomycin or teicoplanin treatment, it was shown that those who received 
teicoplanin experienced resolution of symptoms and no recurrences, with all 
but one apparently clear of C. difficile colonisation (de Lalla et al., 1989). In 
the vancomycin group, 3 of 23 patients suffered a relapse and a further 
asymptomatic patient remained culture positive for C. difficile. Superiority to 
vancomycin has also been demonstrated in more recent studies (Wenisch et 
al., 1996) but in practice it is rarely used in hospitals in the UK.  
1.7.1.10. Oritavancin 
Oritavancin is a second generation lipoglycopeptide antibiotic that is very 
similar to vancomycin in terms of structure and mode of action (Laverty et al., 
2011). The side chains of this drug also bind to the bacterial cell membrane 
and induce profound changes in the membrane potential giving rise to 
increased permeability (Domenech et al., 2009). There are currently no 
clinical recommendations relating to the use of oritavancin in CDI, but high 
efficacy has been demonstrated in an in vitro human gut model study and 
superior activity was observed due to the increased activity against C. difficile 
spores (and hence reduced scope for recurrences) relative to vancomycin 
(Baines et al., 2008).  
1.7.1.11. Fidaxomycin 
Fidaxomicin has recently been approved for use by the FDA (Food and Drug 
Administration) and EMA (European Medicines Agency) as a treatment for 
CDI (Cornely, 2012). It is a novel macrocyclic antibiotic (previously referred to 
as OPT-80) and works by inhibition of bacterial RNA polymerases (Cruz, 
2012) via the active metabolite hydrolysed in the intestine. It is poorly 
absorbed and has a narrow spectrum of activity, making it ideal for use in 
CDI. The clinical efficacy is greater than that of vancomycin based on phase 
III clinical trials, with a greatly diminished rate of recurrence (p ≤ 0.005) (Louie 
et al., 2011) even despite concomitant antimicrobial use (Mullane et al., 
2011), but in patients suffering from CDI caused by the NAP1/027 strain, no 
improvement in the recurrence rate was observed. Synergistic action of 
fidaxomicin with rifaximin and rifampicin has also been reported (Ackermann 
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et al., 2004; Babakhani et al., 2004). The drug has been tolerated with no 
major safety concerns although 5.9% treated with fidaxomicin withdrew from 
the trial due to adverse events, primarily vomiting (Louie et al., 2011). The 
price of fidaxomicin is currently three times that of vancomycin but it 
represents a much needed addition to the repertoire of treatments against 
refractory CDI (Lancaster and Matthews 2012). 
No fidaxomicin resistance has yet been reported but C. difficile isolated from a 
treated patient who suffered a recurrence, gave an elevated MIC of 16 μg/mL 
(Goldstein et al., 2011).  
1.7.2. Novel antimicrobial agents currently in development 
1.7.2.1. RBx14255 
A novel ketolide, RBx14255, has recently been described and shown to have 
potent activity against C. difficile in vitro and in a hamster model of CDI 
(Kumar et al., 2012). Ketolides inhibit bacterial protein synthesis and ribosome 
assembly but show poor activity against Gram-negative anaerobes. The effect 
on the resident gut microbiota was not examined in this study but with MIC 
results for C. difficile spores comparable to those of metronidazole and 
vancomycin, the risk of CDI recurrence still persists. 
1.7.2.2. RBx11760 
RBx11760, a novel oxzolidinone and a potent inhibitor of bacterial protein 
synthesis was shown to exhibit bacteriocidal activity against C. difficile, 
significantly reduce toxin production and lessen sporulation relative to both 
metronidazole and vancomycin in a hamster model of CDI (Mathur et al., 
2011). 
1.7.2.3. CB-183,315 
This new lipopeptide antibiotic has also shown promise against clinical C. 
difficile strains in the hamster model and sustained cure rates highly 
comparable to those obtained following vancomycin treatment. It is currently 
in phase III clinical development (Mascio et al., 2012). The mode of action 
seems to be very similar to that of daptomycin, and causes depolarisation of 
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the cell membrane without increasing permeability (Mascio et al., 2012). It 
may be that this results in the efflux of cytoplasmic ions such as potassium, 
which ultimately leads to cell death.  
1.7.2.4. MBX-500 
MBX-500 is a hybrid antibiotic comprised of an anilinouracil DNA polymerase 
inhibitor fused with a fluoroquinolone DNA gyrase/topoisomerase inhibitor. 
This agent has shown good activity against C. difficile in a hamster model 
relative to vancomycin with relative sparing of many groups of anaerobic and 
aerobic commensals. Unfortunately, relapses were still observed in 30% of 
the animals (Butler et al., 2012). 
1.7.2.5. LFF571 
This agent is a semi-synthetic derivative of dicarboxylic acid with potent 
activity against C. difficile (LaMarche et al., 2012) brought about by inhibition 
of protein synthesis. In hamster model experiments, this agent has been 
shown to give rise to fewer CDI relapses post-treatment relative to 
vancomycin (Trzasko et al., 2012). Encouragingly, LFF571 has low activity 
against Bifidobacterium spp. and Lactobacillus spp. but the effect on other 
Gram-positive organisms is variable (Citron et al., 2012). 
1.7.2.6. Tauroursodeoxycholic acid (TUDCA) 
TUDCA is a hydrophilic bile acid and is used therapeutically to treat 
cholestasis (interruption in the production and excretion of bile) and biliary 
cirrhosis (inflammation of the liver characterised by obstruction of the bile 
duct) (Paumgartner and Beuers, 2002; Saksena and Tandon, 1997). A recent 
study found that bile acid signalling can affect the activity of Rho proteins. It 
was shown that phosphorylation of the RacI/Cdc42 by TUDCA protects these 
proteins from toxin B-catalysed glycosylation and caused a reduction in the 
cytopathic effect observed in HepG2 cells (Brandes et al., 2012).  
1.7.3. Antimicrobial peptides  
Antimicrobial peptides include host defence peptides produced by humans 
and other higher organisms that exhibit direct antibacterial activity on 
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pathogenic bacteria, and post-translationally modified peptides (lantibiotics) 
are produced by Gram positive bacteria to give them competitive advantages 
in mixed populations. They act on (often multiple) membrane and cell wall 
targets and thus the incidence of resistance is rare due to the extensive 
mutations required for evasion (Dawson and Scott, 2012). Their therapeutic 
use in the gut is challenging owing to the presence of proteolytic enzymes that 
degrade the peptides (Lai et al., 2007), but they seem to play an important 
role in homeostasis of the microbiota and the control of inflammation 
(Gersemann et al., 2009; Hua et al., 2010). Peptides can be chemically 
manipulated in attempt to sidestep degradation, improve activity or modify the 
specificity of the antimicrobial action (Wetzler and Barron, 2011) 
The lantibiotic lacticin 3147 has shown promising activity against C. difficile 
but suffers the effects of degradation in the gut environment and is also active 
against groups of commensal bacteria (Gardiner et al., 2007; Rea et al., 
2007). Another lantibiotic, NVB302, has shown good stability and selective 
activity in the GI tract and resolution of CDI in a hamster model (Johnson, 
2010). Clinical development of this agent is now being carried out by Novacta 
Biosystems Ltd.  
Cathelicidin peptides are expressed in some human epithelial cells of the gut 
including epithelial cells and this is up-regulated in response to inflammation 
such as that seen in cases of colitis (Koon et al., 2011). The major 
cathelicidin, LL-37, has been shown to significantly reduce inflammation 
resulting from CDI in mice after colonic administration (Hing et al., 2012). 
When studied in human monocytes it was found to inhibit the activation of the 
NF- B pathway and reduced toxin A mediated TNF  expression (Hing et al., 
2012). No significant antibacterial activity was demonstrated against C. 
difficile suggesting that recurrence following withdrawal of treatment is likely to 
be high.  
Thuricin is a two-component bacteriocin produced by a strain of Bacillus 
thuringiensis isolated from a human faecal sample, which exhibits activity 
against clinical strains of C. difficile but spares many groups of gut 
commensals (Rea et al., 2011). Thuricin compared favourably to the 
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performance of metronidazole in the reduction of C. difficile in an in vitro 
human colon model and it is a promising candidate for potential therapeutic 
use. The limitation impeding development is the difficulty in delivering the 
peptides through the upper GI tract to the colon.  
1.7.4. Probiotics 
Several probiotic bacterial strains thought to impart increased colonisation 
resistance to CDI have been proposed and these include Bacteroides spp. 
and Bifidobacteria spp. (Freeman et al., 2003; Hopkins and MacFarlane, 
2002) on the basis that these strains are mainly absent from patients suffering 
with CDI and present in those that do not develop CDI. Bacteroides spp. 
numbers have been shown to decrease with age, which correlates with the 
increased risk of CDI in later life (Hopkins and MacFarlane, 2002). 
In addition to competitive exclusion, probiotic strains can actually modulate 
the host’s response to pathogens such as C. difficile (1.2), via inhibition of the 
NF- B pathway (the first responder to stressful stimuli that regulates DNA 
transcription and gene expression). This observation has been reported for 
mixtures of Streptococcus thermophilus, Lactobacillus spp and 
Bifidobacterium spp. (Petrof et al., 2004). Conversely, activation of the NF- B 
pathway has been shown to improve cell survival following C. difficile toxin A 
exposure via a reduction in apoptosis (Chae et al., 2006). 
Despite being one of the most studied of the probiotics and having been used 
as such for the prevention of CDI both in animal studies (Kaur et al., 2011) 
and in humans (Biller et al., 1995; Gorbach et al., 1987; Siitonen et al., 1990), 
Lactobacillus spp. have been shown to increase in numbers during CDI 
(Hopkins and MacFarlane, 2002). Specific species, which were not 
scrutinised, are likely to exhibit different properties and probiotic features, for 
example some Lactobacillus gasseri strains have been demonstrated to 
adhere to intestinal mucus, compete with and displace gut pathogens 
including C. difficile (Ferreira et al., 2011). Lactobacillus rhamnosus has also 
been shown to inhibit MAP kinases, which regulate apoptosis amongst other 
roles (Yan and Polk, 2002).  
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Saccharomyces boulardii has also been proposed as a potential probiotic 
strain to help prevent the onset of CDI (Elmer et al., 1996; Sullivan and Nord, 
2002). S. boulardii has been shown to have anti-inflammatory activity via 
inhibition of toxin-mediated IL-8 production and IL-1  in a colonocyte cell line 
(Chen et al., 2006). It also blocked the activation of Erk 1/2 (a MAP kinase), 
and when tested in a mouse ileal loop model resulted in normalised fluid 
secretion relative to a control (Chen et al., 2006). Even some glycan fractions 
from yeasts including S. boulardii have potent anti-inflammatory action in a 
mouse model (Jawhara et al., 2012). S. boulardii also stimulated the intestinal 
Ig A response to C. difficile in a mouse model (Qamar et al., 2001). Despite 
this, a single centre, randomised double-blind, placebo-controlled trial was 
recently carried out, in which patients (over 65 years of age) due to receive 
broad-spectrum antibiotic therapy were started on twice daily capsules 
containing S. boulardii throughout their treatment. No reduction was observed 
in the number of antibiotic-associated diarrhoea cases or the frequency of CDI 
(Lewis et al., 1998). 
The use of S. boulardii is not without issue however, as highlighted in a recent 
case report (Thygesen et al., 2012). An elderly, immunocompromised female 
patient was given S. boulardii in addition to antimicrobial treatment and 
subsequently developed S. boulardii fungemia, requiring a course of 
Ambisome.  
Colonisation with non-toxigenic strains of C. difficile has been shown to offer 
protection from CDI both in hamsters (Borriello and Barclay, 1985) and 
humans (Seal et al., 1987; Wilson and Sheagren, 1983). This approach is 
currently being investigated in a phase II clinical trial (Villano, 2010). 
1.7.5. Prebiotics 
Prebiotics are non-digestible carbohydrates that support the growth and 
activity of probiotic strains in the gut (Delzenne et al., 2011). Certain prebiotics 
can also be expected to aid in the prevention of progression of CDI due to the 
anticipated boost to enteric species that impart C. difficile colonisation 
resistance, for example non-digestible oligosaccharides can be used to boost 
numbers of Bifidobacteria spp. (Hopkins and MacFarlane, 2002). Inulin has 
22 
 
also been used to the same effect (Petry et al., 2012) but other studies have 
found that C. difficile can also ferment this prebiotic (Terada et al., 1992). 
In a fascinating and as yet unsubstantiated study of C. difficile dynamics, the 
concentration of bacterial metabolic products in the gut of experimental mice 
was raised by increasing the amount of fermentable fibre in their diet from 2% 
to 20%. This was associated with exclusion of C. difficile in 6 out of 7 
colonised mice whereas mice fed 2% fermentable fibre continued to excrete 
the organism (Ward and Young, 1997). This implies that a poor diet may be a 
further contributing factor to CDI and represents an additional approach to 
tackling the problem. 
1.7.6. Faecal transplantation 
1.7.6.1. The concept 
Effective antimicrobial therapy does nothing to restore the integrity of the gut 
microbiota that gave rise to the CDI in the first place and indeed, relapses and 
reinfections are commonplace. It is generally accepted that a mature diverse 
intestinal flora itself imparts resistance against C. difficile colonisation and it is 
this concept that gave rise to the idea of transplanting healthy gut flora by 
means of faecal matter from a donor to a patient suffering from CDI in order to 
resolve the dysbiosis and replenish the gut with the normal enteric bacteria 
needed to help resist further attacks.  
The transfer of enteric flora by transplanting faecal material from healthy to 
diseased individuals has long been established in veterinary medicine. 
Transfaunation is the ingestion of manure from healthy adult horses and can 
resolve diarrhoea in foals. Also, anorexia in cattle brought about by 
indigestion can be relieved with a cud transplant from healthy cows (Radostis 
et al., 2000). More recently, experiments in mice have shown that faecal 
transplantation can resolve relapsing CDI caused by the hypervirulent 
NAP1/027 strain (Lawley et al., 2012). 
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1.7.2.1. Typical protocols 
Faecal instillation is a simple and inexpensive procedure that can be 
performed at care institutions with combined efforts of the Gastroenterology, 
Radiology and Microbiology departments. It is currently performed in a small 
number of specialist research centres throughout the world and the individual 
methods vary somewhat. Donor faeces can be infused into either the proximal 
or distal end of the GI tract and, taking into account the patient’s clinical 
situation, clinical history and receptiveness to the method, it is the choice of 
the patient and clinician as to which route is used.  
Basic generalised protocols are indicated in Fig. 1.3 a-b. For upper GI tract 
instillation, a single small volume (about 25 mL) of stool is required and a 
nasoduodenal or nasojejunal tube must be fitted (checked by X-ray imaging). 
NG tubes are used extensively in hospitals and are generally regarded as 
safe provided the correct procedure and checks are in place (Hutchinson et 
al., 2008). Rare complications may include perforation of the oesophagus 
(Lahdes-Vasama et al., 2009), trauma and complications arising from 
incorrect positioning, for example into the lungs (Lo et al., 2008; Zausig et al., 
2008) or the brain (Geissler, 2007) and the risk of aspiration of stomach 
contents giving rise to pneumonia (Metheny et al., 2006). With regards to 
instillation of the lower GI tract, colonoscopies and retention enemas are also 
routine practice in the hospital setting. Their use in patients with severe 
recurrent CDI with or without pseudomembranous colitis however, is a more 
challenging and risky proposition due to the extremely friable nature of their 
colonic epithelium. The risk of bowel perforation is even greater given that this 
protocol calls for a large volume of stool suspension (250-1500 mL) and 
invariably requires several consecutive attempts before resolution of 
diarrhoea is reported (Bakken, 2009). Lower GI administration is certainly less 
desirable from the perspective of the provider but the prolonged leakage of 
material following instillation is also a significant drawback in terms of the 
patient’s experience. Despite this, some studies have reported a strong 
patient preference for colonoscopy rather than NG tube instillation (Rohlke et 
al., 2010). There is the additional risk that colon lavages may pose a 
significant infection control hazard and necessitate clinical deep cleaning (as 
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opposed to routine clinical cleaning) of the endoscopy suite following each 
patient – an additional cost implication for the provider. 
 
 
 
 
 
Figure 1.3 (a). The basic protocol for faecal bacteriotherapy via 
nasogastric instillation. 
 
 
 
 
 
 
 
 
 
 
Identify suitable 
faecal donor i.e. 
spouse, partner or 
household 
contact. Carry out 
comprehensive 
sreening for 
enteric and blood 
borne pathogens  
Administer 
vancomycin over 4 
days preceding the 
procedure and 
give omeprazole 
the evening before 
and the morning 
of the instillation 
Insert a 
nasogastric tube 
into the stomach 
and confirm the 
correct position 
via abdominal 
radiograph  
Obtain the donor 
stool specimen - at 
least 30 g. Add 50-
70 mL sterile 
saline and 
homogenise with 
a household 
blender for 2-4 
min until smooth. 
Filter twice using 
coffee filter paper. 
Instill 25 mL of the filtered 
faecal suspension via the 
nasogastric tube  
Flush the nasogastric tube 
with 15 mL sterile saline 
and remove the tube.  
The patient can resume 
normal diet and physical 
activities immediately but 
should take probiotic 
supplements for 3-6 
months. Carry out C. 
difficile toxin testing 2-4 
weeks after the 
instillation and again if 
symptoms recurr. 
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Figure 1.3 (b). The basic protocol for faecal bacteriotherapy via 
colonoscopic or retention enema instillation.  
 
Donor faeces can be blended with saline or 4% milk  (Aas et al., 2003; Lund-
Tonnesen et al., 1998) The collection time must be as close to the time of the 
procedure as practicably possible and certainly within 24 h prior to instillation 
(Bakken, 2009). In some studies the prepared faecal slurry was frozen at -
20°C in aliquots for later use (Flotterod and Hopen, 1991).  
As part of the preparatory process of faecal bacteriotherapy, treatment with 
oral vancomycin is required to reduce the burden of C. difficile cells for 4-7 
days prior to the time of instillation - 250 mg three times a day (Aas et al., 
2003) or 500 mg twice per day (Borody et al., 2003). In addition, patients 
receiving via the upper GI route require a treatment to increase the pH of the 
proximal small intestine, for example omeprazole to decrease hydrochloric 
acid production, given the evening before and the morning of the instillation 
procedure (Aas et al., 2003). Some studies have also employed the use of a 
colonic lavage prior to upper GI infusion. For patients receiving their 
bacteriotherapy via enema, some studies have recommended an oral lavage 
Identify suitable 
faecal donor i.e. 
spouse, partner or 
household 
contact. Carry out 
comprehensive 
sreening for 
enteric and blood 
borne pathogens  
Administer 
vancomycin over 4 
days preceding the 
procedure and 
give omeprazole 
the evening before 
and the morning 
of the instillation 
Obtain the donor 
stool specimen - at 
least 300 g. Add 
250-1500 mL 
sterile saline and 
homogenise with 
a household 
blender for 2-4 
min until smooth. 
Filter twice using 
coffee filter  
paper. 
Perform a single 
oral lavage with a 
purgative agent 
Instill 250-1500 mL faecal 
suspension via a 
colonoscope or retention 
enema. 
Repeat the procedure 
daily over 3-5 days until 
clinical improvement in 
diarrhoea is observed. 
The patient can resume 
normal diet and physical 
activities immediately but 
should take probiotic 
supplements  for 3-6 
months. Carry out C. 
difficile toxin testing 2-4 
weeks after the 
instillation and again if 
symptoms recurr. 
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with a purgative agent, e.g. polyethylene glycol (PEG) plus electrolytes on the 
day of the therapy (Nieuwdorp et al., 2008). 
1.7.6.3. Efficacy of faecal bacteriotherapy for CDI 
The success rate of faecal transplantations is high, but few studies have 
compared the relative efficacy of upper and lower GI instillation (accepting 
that lower GI treatments require multiple attempts). The reported success 
rates of a comprehensive range of studies are detailed in Tables 1.1 a-b. 
There are over twice the number of reports for lower GI instillation as opposed 
to upper GI administration, but favour for this route is supported by an 
average success rate of 93% relative to 84% for upper GI infusions. This is 
particularly impressive since eligible patients had already suffered repeated 
bouts of CDI and multiple treatment failures. No studies have yet reported on 
the adoption of both these approaches to ensure complete reconstitution of 
enteric flora in recipients. 
The retrospective nature of some case report publications may suggest a 
degree of bias in favour of procedures that give rise to successful outcomes 
and there is certainly a need for controlled trials on faecal bacteriotherapy. 
There may also be long-term sequelae that are currently unrecognised but 
considering the acute life-threatening nature of CDI in eligible patients, these 
are of questionable significance. 
 
Reference Number  
of patients 
Site of 
instillation 
Author-reported 
success rate (%) 
(Eiseman et al., 1958) 1 Upper GI 1 (100%) 
(Flotterod and Hopen, 1991) 1 Upper GI 1 (100%) 
(Lund-Tonnesen et al., 1998) 1 Upper GI 1 (100%) 
(Aas et al., 2003) 16 Upper GI 15 (94%) 
(Nieuwdorp et al., 2008) 4 Upper GI 4 (100%) 
(MacConnachie et al., 2009) 15 Upper GI 11 (73%) 
(Garborg et al., 2010) 38 Upper GI 31 (82%) 
(Russell et al., 2010) 1 Upper GI 1 (100%) 
Upper GI overall success rate: 84% 
 
Table 1.1 (a) Studies reporting outcomes of upper GI faecal instillation. 
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Reference Number of 
patients 
Site of  
instillation 
Author-reported  
success rate (%) 
(Eiseman et al., 1958) 3 Lower GI 3 (100%) 
(Schwan et al., 1984) 1 Lower GI 1 (100%) 
(Tvede and Rask-Madsen, 1989) 6 Lower GI 6 (100%) 
(Paterson et al., 1994) 7 Lower GI 7 (100%) 
(Lund-Tonnesen et al., 1998) 17 Lower GI 14 (82%) 
(Gustafsson et al., 1998) 13 Lower GI 13 (100%) 
(Persky and Brandt, 2000) 1 Lower GI 1 (100%) 
(Faust et al., 2002) 6 Lower GI 6 (100%) 
(Jorup-Ronstrom et al., 2006) 5 Lower GI 5 (100%) 
(Nieuwdorp et al., 2008) 3 Lower GI 3 (100%) 
(Garborg et al., 2010) 2 Lower GI 2 (100%) 
(Mellow and Kanatzar, 2011) 13 Lower GI 11 (85%) 
(Rohlke et al., 2010) 19 Lower GI 18 (95%) 
(Yoon and Brandt, 2010) 12 Lower GI 12 (100%) 
(Silverman et al., 2010) 7 Lower GI 7 (100%) 
(Kelly et al., 2012) 26 Lower GI 24 (92%) 
(You et al., 2008) 1 Lower GI 1 (100%) 
(Khoruts et al., 2010) 1 Lower GI 1 (100%) 
(Fenton et al., 1974) 1 Lower GI 1(100%) 
(Bowden et al., 1981) 16 Lower GI 13 (81%) 
Lower GI overall success rate: 93% 
 
Table 1.1 (b) Studies reporting outcomes of lower GI faecal instillation. 
 
1.7.6.4. Selecting patients for faecal transplantation 
In a review of faecal bacteriotherapy case reports (Bakken, 2009), the 
eligibility criteria was defined as follows:  
a) Recurrent CDI confirmed by the presence of toxins A and/or B in stool and 
the absence of other treatable causes of diarrhoea. 
b) A suitable donor must be available, preferably a spouse or partner but 
household contacts can also be considered  
c) Potential donors must be screened for transmissible enteric pathogens 
including C. difficile and also blood-borne pathogens including hepatitis B, 
hepatitis C and human immunodeficiency virus (HIV). Donors must not be 
undergoing treatment for pre-existing medical conditions such as bowel 
disease or malignancy and cannot have received antibiotic treatment in 
the preceding 3 months. 
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1.7.6.5. Adverse events associated with faecal transplantation 
In the majority of studies, the potential adverse events following faecal 
transplantation cannot directly be associated with the procedure, for example, 
a case of pneumonia that developed 14 days post faecal transplantation (Aas 
et al., 2003) and one upper GI haemorrhage most probably related to 
concomitant use of non-steroidal anti-inflammatory drugs and the fitting of a 
nasogastric tube rather than the faecal transplantation itself (MacConnachie 
et al., 2009). One case of peritonitis however, which developed 3 days after 
the faecal transplant cannot be excluded as being caused by the infusion and 
possible leakage of faecal material following the procedure (Aas et al., 2003).  
1.7.6.6. Synthetic stool instillation 
The success of faecal bacteriotherapy is put down to the resolution of 
dysbiosis by acquisition of normal enteric flora from the healthy donor 
(Grehan et al., 2010). Major concerns associated with the method include the 
potential transmission of pathogens (both documented and as yet unknown) 
despite the comprehensive screening prior to donation. The notion of 
transplanting faecal material is also quite unappealing to patients and some 
reluctance could be expected (Bakken, 2009). Both these concerns could be 
addressed if the key components within the faecal material that give rise to 
the resolution could be identified and prepared synthetically. Cocktails of 
some of the probiotic strains regarded as being protective against C. difficile 
colonisation have been used in place of faecal material. Mixtures comprising 
the commensals Enterococcus faecalis, Clostridium bifermentans and 
Peptostreptococcus productus have been used successfully to treat refractory 
CDI via rectal instillation (Petrof et al., 2013; Tvede and Rask-Madsen, 1989).  
1.7.7. Passive immune products 
In animal studies, it has been shown that concentrated specific 
immunoglobulin (prepared from the colostrum of toxoid-vaccinated cows) 
given orally or parenterally to hamsters colonised with C. difficile was 
protective against diarrhoea and prevented death due to CDI (Kelly et al., 
1996; Lyerly et al., 1991). Application of this work in humans is limited to a 
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study by a different group, who demonstrated that orally administered 
‘Mucomilk’ (bovine IgA concentrate from the milk of vaccinated cows) was not 
as effective as metronidazole in a randomised double-blind study (Mattila et 
al., 2008). 
Human monoclonal antibodies against toxins A and B, generated in 
transgenic mice and administered intra-peritoneally, have also been shown to 
reduce mortality associated with CDI in the hamster model (Babcock et al., 
2006). Safety in humans has also been demonstrated and in a multi-centre, 
randomised, double-blind, placebo-controlled trial, these antibodies 
(administered intravenously) were given alongside the routine antibiotic 
schedule with the purpose of establishing a potential role in the prevention of 
recurrent CDI (Leav et al., 2010; Lowy et al., 2010). Co-administration of anti-
toxin A and B monoclonal antibodies brought about a 72% reduction in the 
CDI recurrence rate but it was noted that there was no difference in the 
severity of the infections (Lowy et al., 2010). It is hypothesised that these 
antibodies may pass through the inflamed colon due to the increased porosity 
of the epithelium (Giannasca et al., 1999; Riegler et al., 1995) but this is 
confounded by the observation that the protective effect of antibodies is less 
marked in severe disease (Kelly and Kyne, 2011). Active transport of the 
antibodies via the FcRn receptor in the epithelium is an alternative 
mechanism (Yoshida et al., 2006). 
For very severe cases of CDI, human normal Ig (HNIg) pooled from blood 
donations is sometimes used, particularly when patients show no or very little 
clinical response to vancomycin treatment. It has been used with successful 
outcomes (Shahani and Koirala, 2012) and the presumed mode of action is 
the neutralisation of toxin A by specific antibodies. So far there have been no 
randomised clinical trials of the use of HNIg in CDI.  
1.7.3. Vaccination 
Since high levels of serum Ig G have been shown to offer protection against 
CDI (Kyne et al., 2000; Leav et al., 2010), developing a vaccination to help 
patients avoid infection is an appealing prospect and economically valuable 
(Lee et al., 2010). Vaccine-induced protection against fatal CDI was first 
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demonstrated in hamsters (Libby et al., 1982) using a toxoid preparation. In a 
similar study it was also shown that these antibodies could be transferred to 
provide protection to non-immune hamsters via serum or ascitic fluid 
(Giannasca et al., 1999). Recombinant vaccines (Ryan et al., 1997) and DNA 
vaccines (Gardiner et al., 2009) have also proved effective. Historically there 
has been more emphasis on developing immunity directed against toxin A, 
since this was thought to be the primary virulence factor. An increasing 
understanding of the role of toxin B in CDI has substantiated the need to 
incorporate it into the vaccination strategy and indeed it has been shown that 
vaccinations encompassing antigenic determinants to both toxin A and B 
afford better protection than those to toxin A only (Babcock et al., 2006; 
Fernie et al., 1983; Kim et al., 1984; Kink and Williams, 1998; Libby et al., 
1982). 
A recent study details the results of a phase I randomised, placebo-controlled, 
double-blind clinical trial to evaluate the immunogenicity and safety of a 
formalin-inactivated adjuvant toxin A and B candidate vaccine (Greenberg et 
al., 2012). Two age groups were included in the trial – participants aged 
between 18-55 and those aged over 65. After two doses of either 2 µg, 10 µg 
or 50 µg of toxin A (administered intramuscularly), IgG seroconversion was 
observed in 100% of the 18-55 age group, although the neutralising capacity 
of the antibodies was not measured. The production of IgG directed against 
toxin B was less relative to IgG targeting toxin A as measured by enzyme 
immunoassay (EIA). For those aged over 65 years, 50 µg was required to 
achieve 100% seroconversion. These antibody levels were shown to 
decrease in the months following vaccination but remained positive (above 
the assay cut-off value) for at least 236 days afterwards. No safety concerns 
were reported. The production of IgA to impart mucosal immunity is also 
important and it has been suggested that co-administration of the probiotic 
yeast, S. boulardii, with vaccination may help to enhance the intestinal IgA 
response (Qamar et al., 2001).  
Vaccinations based on toxins are unlikely to affect rates of colonisation or 
help in the reduction of transmission and so other research groups have opted 
to work on the development of non-toxoid based vaccines in order to prevent 
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the acquisition of C. difficile. Surface-associated proteins including the 
flagellar cap protein FliD and Cwp84 protease (Pechine et al., 2005 a, 2005 
b), and surface layer proteins used for attachment (Eidhin et al., 2008). 
Despite a reduction in the levels of C. difficile in mice (Pechine et al., 2005 a, 
2005 b) and hamsters (Eidhin et al., 2008) the response was not sufficient to 
prevent colonisation.  
1.7.9. Toxin-binding proteins 
Based on the protective effect of neutralising antibodies against C. difficile 
toxins A and B, the potential of agents that bind and therefore inactivate these 
toxins has been explored. Tolevamer is a toxin-binding polymer that has 
shown significant reductions in cytotoxicity in cell monolayers (Hinkson et al., 
2008) and in hamster models of CDI, where 80% protection from mortality 
associated with CDI was observed in addition to a zero relapse rate relative to 
metronidazole (Kurtz et al., 2001). Promising results were also seen in phase 
II clinical trials, with rates of diarrhoea resolution comparable to those 
following vancomycin treatment (Louie et al., 2006). No serious adverse 
events were reported but tolevamer-treated patients were at increased risk of 
hypokalaemia. In phase III clinical trials, however, inferiority to both 
metronidazole and vancomycin was demonstrated (Bouza et al., 2008; Louie 
et al., 2007) and these findings were also corroborated by the results of tests 
using a human in vitro colon model (Baines et al., 2009), despite reporting 
good activity in the presence of faecal material in vitro.  
1.7.4. Other novel strategies 
Some essential oils including nerolidol (found in ginger, lavender, tea tree and 
lemongrass), thymol (common thyme oil), eugenol (found in clove, nutmeg 
and cinnamon) and geraniol (from rose, geranium and citronella oil) have 
shown inhibitory action against C. difficile growth in vitro in a dose dependent 
fashion (Thapa et al., 2012). Although this action was not generally observed 
to the same extent in commensal organisms, Faecalibacterium prausnitzii was 
very sensitive to the effects of the oils in in vitro tests. F. prausnitzii has been 
shown to have anti-inflammatory properties and its absence has been linked 
to the relapse of Crohn’s disease (Sokol et al., 2008). Further investigations 
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into the specific effects of essential oils on C. difficile and commensal 
organisms in the context of the gut are required before considering their use 
as supplements. 
1.8. Bacteriophage biology 
Bacteriophages (hereafter referred to as phages), are viruses that specifically 
infect bacteria and are typically specific to a single species or individual 
strains. Phages are the most abundant life form on earth and are ubiquitous in 
the environment with particularly high numbers found in soil, sewage and 
lakes (Serwer et al., 2007). It is estimated that the total weight of phages in 
the oceans is greater than that exerted by all of the humans on earth (Parfitt, 
2005) and consequently human contact with phages and ingestion is an 
everyday occurrence that has so far not been associated with any known 
harmful effects (Sulakvelidze et al., 2001). In fact, it has been suggested that 
they may play a role in the control of inflammation in response to gut flora and 
normalise levels of TNF  and IL-6 (Gorski and Weber-Dabrowska, 2005).  
Tailed phages can assume either a lytic or a lysogenic life cycle. Lysogenic 
phages contain genes that instruct the integration of the phage genome into 
that of the bacterial host thus replicating with each new bacterial generation 
without causing damage to the host cell (Lamont et al., 1993). When a phage 
has integrated into the host genetic material, it is referred to as a prophage. 
Lytic phages however, (the life cycle of which is illustrated in Fig. 1.4) take 
over host cell machinery to replicate independently of the bacterial genome 
and rapidly induce cell death by lysis. This liberates new virions that can then 
go on to infect other target bacteria until they have all been eliminated (Kutter 
and Sulakvelidze, 2005). 
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Figure 1.4.The life cycle of lytic phages. 
 
Prophages may be released spontaneously or can be induced to adopt the 
lytic life cycle when the host bacteria are treated with ultraviolet (UV) radiation 
or mitomycin C (Goh et al., 2005; Liu et al., 2005). Mitomycin C is a quinone-
containing alkylating agent produced by Streptomyces caespitosus. It causes 
breaks in single-stranded DNA and the cross-linkage of adenine and guanine, 
which results in the complete inhibition of DNA synthesis. This mode of action 
is very comparable to that of ionising radiation and although non-cell specific, 
these effects are seen more frequently in rapidly dividing cells (Kopp and 
Seregard, 2004). 
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1.9. Phage therapy 
1.9.1. History and early research 
The first observation of phage activity was recorded by Ernest Hanbury 
Hankin, a British biologist who in 1896 reported that the water of the Ganges 
in India and Bangladesh had antimicrobial activity against Vibrio cholera 
(Parfitt, 2005). Twenty-one years later this observation was attributed to 
phage activity by Felix d’Herelle at The Pasteur Institute in France and work 
on their use to treat bacterial infections began (d' Herelle, 1917). The results 
of early work into phage therapy were likely to have been misled by the lack of 
knowledge of phage acid sensitivity, exquisite specificity, lytic and lysogenic 
life-cycles and the very crude experimental preparations that were 
administered, which may have contained infectious agents and toxic 
compounds (Sulakvelidze et al., 2001). Indeed, there are reports of treatment 
failures and adverse reactions such as diarrhoea (Hanlon, 2007). This, 
coupled with the widespread availability of penicillin, led phage therapy to fall 
out of favour in the West, but countries such as Georgia and Poland 
continued to pursue this approach to antimicrobial treatment and there are 
many Russian and Polish publications demonstrating excellent clinical 
efficacy for bacterial dysentery (Babalova et al., 1968; Miliutina and 
Vorotyntseva, 1993), skin and soft tissue infections (Cislo et al., 1987), 
pulmonary infections (Ioseliani et al., 1980) and intestinal dysbiosis (Litvinova 
et al., 1978) to name a few. These reports were brought to the Western 
audience in a recent review (Sulakvelidze et al., 2001). 
In 1923 Dr Felix d’Herelle and his co-worker George Eliava founded the 
Eliava Institute in Tblisi, Georgia. This institute has been working on and 
manufacturing phage preparations for routine therapeutic use ever since. 
1.9.2. Recent research in the West 
Phage therapy has recently attracted the attention of clinicians, scientists and 
patients trying to tackle the problem of antibiotic resistant bacterial infections 
(Parfitt, 2005). Work on the reproduction of phage therapy studies in 
accordance with European regulations and standards has begun (Harper et 
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al., 2011) and includes success against the high-profile target, 
Staphylococcus aureus (and Methicillin-resistant S. aureus - MRSA) in a 
mouse model of septicaemia (Matsuzaki et al., 2003). Phage therapy has also 
been demonstrated as an effective agent to reduce the burden of specific 
pathogens in animal guts. A bacteriophage isolated from the faeces of sheep 
that were resistant to colonisation by E. coli O157:H7 resulted in a 2 log10 
reduction in the number of intestinal E. coli O157:H7 when administered to 
colonised sheep (Raya et al., 2006). Similarly, a 0.5-5 log10 reduction in the 
number of Campylobacter jejuni in the cecum of broiler chickens was reported 
when specific phage therapy was administered (Loc Carrillo et al., 2005). 
One concern that remains, both for antibiotic and phage treatment, is the 
release of toxic components when the bacterial cells are lysed. C. difficile 
associated disease is brought about by the action of enterotoxin A and 
cytotoxin B (Voth and Ballard, 2005), and the lysis of C. difficile could liberate 
quantities of toxin that may exacerbate the patient’s symptoms. This concept 
is commonly referred to as the Jarisch-Herxheimer reaction and is typically 
seen in patients treated for syphilis (Li et al., 2012). Heat stable proteins are 
released faster than the body can remove them, leading to a massive 
inflammatory response that resembles bacterial sepsis. The risk of the 
Jarisch-Herxheimer reaction and the extent of the reaction has been shown to 
increase with the burden of organisms (Yang et al., 2010). This issue has 
been addressed in a novel approach to phage therapy using a genetically 
engineered non-replicating phage to tackle Pseudomonas aeruginosa 
(Hagens et al., 2004). A phage export protein gene was replaced by a gene 
coding for a restriction endonuclease, rendering the phage incapable of 
escape from the host cell, yet effectively killing it. In mice heavily infected with 
P. aeruginosa it was found that this tactic improved the survival rates relative 
to the use of the wild-type lytic phage. 
Studies have also included investigations into the safety of phage therapy. 
Orally administered doses of up to 105 plaque forming units (PFU)/mL of the 
coliphage T4 to healthy volunteers resulted in no adverse reactions and 
phage was detectable for no more than 2 days post phage ingestion (Bruttin 
and Brussow, 2005).  
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1.9.3. Phage therapy of C. difficile 
Over seven different lysogenic bacteriophages of C. difficile have been 
described to date and these are detailed in Chapter 3. Induced prophages of 
C. difficile have previously been used to investigate the ability of phages to 
prevent ileocecitis in hamsters (Ramesh et al., 1999). Twenty-four hours after 
clindamycin treatment, gastric acid was neutralised with bicarbonate and 
hamsters were challenged with C. difficile followed immediately by a phage 
suspension containing 108 PFU/mL. Some hamsters also received further 
doses at 8 hour intervals. All of the control animals in this study who did not 
receive any dose of phage died within 72 hours of C. difficile administration, 
however 17 of the 18 hamsters who did receive phage survived until the end 
of the study. The C. difficile strain isolated from the hamster that died was 
shown to be resistant to the phage used, although the mechanism was not 
elucidated. Later studies of phage administration in a hamster model of CDI 
have shown in vivo lysogenisation, which may explain this finding (Govind et 
al., 2011).  
1.9.4. Administration of phage preparations 
The efficacy of phage therapy following differing routes of administration can 
be variable, although this is based mainly on data from veterinary studies for 
which quick and simple mass treatments are sought. In a study comparing the 
relative recovery of different phages in poultry after oral administration, beak 
spray or intra-muscular (IM) inoculation, it was found that IM delivery resulted 
in the most comprehensive dissemination with phage particles being 
recovered from the lungs and air sacs, liver, duodenum and spleen (Oliveira 
et al., 2009). Oral and spray administration was still effective at delivering 
phage to the respiratory tract. Differences in recovery rates between the types 
of phages were observed but this was attributed to the presence of some 
phage-sensitive hosts in the gut resulting in amplification of the phage 
For the purposes of treating gut pathogens, oral administration or delivery via 
colonoscope or enema offers the best access for remedial therapy. Treatment 
via the upper GI tract requires pre-neutralization of stomach acid in order to 
preserve the viability of the phage particles as they pass through. Removal 
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(albeit temporary) of this important barrier to GI pathogens carries its own risk 
of infection (including CDI) and this should be taken into account in terms of 
post-treatment care and advice. The short and longer-term impact of stomach 
acid neutralisation on the gut microbiome is not clear but significant changes 
in pH can be expected to bring about shifts in bacterial populations (Kim et al., 
2010).  
1.9.5. Phage resistance 
Host bacteria are able to develop resistance to phage attack (besides 
lysogeny), for example via the production of repressors, the loss of receptors 
or the masking of phage receptors with a capsule (Hyman and Abedon, 
2010). This is an important consideration when assessing the potential of 
phage therapy and some studies have reported on this phenomenon. Phages 
specific for various serovars of Salmonella enterica were isolated from 
environmental samples including wastewater and poultry excreta and used to 
treat infected poultry (Atterbury et al., 2007). This resulted in up to a 4.2 log10 
reduction in colony forming units of the target Salmonella species in the 
cecum after 24 hours but the authors also noted the development of 
resistance to the phages used in proportion to the dose that was administered 
(a higher dose of phage causing a higher proportion of the bacteria to be 
resistant). Contrary to this however, another study demonstrated that 12 out 
of 13 bacteriophage populations examined were able to overcome the 
expression of specific translational repressor proteins produced by the host 
bacteria (Lindemann et al., 2002). The frequency of fermentation failures 
reported during the production of dairy products would suggest that phages 
have the edge in terms of their capacity to maintain the ability to infect host 
strains (Kutter and Sulakvelidze, 2005). Phage populations will usually contain 
a considerable proportion of highly altered sequences relative to the original 
virus (Domingo et al., 1985) and the likelihood of the target bacteria 
developing resistance to predatory phages is no doubt affected by species-
specific factors.  
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1.9.6. The immune response to phage therapy 
The development of neutralising antibodies post parenteral administration of a 
range of phages has been demonstrated (Kucharewicz-Krukowska and 
Slopek, 1987), which requires thorough investigation in terms of the potential 
impact on host damage and the efficacy of future rounds of therapy. The 
possibility of a weak innate response to phage treatment could also not be 
ruled out in a recent study of pulmonary P. aeruginosa infection in a mouse 
model, based on a heightened cytokine profile relative to controls treated with 
phosphate buffered saline (PBS) (Morello et al., 2011). Despite these reports, 
no treatment failures were attributed to this matter in a comprehensive review 
of phage therapy in former Soviet Union and Eastern Europe (Sulakvelidze et 
al., 2001). 
1.9.7. Overview of phage therapy 
There are many features of phages that theoretically make them superior to 
the anti-infective drugs currently in use for the treatment of CDI. The exquisite 
specificity offered by phage therapy is a significant benefit relative to broad-
spectrum antibiotic therapy and could be expected to slash the risk of relapse 
and secondary bacterial infections due to the preservation of commensal 
microbiota. It does however, mean that new preparations would be required 
on a regular basis to ensure that common strains are covered, and the limited 
repertoire of C. difficile phages described to date highlight the possibility that 
not all strains may be treated in this way. Dosing frequencies may be 
lessened as phage replication will be maximised in areas where there is a 
high burden of target and discontinue only when all of the target bacterial cells 
have been eliminated. Environmental sources offer an endless resource of 
new phages and propagation is quick, straightforward and inexpensive. This, 
in addition to the encouraging experience and success in treating GI 
pathogens ensures phage therapy as a valuable candidate for further work 
into the prevention and remediation of CDI, but the extent of the problems 
associated with lysogenisation, resistance and immune stimulation still 
remains to be determined. 
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1.10. Outline of the thesis 
1.10.1. Background 
CDI represents a major challenge to healthcare services, affecting patients in 
hospital and in the community. Worryingly, the efficacy of our first line 
treatments seems to be diminishing and we are in need of alternative 
therapies. The use of phage has shown potential in the treatment of GI 
infections (Atterbury et al., 2007; Sulakvelidze et al., 2001; Kutter and 
Sulakvelidze, 2005), and the high degree of specificity is particularly 
appealing as limiting the damage to commensal gut microbiota would be 
expected to minimise the risk of CDI recurrence - a major challenge of 
treatment (Kamboj et al., 2011). There is little data exploring the use of phage 
to treat CDI and this is likely to be due to the relative scarcity of phages 
known to infect C. difficile strains and the ability of all those isolated so far to 
lysogenise with their host (Govind et al., 2006; Mahony et al., 1985; Nagy and 
Foldes, 1991; Sell et al., 1983; Horgan et al., 2010; Shan et al., 2012). 
Despite the lysogenic capacity, C. difficile phages haves been shown to 
reduce numbers of C. difficile in an in vivo model (Ramesh et al., 1999). 
1.10.2. Aims  
The initial aims of the study were to carry out screening for novel phages of C. 
difficile, chiefly those with no lysogenic capacity, to search for candidates for 
use as therapuetic agents against CDI. Using a C. difficile phage isolated 
previously (Mayer et al., 2008) and its sensitive hosts, the project set out to 
investigate its impact on C. difficile in simulated gut environments and 
whether the in vitro activity could be improved by phage mutagenesis. Further 
objectives developed during the study were concerned with determination of 
the mechanisms responsible for phenotypic changes in C. difficile toxin 
production as a result of lysogeny.  
This project has aimed to contribute to the foundations of Western phage 
therapy research, which may one day lead to the development of phage 
therapy regimes to treat bacterial infections and reduce our dependency on 
antibiotics.  
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1.10.3. Hypothesis 
The use of bacteriophages will prove effective as a method of controlling CDI 
with minimal damage to the colonic microbiota. 
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Chapter 2 – General methods 
The following methods and consumables were used throughout the project. A 
full table of all the bacterial strains used is provided in Appendix 1. 
2.1 Bacteriology 
2.1.1. Propagation of C. difficile 
2.1.1.1. Liquid culture 
Stocks of C. difficile were maintained in Robertson’s cooked meat media 
(Southern Group Laboratory, Corby). One hundred µL of the stock was used 
to inoculate 25 mL pre-reduced BHI (with complements) or RCM media, which 
was then transferred immediately to the anaerobic cabinet and incubated at 
37°C for 12-18 h. At least one further subculture (but no more than 4) was 
made prior to the culture being used experimentally. 
2.1.1.1.1. Measuring the optical density of liquid cultures. 
The Cecil CE 2041 (2000 series) spectrophotometer and semi-micro cuvettes 
(Fisher Scientific) were used to measure the optical density of cell 
suspensions at a wavelength of 600 nm (OD600). After automatic calibration, 1 
mL of sterile media was used to obtain a blank reading. When anaerobic 
cultures were to be measured, pre-reduced blank media was used as the 
broth contained a colorimetric resazurin indicator. Samples that were clearly 
turbid were always diluted 1 in 10 prior to OD600 measurement to obtain a 
more accurate reading and duplicate readings were taken.  
2.1.1.2. Solid media 
2.1.1.2.1. Non-selective media 
Plates containing approximately 20 mL of BHI or RCM agar were pre-reduced 
in the anaerobic cabinet and cultures were processed in the anaerobic cabinet 
when possible. Twenty µL of pure liquid culture was dispensed in triplicate 
onto the surface of the plates and allowed to sink into the media (for the 
purposes of enumeration) or streaked around the edge of the plate with a 
sterile loop to check for purity. 
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2.1.1.2.2. Selective media 
2.1.1.2.2.1. Enumeration of C. difficile 
Plates containing approximately 20 mL of cefoxitin cycloserine egg yolk agar 
(CCEY) or CCEY with 5 mg/mL lysozyme (CCEYL) were pre-reduced in the 
anaerobic cabinet and cultures were processed in the anaerobic cabinet when 
possible. Three drops of 20 µL liquid sample were dispensed onto the surface 
of the agar and allowed to sink into the media in the anaerobic cabinet prior to 
inversion and incubation for 2 days. Characteristic colony morphologies (Fig. 
2.1) were counted to enumerate the levels of C. difficile. 
2.1.1.2.2.2. Isolation of C. difficile 
Selective agar was also used for the isolation of C. difficile from faecal 
samples. A pea-sized portion of stool was emulsified in 2 mL sterile saline and 
treated with an equal volume of 100% ethanol for 45 min. A 10 μL aliquot of 
the suspension was streak-plated on pre-reduced CCEY or CCEYL agar 
plates and incubated for up to 48 h in the anaerobic cabinet at 37 C. Colonies 
of C. difficile were grey with diffuse edges and a ground-glass appearance as 
shown in Fig. 2.1. 
 
Figure 2.1. Colonies of C. difficile on CCEY agar after 30 h incubation. 
 
2.1.1.3. Spore stocks 
2.1.1.3.1. Production of C. difficile spore stocks for culturing 
One hundred µL of an overnight culture of C. difficile in BHI or RCM was used 
to inoculate pre-reduced Robertson’s cooked meat media (Southern Group 
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Laboratory, Corby). The media was incubated in the anaerobic cabinet at 
37°C for 18-24 h and the stocks were then stored at room temperature. 
2.1.1.3.2. Production of pure C. difficile spore stocks for experimentation 
Five-hundred µL aliquots of C. difficile culture grown in BHI or RCM media 
were used to inoculate the centre of 10 pre-reduced blood agar plates. The 
inocula were spread around using a sterilised glass rod and the plates were 
incubated in the anaerobic cabinet. After 24 h the plates were placed inside a 
plastic bag to prevent drying and incubated for a further 12 days. On day 13 
the plates were removed from the anaerobic cabinet and exposed to air for 24 
h. After this the plates were checked for contamination and all C. difficile 
growth was scraped off aseptically using sterile loops, and transferred to 10 
mL of pre-chilled PBS on ice. An equal volume of chilled ethanol (96%) was 
added, mixed by gentle inversion and the suspension incubated on ice for 1 h. 
The spore stocks were then washed 4 times with chilled PBS and centrifuged 
at 3220 x g for 10 min at 4ºC. Serial dilutions in pre-reduced PBS were 
enumerated using CCEY agar. 
2.1.1.3.2.1. Purification of C. difficile spore stocks 
Urografin (Schering Healthcare Ltd) is a prescription medication used as 
contrast in medical imaging, but can also be used for centrifugal separation of 
bacterial spores from cell debris and vegetative cells. The concentration and 
centrifugation parameters were optimised for C. difficile cells. Spore stocks 
were sonicated for 15 min in a chilled bath. Five-hundred µL chilled Urografin 
(35% v/v) was added to a microtube and 400 µL spore stocks was layered on 
top. The microtubes were centrifuged at 11,000 x g for 1 h, after which the top 
layer of liquid was removed. The bottom layer (containing the spores) was 
washed twice in chilled PBS and re-suspended in 250 µL chilled PBS. A 10 
µL aliquot was examined under a light microscope to determine the quantity of 
spores. The preparation was concentrated or diluted to give approximately 5 
spores per visual field. 
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2.1.2. Media for culturing commensal bacteria 
A range of commensal gut bacteria were enumerated by culture using 
selective media as shown in Table 2.1. 
 
Organism Media  Pre-
reduced 
An/aerobic Duration of 
incubation 
Lactobacillus spp. Rogosa (2.5.6) Yes Anaerobic 3 days 
Bifidobacterium 
spp. 
Beeren’s (2.5.7) Yes Anaerobic 5 days 
Bacteroides spp. Bacteroides 
(2.5.8) 
Yes Anaerobic 5 days 
Enterobacteriaceae MacConkey 
(2.5.9) 
No Aerobic 1 day 
Total anaerobes Wilkens-
Chalgren(2.5.10)  
Yes Anaerobic 3 days 
Total aerobes Nutrient (2.5.11) No Aerobic 2 days 
Total Clostridium 
spp. 
Clostridia (2.5.12) Yes Anaerobic 5 days 
Gram-positive cocci Slanetz-Bartley 
(2.5.13) 
No Aerobic 2 days 
 
Table 2.1. Media and conditions for culture of commensal gut bacteria. 
 
2.1.3. C. difficile toxin A and B quantification 
The Premier Toxins A and B EIA (Meridian BioSciences Inc) was used for 
detection of C. difficile toxins A and B in the batch fermentation and colon 
model vessels. Briefly, 200 μL sample diluent was measured into a sterile 
microtube and 50 μL of sample added to it before thorough vortex mixing for 
15 s. One well was used for each sample plus one for a negative control, a 
positive control and an in-house control (fresh culture of NCTC 11204). One-
hundred μL of the controls and diluted samples were added to the 
corresponding wells. Fifty μL of enzyme conjugate was added to each well 
before sealing the plate with the covers provided and shaking gently to mix 
the samples and reagents. The plates were incubated at 37°C for 50 min. 
Next, 6 plate washes were carried out manually with 1 x wash buffer, tapping 
the plate over tissue paper to completely remove well contents between each 
wash. Two drops of substrate (~50 μL) were added to each well before 
shaking firmly and incubating in the dark at ambient temperature for 10 min.  
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Finally, 2 drops of stop solution were added to each well and the plate was 
carefully agitated to mix the contents. The absorbance values were measured 
using a plate reader (Molecular Devices, California, USA) at a single 
wavelength of 450 nm as instructed by the manufacturer. The approximate 
concentration of toxins relative to the absorbance reading obtained using this 
assay has previously been determined (Novak-Weekley and Hollingsworth, 
2008) and this is illustrated in Fig. 2.2. 
 
Figure 2.2. Absorbance measurements (450nm) using the Meridian 
Premier Toxins A and B assay, determined from a range of C. difficile 
toxin concentrations. (Novak-Weekley and Hollingsworth, 2008). 
 
2.2. Phage biology 
2.2.1. Mitomycin C induction of phages 
Mitomycin C induction was performed by the method of Sell et al. (1983). 
Fresh turbid cultures of Clostridium spp. (OD600 0.6-1) were used for 
inductions. Mitomycin C (Sigma) at a final concentration of 3 mg/mL was 
added to the cultures and mixed by inversion before further incubation for 4 h. 
Decreases in the OD600 could often be demonstrated at this time if the strain 
contained an inducible phage. Cultures were centrifuged at 3320 x g for 10 
min and the resulting supernatant was passed through a 0.45 µm syringe filter 
(Millipore) to a sterile glass container. Aliquots of the filtered supernatant were 
used in spot or overlay plaque assays to check for the presence or to build up 
stocks of phage.  
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2.2.2. Plaque assays 
2.2.2.1. Overlay plaque assays 
One-hundred μL of an active C. difficile culture in BHI or RCM broth and 100 
μL of the phage-containing liquid at the required dilution was added to cooled 
molten soft BHI or RCM agar and poured over the surface of pre-reduced BHI 
or RCM agar plates. This was allowed to set for 5 min in air before 
transferring to the anaerobic cabinet for incubation. After 18-24 h plates were 
examined for distinct plaques, as shown in Fig. 2.3. The number of plaques 
can be enumerated to calculate the number of PFU per mL of sample.  
A plate without added phage was also set up with each test to verify that the 
culture conditions were suitable for C. difficile growth. 
 
 
Figure 2.3. Overlay plaque assay showing phage activity. 
 
2.2.2.2. Spot plaque assays 
One-hundred μL of an active C. difficile culture in BHI or RCM broth was 
added to cooled molten soft BHI or RCM agar, which was poured over the 
surface of a pre-reduced BHI or RCM agar plate and allowed to set for 5 min 
in air before transferring to the anaerobic cabinet. Twenty μL of the required 
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dilution of phage-containing liquid was dispensed onto the surface of the agar 
and allowed to sink into the media prior to inversion and incubation for 18-24 
h at 37 C. Plates were examined for zones of clearing or distinct plaques as 
pictured in Fig. 2.4. 
 
Figure 2.4. Spot plaque assays showing phage activity. 
 
2.2.2.3. Production of lysogens 
Lysogenic strains of NCTC 11204 containing ΦCD27 as a prophage were 
made by carrying out spot plaque assays as described above, only with one 
spot of 500 μL highly concentrated (greater than 107 PFU/mL) phage 
suspension to give what appears to be confluent lysis within the zone. By 
incubating the plate for 24-36 h and sub-culturing material from the centre of 
the zone, lysogens were isolated, which were confirmed by mitomycin C 
induction (2.2.1). 
2.2.3. Propagation of phages 
2.2.3.1. Plate harvests 
Overlay plaque assays were carried out as previously described (2.2.2.1). 
Plates containing phage produced semi-confluent plaques. Phage progeny 
were harvested by overlaying the agar with 15 mL of BHI and incubating at 
room temperature on an orbital shaker (Stuart SSL1, 30 rpm) for 3 h. The BHI 
was harvested and filtered through a 0.45 μm membrane and stored at 4-8°C. 
Fresh phage stocks were made for each experiment.  
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2.2.3.2. Propagation of phage in broth cultures 
Cultures of susceptible C. difficile strains were grown in 20 mL BHI broth (with 
complements) to approximately 0.4 OD600 as previously described (2.1.1.1). 
Five mL of fresh induced phage was added to the culture and returned to 
incubation in the anaerobic cabinet for 2-5 h. Decreases in OD600 were 
measured and the phage was harvested by centrifugation at 3320 x g and 
passing the phage-containing supernatant through a 0.45 µm syringe filter. 
2.2.3.3. Storage of phage stocks 
Phage stocks were kept at 4°C for up to 3 months. 
2.2.4. Concentration of phages 
Bacteriophages were concentrated by PEG precipitation as described 
previously (Sambrook et al., 1989). Using a sterile Pasteur pipette, 20 mL of 
phage-containing liquid was dispensed into a sterile 50 mL centrifuge tube. 
DNase and RNase (2.5.20/2.5.21) were added to a final concentration of 10 
µg/mL each and the tubes were incubated for 1-2 h in a 37ºC water bath. 
Sodium chloride was added to a final concentration of 1 M and the tubes were 
kept on ice for 1 h, agitating at frequent intervals. The tubes were centrifuged 
at 11,000 x g at 4ºC for 10 min and the supernatant was transferred to a new 
sterile 50 mL centrifuge tube. PEG molecular weight 8000 g was added to 
obtain a final concentration of 10%. This was agitated to aid dissolution and 
then incubated on ice for 2 h. The tubes were centrifuged again for 10 min at 
11,000 x g at 4ºC. The supernatant was removed and the pellet re-suspended 
in 1 ml of BHI broth (with complements) or suspension media (SM). Finally the 
suspension was filtered through a 0.45 µm pore membrane into a sterile 
container and stored at 4ºC.  
2.2.5 Microscopy 
2.2.5.1. Light microscopy 
Light microscopy was used to verify cell morphology from pure cultures and in 
the preparation of spore suspensions. Fifteen µL of the sample to be viewed 
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was added to clean glass microscope slide. A cover slip was placed over the 
liquid and slides were viewed at x400 magnification.  
2.2.5.2. Electron microscopy 
2.2.5.2.1. Transmission Electron Microscopy (TEM) 
Formvar/carbon grids (Agar Scientific) were processed in duplicate. A grid 
was picked up using tweezers and bent slightly at the edge by holding the 
dark shiny (coated) side against the bottom of a petri-dish and turning the 
tweezers. This ensured that the grids were level and were held in place in an 
upright position. Approximately 30 µL of sample was pipetted onto each grid 
and incubated for 1 min at room temperature. The grids were held vertically 
over a waste container and 5 drops of uranyl acetate (saturated solution in 
water) (Sigma) were pipetted over to wash off the sample and stain the 
adhered material. Excess stain was blotted from the edge of the grids using a 
piece of filter paper and they were placed face-up onto a steel wire mesh 
platform in a petri dish, taking note of the positions relating to each sample. 
When all the grids were prepared, the dish was transferred to a fume cabinet 
and 5 mL of 25% glutaraldehyde (Fisher Scientific) was pipetted into a plastic 
cap placed next to the wire mesh in the petri dish. The lid of the dish was 
immediately replaced and the grids were incubated in the cabinet for 30 min. 
After 1 h, the grids were turned over and left for a further 30 min before being 
turned back and allowed to incubate for 12-15 h. The grids were transferred to 
a new clean petri dish and submitted to the electron microscopy department 
for analysis.  
2.2.5.2.2. Scanning electron microscopy (SEM) 
One mL of turbid bacterial suspensions (concentrated by centrifugation if 
required) was transferred to a sterile 1.5 mL microtube. One-hundred and ten 
μL of 25% glutaraldehyde was added and mixed well into the bacterial 
suspension. Samples were left to fix for 1 h before being submitted for SEM 
analysis. 
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2.3. Molecular methods 
Molecular biology methods were conducted according to protocols in 
(Sambrook et al., 1989) unless stated otherwise. 
2.3.1. Equating CFU/PFU with DNA quantity 
The total amount of DNA (ng) based on the yield of viable organism was 
calculated using the following equation to indicate the number of PFU/mL 
required to obtain sufficient DNA for extraction: 
 
   Size of                    Molecular                 
 genome (bp)    x    weight of DNA           109    
        (660)                                       x PFU (total) = DNA (ng) 
_____________________________________ 
                          6.023 x 1023mol-1 
 
In order to recover up to 60 μg using the Qiagen Lambda Midi kit (detailed 
below), approximately 1 x 1012 PFU must be extracted. (The genome of 
ΦCD27 is 50930 bp meaning the expected yield would be 55.8 μg). 
2.3.2. Nucleic acid extraction 
2.3.2.1. DNA extraction 
Samples (1.5 mL) of cultures and colon model samples were transferred to a 
microtube and centrifuged for 5 min at 12,000 x g. The supernatant was 
removed and the pellets were frozen at -20°C prior to DNA extraction using 
the methods described below.  
2.3.2.1.1. Qiagen stool mini kit 
Nucleic acid from defrosted pellets was extracted as instructed by the 
manufacturer. ASL lysis buffer (1.4 mL) was added and the tube was vortex 
mixed thoroughly until completely homogenised. The tube was then heated 
for 5 min at 95°C, after which the sample was vortex mixed and centrifuged 
for 1 min at 12,000 x g. Supernatant (1.4 mL) was carefully transferred to a 
new sterile tube. An inhibitEX tablet was added using sterile tweezers and the 
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tube was vortex mixed until the tablet had dissolved. After incubation for 1 min 
at ambient temperature the tube was centrifuged for 3 min at 12,000 x g. The 
supernatant was transferred to a new sterile microtube and centrifuged again. 
Fifteen μL of proteinase K was added to a new sterile microtube. Two-
hundred μL of the second supernatant was added followed by 200 μL buffer 
AL. The tube was vortex mixed for 15 s and incubated at 95°C for 10 min. 
Next, 200 μL of 100% ethanol was added. The lysate was transferred to a 
QIAamp spin column in a 2 mL collection tube and centrifuged at 12,000 x g 
for 1 min. The flow-through was discarded and the spin column was placed 
into a new collection tube. Five-hundred μL of buffer AW1 (wash buffer) was 
added to the spin column before centrifuging again at 12,000 x g for 1 min. 
Again the flow-through was discarded and the column placed into a new 
collection tube. Five-hundred μL of AW2 (wash buffer) was added to the 
column, after which it was centrifuged at 12,000 x g for 3 min. The flow-
through was discarded and the spin column was transferred to a new 
collection tube. The spin column was centrifuged for 1 min at 14,000 x g to dry 
the membrane, and then transferred to a new sterile 1.5 mL microtube. One-
hundred μL of elution buffer was added directly onto the membrane and 
incubated for 5-10 min. Finally, the tube was centrifuged at 14,000 x g for 1 
min and the resulting eluate was stored at 4°C. 
2.3.2.1.2. Phenol chloroform method 
Pellets were defrosted and re-suspended in 1 mL lysis mix (1 units/100 μL 
mutanolysin and 166 mg lysozyme dissolved in 20 mL TE, pH 7.5), vortex 
mixed vigorously and incubated at 37°C for 1 h. Next, 20 µL 10 mg/mL RNAse 
(2.5.21) was added followed by 84 μL clearing mix (49 μg/mL proteinase K, 
9.5 mM EDTA pH 8, 0.24 M NaCl and 0.8% sodium dodecyl sulphate (SDS) 
dissolved in sterile deionised water) and incubated at 60°C with occasional 
inversion for 1 h or until the mixture had cleared. The mixture was divided into 
2 clean microcentrifuge tubes and mixed with 500 μL phenol, inverted for 30 s 
and centrifuged for 5 min at 11,000 x g. The aqueous layer was transferred to 
a clean tube and the process was repeated with 
phenol:chloroform:isoamylalcohol (25:24:1) and then chloroform. Next, 1 mL 
of ice cold ethanol was added, mixed thoroughly and centrifuged for 30 min at 
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13,000 x g, after which the supernatant was removed and the pellet washed 
with 1 mL 70% ethanol. After removing the ethanol, the pellet was air dried for 
10 min and finally re-suspended in 200 μL Tris EDTA (TE) buffer, pH 8 
(2.5.26).  
2.3.2.1.3. Boom method 
The Boom method was carried out as previously described 
(Health_Protection_Agency, 2008). Briefly, the pellets were defrosted and re-
suspended in 200 μL sterile distilled water. This was added to a tube 
containing 900 μL L6 buffer (Severn Biotech) and 20 μL isoamyl alcohol 
(Sigma). The tube was vortex mixed for 1 min and centrifuged for 15 s at 
12,000 x g. The supernatant was transferred to a new sterile 1.5 mL 
microtube. Extraction matrix (100 μL silica beads from Severn Biotech) was 
added. The mixture was vortex mixed for 15 s and then shaken on a rocking 
platform for 15 min. The tube was centrifuged at 12,000 x g for 15 s and the 
supernatant discarded. Five-hundred µL of L2 buffer (Severn Biotech) was 
added and mixed. The tube was centrifuged at 12,000 x g for 15 s and the 
supernatant was discarded. This washing step was repeated with L2 buffer, 
then with 500 μL 70% ethanol twice and finally with 500 μL acetone. The silica 
pellet was dried by placing the opened tubes into a heating block set at 50°C 
for 5-10 min. The nucleic acid was re-suspended by adding 150 μL PCR-
grade water, mixed well and heating at 56°C for 5 min. The tube was then 
centrifuged at 12,000 x g for 20 min and 100 μL of the supernatant carefully 
withdrawn to a new sterile tube. In the event of any silica becoming 
disassociated from the pellet, the tube was centrifuged again to ensure that 
no silica was transferred. Extracted nucleic acids were stored at 4°C and 
diluted 1 in 10 prior to use in PCR assays. These extractions were not 
suitable for spectrophotometric quantification due to the potential interference 
from the silica beads. 
2.3.2.1.4. Freeze-thaw cell disruption 
When required, frozen pellets were thawed at ambient temperature, mixed 
thoroughly using a vortex mixer and centrifuged for 1 min at 3320 x g to 
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clarify. Material was then used directly as a PCR template for density gradient 
gel electrophoresis (DGGE) analysis. 
2.3.2.1.5. Phage DNA extraction 
Reagents were kit components unless otherwise stated. Lambda DNA kits 
(Qiagen) were used to extract phage DNA. One hundred μL of buffer L1 
(containing RNase and DNase) was added to 50 mL of the phage-containing 
plate harvest (~1 x 1011 PFU). Next, 19 mL ice-cold L2 was added, mixed 
gently by inversion and incubated on ice for 60 min. The tubes were 
centrifuged at 11,000 x g for 10 min at 4°C and the supernatant was carefully 
discarded. The pellet was completely re-suspended in 3 mL L3 before adding 
3 mL L4 and immediately inverting 6-8 times to mix. The suspension was then 
incubated at 70°C for 20 min and cooled on ice. Three mL of L5 buffer was 
added and promptly mixed by inversion. The suspension was centrifuged at 
4°C for 30 min at 17,000 x g and the supernatant was carefully transferred to 
a fresh tube. The centrifugation step was repeated for 10 min to obtain a clear 
supernatant. A Qiagen tip-100 was equilibrated with 4 mL QBT and allowed to 
empty by gravity flow before applying the supernatant. When this had passed 
through, the column was washed with 10 mL buffer QC. DNA was eluted with 
5 mL buffer QF and precipitated by mixing with 3.5 mL isopropanol at ambient 
temperature. The DNA was centrifuged at 17,000 x g for 30 min at 4°C and 
the supernatant was carefully removed and discarded. The DNA pellet was 
washed with 2 mL 70% ethanol and centrifuged at 17,000 x g for 10 min. The 
supernatant was discarded as before and the pellet was air-dried for 5-10 min 
before re-suspension in 60-100 μL nuclease-free water (Promega). 
2.3.2.2. RNA extraction 
Cultures of C. difficile were prepared as described previously (2.1.1.1). 
Samples of turbid cultures were taken after 10 h growth in order to evaluate 
the differential expression of the toxins of C. difficile. 
Before all work with RNA, clean surfaces and pipettes were wiped with RNase 
AWAY (Sigma) to inactivate RNase enzymes and gloves were replaced 
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regularly throughout the protocol. All consumables that were not certified 
RNase-free were double-autoclaved. 
The SV Total RNA Isolation System (Promega) was used for RNA extractions. 
Reagents were kit components unless otherwise stated. The protocol adapted 
for Gram-positive organisms was used, with some modifications. A 1.5 mL 
aliquot of culture was transferred to a microtube and centrifuged at 11000 x g 
for 2 min to pellet the cells. The supernatant was removed and this was 
repeated twice to obtain the equivalent of 4.5 mL culture. The pellet was re-
suspended in 100 µL freshly prepared TE buffer containing 3 mg/mL 
lysozyme (Sigma) and tapped to mix. The re-suspended pellet was incubated 
at ambient temperature for 8 min before 75 µL of RNA lysis buffer was added 
followed by 350 µL RNA dilution buffer and mixed by gentle inversion. Next, 
200 µL ethanol was added and pipetted up and down several times. This 
mixture was transferred to an assembled spin column and centrifuged at 
13,000 x g for 1 min. Flow-through from the collection tube was discarded and 
600 µL wash solution was added. The spin columns were centrifuged at 
13,000 x g for 1 min. To a separate tube 40 µL yellow core buffer, 5 µL 0.09 M 
MnCl2 and 5 µL DNase I was combined and mixed by pipetting. The entire 
mix was applied to the spin column membrane and incubated at 20-25°C. 
After 15 min, 200 µL DNase stop solution was added and the spin column 
was centrifuged at 13,000 x g for 1 min. Another wash step with 600 µL wash 
solution followed, after which the columns were centrifuged at 14,000 x g for 2 
min to dry the membrane. The column was removed from the collection tube 
and placed into a 1.5 mL microtube. One-hundred µL of nuclease-free water 
was added and the column was centrifuged at 13,000 x g for 1 min. The 
resulting eluate was used immediately or flash-frozen in liquid nitrogen before 
being stored at -80°C. 
The DNase step included in the SV Total RNA Isolation System was not 
sufficient to remove all traces of contaminating DNA. Frozen samples (50 μL) 
were defrosted gently on ice and 5 μL TURBO DNase buffer (Invitrogen) and 
1 μL TURBO DNase (Invitrogen) was added, mixed gently and incubated at 
37°C. After 30 min, 5 μL DNase inactivation reagent (Invitrogen) was added. 
The tube contents were mixed well at regular intervals during a 5 min 
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incubation at 25°C. The tubes were centrifuged at 10,000 x g for 90 s at 4°C 
and the RNA was transferred to a fresh tube. In order to verify that all DNA 
had been eliminated, 1 μL was used as a template for PCR with Hotmaster 
Taq (2.3) using the following primers (Eurofins MWG) targeting the 16S v3 
region: 
 V3_F: 5’-CCTACGGGAGGCAGCAG-3’  
 V3_R: 5’-ATTACCGCGGCTGCTGG-3’  
 
2.3.2.2.1. Production of cDNA 
Superscript® III Reverse Transcriptase (Invitrogen) was used to produce 
complementary DNA (cDNA) copies of pure extracted RNA. Reagents were 
kit components unless otherwise stated. To 13.9 μL of the RNA extract, 0.3 
μL of random primers was added and incubated at 65°C for 5 min. The 
reaction was cooled slowly to ambient temperature for 15 min. Two microliters 
of reverse transcription buffer, 2 μL 100 mM dithiothreitol (DTT), 0.8 μL 100 
mM deoxyribonucleotide triphosphate (dNTP) mix and 1 μL reverse 
transcriptase were added. The reaction was incubated at 25°C for 10 min and 
then at 48°C for 1 h. The transcriptase was inactivated by incubating at 70°C 
for 15 min and the reations were cooled before use as a template for PCR. 
2.3.3. Concentration of nucleic acid 
To a starting volume of 1 mL in an 50 mL centrifuge tube, 100 μL of 3 M 
sodium acetate at pH 5.2 (Sigma) was added and mixed by inversion. Next, 
800 μL iso-2-propanol (Fluka) was added, mixed again and left on ice for 30 
min. The tubes were centrifuged at 13,000 x g for 30 min and the pellet 
washed in 1 mL 70% ethanol (Sigma). After centrifugation and removal of the 
supernatant, the pellet was re-suspended in 200 μL nuclease-free water 
(Promega). 
2.3.4. Quantification of nucleic acid 
The Nanodrop instrument and software (Thermo Scientific) was used 
according to the manufacturer’s instructions. The type of nucleic acid (DNA or 
RNA) to be measured was selected and the instrument was cleaned with lint-
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free tissue moistened with ultra-pure water. It was calibrated by taking a blank 
measurement with 1 µL ultra-pure water and dried with tissue. One µL of 
sample was used to obtain a reading, cleaning with tissue between each. 
Nucleic acid peaks were typically at 260 nm. Peaks at 280 nm were indicative 
of protein contamination and samples with high absorption at 280 nm were re-
extracted. An absorbance ratio (260/280) of between 1.7 and 2 indicated a 
pure extraction of good quality.   
The approximate quantity of nucleic acid could also be estimated by running a 
1 and 5 µL aliquot on a 1% agarose gel (Melford Laboratories Ltd) and 
comparing the intensity of the bands obtained with the known quantities of the 
Hyper I DNA ladder (BioLine Ltd., Fig. 2.5). 
2.3.5. Polymerase chain reaction (PCR) 
PCR was performed using PCR Sprint (Thermo Scientific) and the 
TProfessional Basic (Biometra) thermal cyclers, with the polymerases GoTaq 
(Promega) for colony PCR, Hotmaster (5 Prime) for DGGE (see 6.4.3) and 
Phusion (New England Biolabs (NEB)) for high fidelity applications including 
amplification of genes for protein expression. Protocols were as per 
manufacturer’s instructions. Primers were obtained from Sigma Genosys and 
annealing temperatures were calculated using the website 
http://www.basic.northwestern.edu/biotools/oligocalc.html (Kibbe, 2007). 
2.3.5.1. Go Taq DNA Polymerase (Promega) 
Amplification of DNA using Go Taq Polymerase was carried out with the 
reaction compositions detailed in Table 2.2 a. Amplification of DNA with Go 
Taq Polymerase was carried out using the cycling parameters given in Table 
2.2 b.  
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Component Quantity 
DNA template 1 µL  
(~500 ng) 
5 x GoTaq reaction buffer  
(Promega) 
10 µL 
dNTP 100 mM (Bioline) 0.4 µL 
Forward primer 20 µM 1 µL 
Reverse primer 20 µM 1 µL 
Deionised water 36.35 µL 
Go Taq polymerase (Promega) 0.25 µL 
 
 
 
 
 
 
Table 2.2. (a) Go Taq Composition and (b) cycling parameters. 
*Adjusted depending on primer melting temperature (Tm). 
 
2.3.5.2. Phusion DNA Polymerase (NEB) 
Phusion is a high fidelity polymerase enzyme. Amplification of DNA using 
Phusion Polymerase was carried out with the reaction compositions detailed 
in Table 2.3 a. Amplification of DNA with Phusion Polymerase was carried out 
using the cycling parameters given in Table 2.3 b.  
 
 
 
 
 
 
 
 
 
 
 
Temperature Duration Number of cycles 
95°C 2 min 1 
95°C 30 s 25-30 
55°C* 30 s 
72°C 1 min per kb 
72°C 5 min 1 
a 
b 
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Component Quantity 
DNA template 1 µL  
(~ 500 ng) 
5 x Phusion reaction buffer (NEB) 10 µL 
dNTP 10 mM (Bioline) 1 µL 
Forward primer 20 µM 1.25 µL 
Reverse primer 20 µM 1.25 µL 
Deionised water 34.5 µL 
Phusion polymerase (1 U/µL) (NEB) 0.5 µL 
 
 
 
Table 2.3. (a) Phusion composition and (b) cycling parameters. 
 
2.3.5.3. Hotmaster Taq DNA Polymerase  (5 PRIME) 
Amplification of DNA using Hotmaster Taq Polymerase was carried out with 
the reaction composition described in Table 2.4 a. Amplification of DNA using 
Hotmaster Taq Polymerase was carried out with the cycling parameters 
detailed in Table 2.4 b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Temperature Duration Number of cycles 
98ºC 30 s 1 
98°C 10 s  
25-30 Tm or Tm+3°C for >20 bp primers 30 s 
72°C  15-30 s per kb 
72°C 5 min 1 
a 
b 
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Component Quantity 
DNA template 2 μL 
5 x Hotmaster reaction buffer (5 PRIME) 5 µL 
dNTP 2.5 mM (Bioline) 4 µL 
Forward primer 10 µM 1 µL 
Reverse primer 10 µM 1 µL 
Bovine serum albumin (BSA) (10 mg/mL New England BioLabs) 1 μL 
Deionised water 35.8  μL 
Hotmaster polymerase (1 U/µL) (5 PRIME) 0.2 µL 
 
 
 
 
 
 
 
Table 2.4. (a) Hotmaster composition and (b) cycling parameters. 
*Adjusted depending on primer melting temperature. 
 
2.3.6. Gel electrophoresis of nucleic acid 
Agarose gels were made at a concentration of 0.8-1.5% (Melford Laboratories 
Ltd) and run in 0.5 x Tris borate EDTA (TBE) (Fisher Scientific). A positive 
and a negative control were tested on each gel and the sample volume was 
typically 5-10 µL. If samples required a loading dye, 1 µL spots of loading 
buffer (0.015% bromethyl blue (Sigma), 10% glycerol (Sigma) in 0.5 x TBE 
buffer) were dispensed onto parafilm (M Laboratory) and mixed with samples 
prior to loading into the gel.  
The gels were stained in 1 mg/L ethidium bromide for 30 min, briefly rinsed in 
deionised water and visualised with transilluminating UV light using the 
AlphaImager software (ProteinSimple).  
2.3.6.1. Hyperladder I 
Hyperladder I (Bioline) was used as a DNA ladder in every electrophoretic gel. 
The quantities and sizes of the fragments are shown in Fig. 2.5. 
Temperature Duration Number 
of cycles 
94ºC 2 min 1 
94°C 20 s  
29 58°C* 10 s 
65°C  20 s  
65°C 5 min 1 
b 
a 
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Figure 2.5. Hyperladder I fragment sizes and quantities based on 5 μL 
loaded onto a 1% agarose gel stained with ethidium bromide. 
 
2.3.7. PCR clean-up 
Nucleic acids (greater than 100 bp) were cleaned with SureClean (Bioline) to 
remove primers and restriction enzymes in preparation for sequencing and 
other sensitive downstream applications. Microtubes (0.5 mL) (Amicon) 
suitable for PCR clean-up were used for each sample to be purified. An equal 
volume of SureClean was added to the PCR product. The samples were 
vortex mixed for 30 s and incubated at ambient temperature for 30 min before 
being centrifuged at 13,000 x g for 30 min. The supernatant was carefully 
removed by aspiration and a volume of 70% ethanol 2 times that of the 
original PCR product volume was added. The tubes were vortex mixed for 30 
s and centrifuged as before. The supernatant was air-dried at 55˚C for 
approximately 5 min to ensure complete removal of the ethanol, and re-
suspended in 10-20 μL nuclease-free water (Promega).   
2.3.8. Restriction digestion of nucleic acid 
DNA was purified with SureClean to remove proteins, primers and dNTPs. 
The concentration of DNA to be digested depended on the size of the 
smallest fragment to be obtained and the intended downstream application. 
Digests were carried out according to the NEB guide with water baths used 
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for the incubations. Restriction enzymes were heat-inactivated after the 
incubations and products were purified with SureClean to remove the 
enzymes. 
2.3.9. Phosphatase treatment of nucleic acid 
Antarctic Phosphatase (NEB) was used to remove 5’ phosphate groups from 
plasmid vectors after restriction digestion and prevent self-ligation as per 
manufacturer’s instructions. The reactions were comprised of 1 x Antarctic 
Phosphatase buffer (NEB), up to 1 μg restricted DNA in any buffer, sterile 
ultra-pure water (if dilution was required) and 10 units of Antarctic 
Phosphatase. This was incubated for 15 min at 37°C in a water bath for 5’ 
extentions or blunt ends or 60 min for 3’ extensions. Reactions were then 
inactivated at 65°C for 5 min. Products were purified using SureClean to 
remove the enzyme. 
2.3.10. Sequencing 
Purified PCR products and plasmid preps were sequenced using BigDye v. 
3.1. (Applied Biosystems). DNA was quantified using the Nanodrop 
spectrophotometer and diluted according to the size of the product to be 
sequenced as shown in Table 2.5. 
 
Template Quantity 
PCR product 
100-200 bp 
200-500 bp 
500-1000 bp 
1000-2000 bp 
>2000 bp 
 
3 ng 
3-10 ng 
5-20 ng 
10-40 ng 
40-100 ng 
Double stranded 30-40 ng/kb 
Bacterial genomic DNA 2-3 µg 
 
Table 2.5. Guide of nucleic acid quantities required for BigDye 3.1. 
sequencing. 
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The reaction components were as shown in Table 2.6 a and were added in 
this order. The cycling parameters are given in Table 2.6 b. 
Component Quantity 
DNA template  
13.5 μL Water 
5 x BigDye 3.1 reaction buffer 3.5 μL 
Forward or reverse primer 1.6 pmol/µL 2 μL 
BigDye v. 3.1 thawed on ice 1 μL 
 
 
Table 2.6 (a) BigDye v. 3.1 composition and (b) cycling parameters prior 
to capillary sequencing 
 
Samples were submitted to Genome Enterprise Ltd for capillary sequencing 
using the 3730XL DNA analyser (Life Technologies). 
The capillary sequencing carried out as part of the phage integration site 
determination was performed by the Wolfson Institute for Biomedical 
Research, UCL. 
2.3.11. Subcloning 
2.3.11.1. Adding 3’ Adenosine-overhangs onto PCR products 
Many polymerase enzymes such as Phusion produce blunt ended products 
and for the purposes of cloning it was necessary to add adenosine overhangs 
to the 3’-ends. This was achieved by incubating 39.35 μL DNA (diluted in 
nuclease-free water if required) with 10 μL 5 x GoTaq buffer, 0.4 μL 100 mM 
dNTP and 0.25 μL GoTaq polymerase for 20 min at 72°C. Samples were then 
stored at 4°C and cloning was carried out within 2 days of adding the 
overhangs. 
 
 
Temperature Duration Number of cycles 
96°C 2 min 1 
96°C 30 s (ramp 1°C/s) 25 
50°C 15 s 
60°C 4 min 1 
a 
b 
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2.3.11.2. Ligation 
2.3.11.2.1. Cloning of products for sequencing using pCR®2.1 
Cloning of PCR products was performed using the TA cloning kit (Invitrogen). 
A map of pCR®2.1 is shown in Fig. 2.6. The following was used to calculate 
the amount of PCR product (X) needed for each ligation reaction based on a 
1:1 molar ratio.  
X ng PCR product = (Y base pairs PCR product) x (50 ng pCR®2.1)/3900* 
* The size in base pairs of the pCR®2.1 vector. 
 
 
Figure 2.6. The plasmid vector pCR®2.1 (reproduced from the Invitrogen 
manual). 
 
A 3:1 ratio (insert:vector) often gave a better transformation efficiency but no 
more than 3 µL of the PCR product was added to the ligation reaction mixture 
due to the inhibitory effect of the salts on the ligase. Dilutions of the PCR 
products were made using nuclease-free water (Promega) where required. 
The plasmid vector pCR®2.1(Invitrogen) was defrosted on ice and centrifuged 
briefly to collect all liquid at the bottom of the vial. The ligation reactions were 
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set up as follows: X µL fresh PCR product (with 3’-A overhangs); 1 µL 10 x 
ligation buffer; 2 µL 25 ng/µL pCR®2.1 vector and water to make a total 
volume of 9 µL. Finally, 1 µL of T4 DNA ligase (4 Weiss units) was added and 
the reactions were incubated at 14°C for 12-18 h. To confirm that a product of 
the correct expected size was achieved, 1 μL of the ligation mixture was used 
as a template in PCR using GoTaq (2.3.5.1) and the following primers (Sigma 
GenoSys): 
 M13_F: 5’-CTG GCC GTC GTT TTA C-3’  
 M13_R: 5’-GTC ATA GCT GTT TCC TG-3’ 
 
Products were visualised by gel electrophoresis and successful ligations could 
then be used for transformations (2.3.11.3). 
2.3.11.2.2. Cloning of products for protein expression using pET15b 
A map of pET15b is shown in Fig. 2.7. The pET15b vector and the fragments 
to be ligated were digested with restriction enzymes NdeI and XhoI. One μg in 
6 μL was incubated at 37°C for 1 h with 1 μL buffer 4 (NEB), 2 μL nuclease-
free water (Promega) and 1 μL NdeI (NEB). A second digestion under the 
same conditions was carried out by adding 1 μL buffer 4, 8 μL nuclease-free 
water and a further 1 μL NdeI. Next, 1 μL buffer 4 was added, 5 μL nuclease-
free water and 3 μL BSA (NEB) with 1 μl XhoI (NEB). The reaction was 
incubated for 1 h at 37°C before a further digestion with 1 μL buffer 4, 1 μL 
BSA, 7 μL nuclease-free water and 1 μL XhoI. The vector was also treated 
with Antarctic phosphatase (2.3.9) after restriction digestion (2.3.8). The 
vector and the fragments were purified with SureClean (Bioline, 2.3.7) and the 
yields and quality of the products assessed using the Nanodrop 
spectrophotometer. A ratio of 3:1 insert: vector was used, calculated as 
previously described. The ligation reactions were set up using Fastlink ligase 
(Epicentre) as described by the manufacturer: X μL digested cleaned PCR 
product (diluted in nuclease-free water); 1.5 µL 10 x Fastlink ligation buffer; 
1.5 μL 10 mM ATP; 3 µL (~150 ng) restricted phosphotased pET15b vector; 1 
µL of Fastlink DNA ligase made up to 15 μL with nuclease-free water. The 
mixture was mixed gently, centrifuged briefly to draw liquid to the bottom of 
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the tube and incubated at ambient temperature for 2.25 h. To confirm that a 
product of the correct expected size was achieved, 1 μL of the ligation mixture 
was used as a template in PCR using GoTaq and the following primers 
(Sigma GenoSys): 
 T7P2: 5’-TGA GCG GAT AAC AAT TCC C-3’ 
 T7_T: 5’-GCT AGT TAT TGC TCA GCG G-3’ 
 
PCR product sizes were checked by gel electrophoresis and successful 
ligations could then be used for transformations (2.3.11.3). 
 
  Figure 2.7. The plasmid vector pET15b (reproduced from 
the Novagen datasheet). 
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2.3.11.3. Transformation of E.coli 
2.3.11.3.1. Basic protocol for TOP10 and BL21 (DE3) 
Chemically competent Escherichia coli TOP10 cells (Invitrogen) were used for 
transformations for basic cloning and E. coli BL21 (DE3) cells (Invitrogen) 
were used for transformations with pET15b for protein expression. One vial of 
One Shot® cells (sufficient for 2-4 transformation reactions) was transferred 
from -80°C to an ice bucket and allowed to defrost for 8 min. Cells aliquots of 
12 µL were dispensed into pre-chilled microtubes for each transformation 
reaction. Empty vector controls were included to permit calculation of 
transformation efficiency. Five to 10 ng of chilled ligated DNA (in a volume 
between 1-5 µL) was transferred to the cells, tapped twice to mix and 
immediately returned to the ice for 30 min. The tubes were then placed in a 
42°C water bath for exactly 30 s without mixing and immediately returned to 
the ice for 2 min. Two hundred and fifty µL pre-warmed (37°C) SOC broth was 
added to the cells and the tubes were taped in a rack and placed in a shaking 
incubator at 37°C for 1 h at 225 rpm. Fifty and 100 µL of each transformation 
reaction was spread onto 2 L agar plates containing 100 µg/mL ampicillin 
(plus 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (XGAL, 2.5.19) for 
pCR®2.1), and incubated at 37°C for 18-24 h.  
2.3.11.3.2. Confirmation of positive transformants  
Where possible, a minimum of 10 (white or pale blue for pCR®2.1 
transformations) colonies were tested per transformation reaction. A sterile 
toothpick was used to touch the colony and transfer the material to 10 µL of 
sterile ultra-pure water in a microtube, which was then mixed and briefly 
centrifuged. The choice of primers depended on the vector used for the 
transformations, as described previously (section 2.3.11.2). GoTaq 
polymerase and 1 µL of the suspended colony material as the template were 
used for PCR. The presence and size of a product was confirmed by gel 
electrophoresis. 
 
 
67 
 
2.3.11.3.3. Transformation efficiency 
Empty vector controls were carried out to calculate the efficiency of the 
transformation reactions using the following equation: 
(Numbers of colonies) x (1000 ng/µg)/(ng of control DNA) = transformants/µg   
2.3.11.4. Plasmid extractions 
Reagents were prepared as instructed in the kit insert. Confirmed positive 
transformants were grown in L broth containing ampicillin (100 µg/mL) for 8 h 
in a shaking incubator at 37°C, sub-cultured to fresh L broth and grown for a 
further 12-16 h. A 1.5 mL aliquot of culture was transferred to a microtube and 
centrifuged at 11000 x g for 2 min to pellet the cells. The supernatant was 
removed and this was repeated twice to obtain the equivalent of 4.5 mL 
culture. 
2.3.11.4.1. Qiagen plasmid mini kit 
Reagents were kit components from the plasmid mini kit (Qiagen) unless 
otherwise stated. Cell pellets were thoroughly re-suspended in 0.3 mL of 
buffer P1 containing LyseBlue. Buffer P2 (0.3 mL) was added and the tubes 
were inverted 4-6 times and incubated at room temperature for 5 min. Chilled 
buffer P3 (0.3 mL) was added and the tubes were vigorously inverted 4-6 
times and incubated on ice for 5 min to precipitate the genomic DNA, proteins, 
cell debris and potassium dodecyl sulphate. The mixtures were centrifuged for 
10 min and the supernatant containing the plasmid DNA was promptly 
transferred to a fresh tube. A QIAGEN-tip was equilibrated by adding 1 mL of 
buffer QBT and allowing it to empty by gravity flow. When all of the buffer 
QBT had drained, the supernatant was added to the resin and again allowed 
to empty by gravity flow. Next the QIAGEN-tip was washed twice with 2 mL 
buffer QC and the DNA eluted with 0.8 mL buffer QF. The DNA was 
precipitated by adding 0.7 volumes of isopropanol at room temperature, 
mixing and centrifuging at 14,000 x g for 30 min. The supernatant was 
removed and the DNA pellet was washed with 1 mL 70% ethanol before being 
centrifuged at 14,000 x g for 5 min. The supernatant was carefully removed, 
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taking care not to disrupt the pellet. The pellet was air-dried for 10 min and re-
dissolved in 20 µL nuclease-free water (Promega).  
2.3.11.4.2. Omega E.Z.N.A. Plasmid Mini Kit 
Reagents were kit components unless otherwise stated. The spin protocol 
was used according to manufacturer’s instructions and reagents were 
prepared as instructed in the kit insert. Pellets were re-suspended in 250 μL 
solution I containing RNase A and vortex mixed until no cell clumps were 
visible. The suspension was transferred to a fresh 1.5 mL tube and 250 µL 
solution II was added to lyse the bacterial cells. The tube was mixed gently by 
inversion and after 4 min 350 µL of solution III was added and immediately 
mixed by gently inversion. A white flocculent precipitate formed and was 
pelleted by centrifugation at 13,000 x g for 10 min at ambient temperature. A 
HiBind DNA Mini Column was placed into a collection tube and equilibrated 
with 100 μL of equilibration buffer. The column was centrifuged at 13,000 x g 
for 30 s and the filtrate was discarded. The cleared supernatant was applied 
to the column ensuring not to disturb the white pellet, and the column was 
centrifuged again. The flow-through was discarded and the column was 
placed back in the same collection tube. Five hundred μL of buffer HB was 
added to the column and centrifuged as described previously to remove 
residual protein contamination. The flow-through liquid was again discarded. 
Next 700 μL of DNA wash buffer was added to the column, which was 
centrifuged as before, discarding the flow-through. The wash buffer step was 
repeated and a further centrifugation at 13,000 x g for 2 min was carried out to 
dry the column completely. The column was placed into a fresh 1.5 mL tube 
and 30 μL of nuclease-free water (Promega) was added directly to the centre 
of the matrix. The column was incubated at ambient temperature for 1-2 min 
and centrifuged at 13,000 x g for 1 min. A second elution with a further 30 μL 
nuclease-free water was carried out to increase the yield of DNA. 
 
 
 
69 
 
2.4. Protein analysis 
2.4.1. Protein induction 
2.4.1.1. Protein induction from E. coli BL21(DE3) to optimise induction 
and harvest conditions. 
With each induction an empty vector control was also tested to serve as a 
negative control. A colony from a fresh E. coli BL21 (DE3) transformation was 
added to 10 mL L broth containing 100 µg/mL ampicillin and incubated for 12-
18 h at 37°C. Two-hundred µL of this culture was added to 3 fresh 10 mL 
aliquots of pre-warmed L broth with ampicillin and incubated at 37°C in a 
shaking incubator. When cultures reached OD600 0.4-0.5 (approximately 2-3 h 
post inoculation) indicating mid-log phase, isopropyl-β-D-
thiogalactopyranoside (IPTG) (Promega) at a final concentration of 0.5 mM 
was added to induce β-galactoside production and hence protein production 
due to the shared promoter. Cultures were returned to the 37°C shaking 
incubator. Cultures were harvested at 3 and 4 h (to assess differences in 
protein yield at the different times) by centrifugation at 3320 x g for 15 min at 
4°C. The supernatants were removed and the pellet immediately frozen at  
-20°C.  
2.4.1.2. Protein induction from E. coli BL21 (DE3) for downstream 
applications 
His-tagged protein production was induced as recommended by the 
Qiaexpress Ni-NTA FastStart handbook (Qiagen). Ten mL of an overnight 
culture was added to 250 mL pre-warmed L broth containing 100 µg/ml 
ampicillin. When cultures reached OD600 0.6 (approximately 3-4 h post 
inoculation) indicating mid-log phase, IPTG at a final concentration of 1 mM 
was added to induce protein production. Cultures were returned to the 37°C 
shaking incubator and after 4 h they were harvested by centrifugation at 3320 
x g for 20 min at 4°C. The supernatants were removed and the pellet 
immediately frozen at -20°C. 
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2.4.2. Protein extraction 
2.4.2.1. Crude protein extraction 
Frozen pellets were defrosted on ice for 15 min and 500 μL of extraction 
buffer (20 mM Tris, 50 mM sodium chloride, pH 7.5 or 50 mM sodium 
phosphate, 300 mM sodium chloride and 20 mM imidazole) was added. The 
cell pellet was vortex mixed rigorously to completely re-suspend the cells and 
this suspension was then transferred to a fresh 2 mL screw-top tube 
containing 100 μg sterile acid washed 0.1 mm glass beads (Sigma) on ice. 
The suspension was bead-beaten using the FastPrep FP 120 cell disruptor for 
4 cycles of 30s with 5-10 min on ice in between each. The sample was 
centrifuged at 13,000 x g for 30 min at 4°C and the supernatant was carefully 
transferred to a fresh tube and stored at 4°C until further use.  
2.4.2.2. Purification of His tagged proteins under native conditions for 
downstream applications. 
His-tagged proteins were partially purified using the Ni-NTA Fast Start kit 
(Qiagen). A frozen pellet from a 250 mL culture of induced E.coli BL21(DE3) 
cells was defrosted on ice for 15 min, re-suspended with 10 mL native lysis 
buffer supplemented with 1 mg/mL lysozyme and 3 U/mL benzonase  and 
incubated on ice for 30 min. The cell suspension was gently swirled to mix 
every 10 min. The lysate was centrifuged at 14,000 x g for 30 min at 4°C to 
pellet the cellular material and the supernatant was transferred to a fresh, 
chilled container.  
The resin in a Fast Start column was re-suspended by inverting several times 
and the storage buffer drained from the column. The lysate was applied to the 
column and 5 µL of the flow-through was saved for analysis by gel 
electrophoresis. The column was washed twice with native wash buffer and 
5µL of each flow- through was saved for analysis by gel electrophoresis. The 
6xHis-tagged protein was eluted with 3 consecutive 1 mL aliquots of native 
elution buffer (50 mM Na2HPO4, 300 mM NaCl and 250 mM imidazole, pH 8). 
All 3 fractions were analysed by gel electrophoresis. 
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2.4.3. Bradford assays 
Assay standards were prepared using Purified BSA (NEB) at concentrations 
of 200, 180, 160, 140, 120, 100, 80, 60, 40, 20 and 0 μg/mL. Dilutions were 
made with the buffer used for the protein extraction or purification. Dilutions of 
sample were also made depending on the anticipated concentration of the 
neat extraction. Ten μL of the standard concentrations and the samples in 
duplicate were pipetted into designated wells of a sterile, flat-bottomed, 96-
well microtitre plate (Sterilin). The colorimetric indicator was freshly prepared 
using 4 mL Bradford’s reagent (Biorad) with 16 mL H20, mixed by gentle 
inversion. Next, 190 μL of the diluted Bradford’s reagent was dispensed into 
each well and the samples were mixed on the SoftMax plate reader 
(Molecular Devices). After mixing, any bubbles were removed and the plates 
were incubated at ambient temperature for 5 min before reading at 600 nm 
(single wavelength). A standard curve of the standards was made and the 
concentration of protein was calculated using the equation generated by the 
curve. The mean concentration of the duplicate samples was taken. 
2.4.4. Protein gels 
NuPage Novex Bis-Tris gels and reagents were purchased from Invitrogen 
and the protocol was carried out according to the manufacturer’s instuctions. 
A protein concentration of between 5 and 10 µg (based on results of the 
Bradford assay) was required for clear visualisation on the gel. Samples were 
prepared in 0.5 mL tubes in a total volume of 10, 15 or 20 µL as shown in 
Table 2.8. 
Component µL µL µL 
Total volume of sample + H20 6.5 9.75 13 
Reducing agent 1 1.5 2 
LDS sample buffer 2.5 3.75 5 
Total volume 10 15 20 
 
Table 2.7. Composition of protein samples prior to running on NuPage 
Novex gels. 
Prepared sample mixtures were heated to 70°C for 10 min and chilled on ice. 
The tubes were briefly centrifuged. Gels were rinsed with deionised water and 
secured in the XCell SureLock system (Invitrogen). Two-hundred mL of MES 
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buffer (Invitrogen) was added to the inner chamber to submerge the wells and 
500 µL of antioxidant was added and mixed well. Ten microlitres of SeeBlue 
Plus 2 pre-stained standard (Fig. 2.8) (Invitrogen) and the heated and chilled 
samples were loaded on to the gel. The remaining 400 mL MES buffer was 
poured into the outer chamber. Gels ran for 35 min at 200 V (start 110-125 
mA, end 70-80 mA). The gel was removed from the outer casing and stained 
with Simply Blue Safestain (2.4.5) or were used for Western blot analysis 
(2.4.6). 
 
 
Figure 2.8. The See Blue Plus 2 pre-stained protein standard. 
 
2.4.5. Staining protein gels. 
Gels were washed 3 times with deionised water with gentle shaking and were 
then submerged in SimplyBlue SafeStain (Invitrogen) and placed on a rotary 
shaker (Stuart SSL1) at 40 rpm for 1 h. Gels were then de-stained in 
deionised water for 1 h on the shaker, placed between 2 acetate sheets and 
imaged on a flatbed scanner (Hewlett Packard). 
2.4.6. Western blot analysis. 
A protein gel was run as previously described, ensuring that the order of the 
samples was the same as on the initial stained gel. Proteins were transferred 
to membranes as described by the Invitrogen Western transfer protocol. 
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NuPAGE transfer buffer was prepared by adding 25 mL 20 x NuPAGE 
transfer buffer (Invitrogen), 50 mL methanol (Fisher Scientific) and 500 μL 
NuPAGE antioxidant (Invitrogen), made up to 500 mL with deionised water. 
The 4 blotting pads in the XCell II Blot Module (Invitrogen) were soaked in 
approximately 350 mL of the transfer buffer (prepared as above). A 
polyvinylidene fluoride (PVDF) transfer membrane was submerged in 
methanol for 30 s. It was then placed into deionised water to wash briefly 
before transferring to 50 mL NuPAGE transfer buffer for several minutes. 
When the protein gel had finished running, it was removed from the outer 
casing, rinsed briefly in deionised water and placed into a plastic dish. The 
blot was prepared in the order shown in Fig. 2.9. 
 
Figure 2.9: Assembly of the Western blot 
 
The assembled blot was placed directly into the XCell II module and secured. 
Transfer buffer was carefully added to the inner chamber of the blot module 
until the membrane was covered. Approximately 650 mL of deionised water 
Soaked pad 
Soaked pad 
Filter paper (briefly soaked) 
PVDF transfer membrane (ensuring that it covers the 
gel completely) 
Protein gel 
Filter paper (briefly soaked) 
Soaked pad 
Soaked pad 
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was used to fill the outer chamber. Transfer was carried out at 30 V for 1 h 
(170 mA start, 110 mA end). The blot module was then removed from the gel 
tank and the PVDF transfer membrane was lifted into a plastic dish containing 
50 mL Tris buffered saline (TBS) buffer (2.5.29) to wash for 10 min. After 10 
min the wash was repeated with fresh TBS. A 3% BSA (Sigma) solution was 
made in TBS buffer and 10 mL was added to the PVDF transfer membrane in 
a fresh plastic dish to block non-specific binding. This was incubated for 15-18 
h at 4°C on a tilting platform. The remaining BSA stock and the transfer 
membrane was brought to room temperature and the membrane was placed 
into the larger washing dish with 50 ml of TBS with tween (TBS-Tween) with 
Triton  (2.5.30). This was incubated on a rotating platform for 10 min at room 
temperature. After 10 min the wash was repeated with fresh TBS-
Tween/Triton. After 10 min the TBS-Tween/Triton was replaced with TBS and 
incubated on the rotating platform for 10 min. Anti-His-TAG antibody 
(Novagen) was prepared as a 1 in 2000 dilution (2.5 μL in 5 mL 3% BSA). The 
PVDF transfer membrane was placed in a fresh plastic dish with the antibody 
dilution and incubated on a tilting platform for 1 h. The PVDF transfer 
membrane was then washed twice in TBS-Tween/Triton and once in TBS as 
before. Anti-Murine IgG whole molecule-alkaline phosphatase (Invitrogen) 
was also prepared as a 1 in 2000 dilution (2.5 μL in 5 mL 3% BSA) and 
incubated with the transfer membrane as before. 
A FAST™ BCIP/NBT alkaline phosphatase substrate tablet (Sigma) was 
defrosted 20 min prior to the end of the incubation. The PVDF transfer 
membrane was washed in 50 ml TBS-Tween/Triton 4 times for 10 min on a 
rotating platform, each with fresh buffer. After the second wash, the 
BCIP/NBT tablet was re-suspended in 10 mL sterile ultra-pure water and 
vortex mixed to completely re-suspend the tablet. After the washing steps the 
membrane was carefully placed into a fresh plastic dish on a level surface. 
The dissolved BCIP/NBT development solution (10 mL) was poured evenly 
over the membrane and incubated at ambient temperature. The reaction was 
stopped by submerging both sides of the PVDF transfer membrane in 
deionised water when the expected bands became visible (up to 15 min).  
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2.4.7. Protein purification 
2.4.7.1. Protein dialysis 
Protein samples were dialysed using International dialysis membrane/visking 
tubing (Medicell), cut according to the sample volume. The tubing was 
sterilised by boiling in ultra-pure water for 15 min and then cooled in fresh 
deionised water for 10 min. One end of the tubing was sealed with a plastic 
clip and the sample was dispensed inside. The other end was secured with a 
clip and the tubing was checked for leaks. The sample was placed into 5 L of 
chilled ultra-pure water with a magnetic stirrer for gentle agitation and dialysed 
for 3 h at 4°C. The sample was then placed into fresh chilled ultra-pure water 
(with a magnetic stirrer) for a further 3 h at 4°C. After a final change of water, 
the dialysis was carried out for further 8-12 h at 4°C. The samples were 
carefully removed from the tubing and incubated at 37°C for 1 h to dissolve 
any precipitates.  
2.4.8. Protein concentration 
Dialysed proteins were concentrated using a 10 K 0.5 mL ultra-centrifugal 
filter (Amicon). Five-hundred µL was loaded into the device, which was 
centrifuged at 14,000 x g for 3 min. The filter device was removed, placed 
inverted into a fresh 1.5 mL microtube and centrifuged again for 2 min at 1000 
x g. The concentrated protein was stored at 4ºC. 
2.5. Media and supplements  
2.5.1. Cefoxitin cycoserine egg yolk media (CCEY) 
Forty-eight g CCEY media (Bioconnections) was suspended in 1 L deionised 
water, allowed to soak for 10 min before thoroughly mixing and sterilising by 
autoclaving at 121 C for 15 min. The medium was cooled to 47 C and 2 vials 
of supplements (containing 250 mg cycloserine and 8 mg cefoxitin), 40 mL 
egg yolk emulsion and 10 mL laked horse blood were added. Plates of 25 mL 
were poured and cooled. For some experiments 5 mg/mL lysozyme was 
added to promote spore germination (CCEYL). 
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2.5.2. Brain Heart Infusion (BHI) broth with complements  
Thirty-seven g BHI broth (Oxoid) was dissolved in 1 L deionised water. 
Complements (10 μL 0.5% v/v vitamin K, 5 mg/L hemin, 1mg/L resazurin and 
0.5g/L L-cysteine) were added and the medium was autoclaved at 121°C for 
15 min and cooled ready for use. Hemin stock was prepared by dissolution of 
100 mg hemin and 0.28 g potassium hydroxide in 25 mL ethanol (96%) 
followed by the addition of ultra-pure water to 200 mL and autoclaving at 
121 C for 15 min. 
2.5.3. Reinforced Clostridial Media (RCM) 
Thirty-eight g RCM (Oxoid) was dissolved in 1 L deionised water and 
autoclaved at 121°C for 15 min. The media was then cooled ready for use. 
2.5.4. Agar plates 
To make plates, medium was prepared as described, with 15 g agar base 
(Oxoid). Plates of 25 mL were poured at 50°C.  
2.5.5. Soft agar 
BHI, RCM or L broth were made as previously described but with agar base 
(Oxoid) or agarose (Melford Laboratories) at a concentration of between 0.6 
and 0.7%. Medium was mixed and autoclaved at 121°C for 15 min and used 
once cooled to 50°C. 
2.5.6. Rogosa agar 
Eighty-two g Rogosa medium (Oxoid) was disolved in 1 L deionised water and 
autoclaved at 121°C for 15 min. Plates of 25 mL were poured at 50°C.  
2.5.7. Beeren’s agar 
Fifteen point six g Columbia base agar (Oxoid), 2 g glucose (Sigma), 0.2 g 
cysteine HCl (BDH Prolabo), 2 g agar base (Oxoid), 2 mL propionic acid 
(Sigma) and 16 mL 1 M NaOH (Sigma) were added to 400 mL deionised 
water and autoclaved at 121°C for 15 min. Plates of 25 mL were poured at 
50°C. 
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2.5.8. Bacteroides agar 
Eleven point two g Brucella broth (BD) and 6 g agar base (Oxoid) were 
dissolved in 400 mL deionised water and autoclaved at 121°C for 15 min. The 
medium was cooled to 50°C and 4 mL 0.5 mg/mL hemin solution (Sigma), 80 
µL 5% v/v vitamin K solution (Sigma), 1.2 mL 25 mg/mL kanamycin, 3 mL 1 
mg/mL vancomycin and 20 mL laked horse blood (Oxoid) were added. Plates 
of 25 mL were poured. 
2.5.9. MacConkey agar 
Fifty-two g MacConkey agar (Oxoid) was dissolved in 1 L deionised water and 
autoclaved at 121°C for 15 min. Plates of 25 mL were poured at 50°C.  
2.5.10. Wilkens-Chalgren agar 
Forty-three g Wilkens Chalgren agar (Oxoid) was dissolved in 1 L deionised 
water and autoclaved at 121°C for 15 min. Plates of 25 mL were poured at 
50°C.  
2.5.11. Nutrient agar 
Thirteen g Nutrient broth (Oxoid) and 15 g agar base (Oxoid) were dissolved 
in 1 L deionised water and autoclaved at 121°C for 15 min. Plates of 25 mL 
were poured at 50°C.  
2.5.12. Clostridia agar 
Seventeen point two g Wilkens Chalgren agar (Oxoid) was dissolved in 400 
mL deionised water and autoclaved at 121°C for 15 min. The media was 
cooled to 50°C and 3.2 mL 1 mg/mL novobiocin and 3.2 mL 1 mg/mL colistin 
were added. Plates of 25 mL were poured. 
2.5.13. Slanetz Bartley agar 
Sixteen point eight g Slanetz-Bartley agar (Oxoid) was dissolved in 400 mL 
deionised water, autoclaved at 121°C for 15 min and cooled to 50 C. Plates of 
25 mL were poured. 
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2.5.14. Batch fermentation media 
Batch fermentation medium was made according to previous published 
experiments (Mandalari et al., 2007) as shown in Table 2.9. 
Component g/L 
Peptone water (Oxoid) 2 
Yeast extract (Oxoid) 2 
NaCl (Sigma) 0.1 
K2HPO4 (Fisher Scientific) 0.04 
KH2PO4 (Fisher Scientific) 0.04 
MgSO4.7H2O (Riedel-de-Haën) 0.01 
CaCl2.2H2O (Riedel-de-Haën) 0.01 
NaHCO3 (Fisher Scientific) 2 
Tween 80 (Sigma) 2mL 
Vitamin K 5% v/v aqueous solution (Sigma) 10uL 
Cysteine.HCl (BDH Prolabo) 0.5 
Bile salts (Oxoid) 0.5 
Hemin (Sigma) dissolved in 300 μL 1M 
NaOH (Sigma) 
0.02 
 
Table 2.8. Composition of the batch fermentation media 
 
The components were dissolved in 1 L deionised water and autoclaved at 
121°C for 15 minutes. 
2.5.15. Colon model media 
The medium composition for the colon model system was made as described 
in previous studies of CDI (Baines et al., 2005) and is shown in Table 2.10.  
 
 
 
 
 
 
 
 
79 
 
Component g/L 
Starch 3 
Pectin (Sigma) 2 
Arabinogalactan (Sigma) 1 
Peptone water (Oxoid) 2 
Bile salts (Oxoid) 0.5 
Yeast extract (Oxoid) 2 
NaCl (Sigma) 0.1 
KH2PO4 (Fisher Scientific) 0.04 
MgSO4.7H2O (Riedel-de- Haën) 0.01 
CaCl2.6H2O (Riedel-de- Haën) 0.01 
NaHCO3 (Fisher Scientific) 2 
Cysteine HCL (BDH Prolabo) 0.5 
Hemin (Sigma) dissolved in 300 μL 1M 
NaOH (Sigma) 
0.005 
Tween 80 (Sigma) 2 (mL) 
K2HPO4 (Fisher Scientific) 0.04 
Vitamin K 5% v/v aqueous solution 
(Sigma) 
10 (μL) 
 
Table 2.9. Composition of the colon model media 
 
The components were dissolved in 1 L deionised water and autoclaved at 
121°C for 15 minutes. When cooled to 50°C 0.4 g glucose (Sigma) was added 
to the medium. 
2.5.16. LB broth 
Ten g tryptone (BD), 5 g yeast extract (Oxoid) and 10 g NaCl (Sigma) were 
dissolved in 1 L deionised water, adjusted to pH 7 and autoclaved at 121°C 
for 15 min.  
2.5.17. L broth 
Ten g tryptone (BD), 5 g yeast extract (Oxoid) and 5 g NaCl (Sigma) were 
dissolved in 1 L deionised water and autoclaved at 121°C for 15 min. When 
cooled to 50°C, 1 g glucose was added. 
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2.5.18. Blood agar 
Forty g blood agar base (Oxoid) were dissolved in 1 L deionised water and 
autoclaved at 121°C for 15 min. When cooled to 50°C, 5% oxalated horse 
blood was added and mixed. Plates of 25 mL were poured. 
2.5.19. 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) 
Forty mg was dissolved in 1 mL dimethyl formamide, wrapped in foil and 
stored at -20°C. For blue-white selection, 40 μL was spread onto L agar and 
dried 40 min prior to inoculation with transformation reactions. 
2.5.20. DNase 
In a sterile glass bottle, 100 µL of 1 M Tris, pH 7.5 was added, followed by 30 
µL of 5 M NaCl. This was made up to 20 mL with sterile ultrapure water to 
make the nuclease buffer. Ten milligrams of DNase I (Sigma) was weighed 
into a sterile screw-top vial and 1 mL of the nuclease buffer was added. This 
was allowed to dissolve completely, divided into aliquots of 200 µL and stored 
at -20ºC.  
2.5.21. RNase 
RNase A (Sigma) was made as described in 2.5.20 (10 mg dissolved in 1ml of 
nuclease buffer), but the solution was boiled for 15 minutes prior to storage at 
-20°C.  
2.5.22. Super optimal with catabolite repression (SOC) broth 
Twenty g tryptone (BD), 5 g yeast extract (Oxoid) and 0.5 g NaCl (Sigma) 
were dissolved in 1 L deionised water and autoclaved for 15 min at 121°C. 
When cooled, 10 mL autoclaved 1 M MgCl2 (Fisher Scientific), 10 mL 
autoclaved 250 mM KCl (Sigma) and 27.8 mL filter sterilised 2 M glucose 
(Sigma) was added.  
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2.5.23. Phosphate buffered saline (PBS) buffer 
KCl (0.2 g), 0.2 g KH2PO4, 8 g NaCl and 1.15 g Na2HPO4 were dissolved in 1 
L deionised water and adjusted to pH 7.3. Aliquots were autoclaved for 10 min 
at 115°C. 
2.5.24. Antibiotic stocks 
2.5.24.1. Ampicillin (50 mg/mL stock) 
Ampicillin (0.05 g) (BioGene Ltd) was dissolved in 1 mL deionised water, filter 
sterilised and stored at -20°C. 
2.5.24.2. Clindamycin (9.4 mg doses) 
Clindamycin (0.0094 g) (Melford Laboratories Ltd) was dissolved in 500 μL 
sterile, ultra-pure water and used immediately. 
2.5.24.3. Colistin (1 mg/mL stock) 
Colistin (0.2 g) (Duchefa Biochemie Ltd) was dissolved in 20 mL deionised 
water, filter sterilised and stored at -20°C. 
2.5.24.4. Kanamycin (25 mg/mL stock) 
Kanamycin (0.5 g) (Sigma) was dissolved in 20 mL deionised water, filter 
sterilized and stored at -20°C. 
2.5.24.5. Metronidazole (150 mg doses) 
Metronidazole (0.015 g) (Duchefa Biochemie Ltd) was dissolved in 500 μL 
sterile, ultra-pure water and used immediately. 
2.5.24.6. Novobiocin (1 mg/mL stock) 
Novobiocin (0.02 g) (Sigma) was dissolved in 20 mL deionised water, filter 
sterilised and stored at -20°C. 
2.5.24.7. Rifampicin (25 mg/mL stock) 
Rifampicin (0.5 g) (Duchefa Biochemie Ltd) was dissolved in 20 mL DMSO, 
wrapped in foil and stored at -20°C. 
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2.5.24.8. Vancomycin (1 mg/mL stock) 
Vancomycin (0.02 g) (Duchefa Biochemie Ltd) was dissolved in 20 mL 
deionised water, filter sterilized and stored at -20°C. 
2.5.25. T2 buffer 
Seven point five g K2SO4, 6 g NaCl, 2.25 g KH2PO4 and 4.5 g Na2HPO4 were 
dissolved in 1 L of deionised water. A further 1.5 L deionised water was 
added, mixed and the solution was dispensed into 100 mL aliquots. The 
aliquots were autoclaved at 121°C for 15 min and cooled. One hundred µL 1 
M MgSO4, 1 mL 0.1% gelatine and 1 mL 0.01 M CaCl2 were added to each 
aliquot. 
2.5.26. Tris EDTA (TE) 
A solution of 10 mM Tris and 1 mM EDTA pH 8 was made in deionised water. 
The buffer pH was adjusted depending on requirments, autoclaved and stored 
at ambient temperature. 
2.5.27. Sodium Tris EDTA (STE) 
A solution of 0.1 M NaCl, 10 mM Tris-HCl (pH 8) and 1 mM EDTA (pH 8) was 
made in deionised water, autoclaved and stored at ambient temperature. 
2.5.28. Suspension media (SM) 
A solution of 50 mM Tris, 0.1 M NaCl, 8 mM MgSO4 and 0.01% gelatin was 
made in deionised water. The pH was adjusted to 7.5 before autoclaving at 
121°C for 15 min and cooling prior to use. 
2.5.29. Tris buffered saline (TBS) 
A solution of 10 mM Tris and 150 mM NaCl was made in deionised water. The 
pH was adjusted to 7.5 before autoclaving at 121°C for 15 min and cooling 
prior to use. 
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2.5.30. Tris buffered saline with Tween ± Triton (TBS/Tween/Triton) 
A solution of 20 mM Tris and 500 mM NaCl was made in deionised water. 
Tween 20 (Sigma) at 0.05% v/v was added and when required, 0.05% v/v 
Triton was also included. The solution was autoclaved at 121°C for 15 min 
and cooled prior to use. 
2.5.31. De Man Rogosa Sharpe (MRS) media 
Sixty-two g MRS media (Oxoid) was dissolved in 1 L deionised water, brought 
to the boil, autoclaved at 121˚C for 15 min and cooled prior to use. 
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Chapter 3 - Bacteriophages of C. difficile 
3.1. Abstract 
C. difficile genomes contain a high frequency of prophages and phage 
elements. Prophages can be induced using agents such as mitomycin C and 
norfloxacin, with different chemicals sometimes giving rise to the induction of 
different phages. All C. difficile phages characterised to date contain elements 
that indicate the potential to lysogenise with their host and so far no 
successful attempts at disabling this capacity have been reported. This 
chapter describes the range of C. difficile phages that have been 
characterised and documents efforts to mutate ΦCD27 (a temperate phage 
induced from C. difficile National Collection of Type Cultures 12727) using 
ethylmethane sulphonate, hydroxylamine and sodium pyrophosphate in order 
to hinder or eliminate its ability to lysogenise. 
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3.2. Introduction 
The earliest report of a bacteriophage active against a species of Clostridium 
was in 1934 by Cowles, who isolated a phage of C. tetani from sewage. Since 
then, a variety of both exclusively lytic and lysogenic phages of this genus 
have been described (Dolman and Chang, 1972; Grant and Riemann, 1976; 
Nieves et al., 1981; Roseman and Richardson, 1969; Sebald and Popovitch, 
1967; Shimamura et al., 1974). Some clostridial phages have been shown to 
cross react with different species, such as the C. sordellii phages P50, PL73, 
PL78 and PL81 (Schallehn, 1985), for which activity against C. difficile (strain 
2) was also demonstrated.  
3.2.1. Phages of C. difficile 
With regards to C. difficile, a limited number of phages have been described 
and characterised to date, despite the high frequency of prophage carriage 
(Goh et al., 2007; Horgan et al., 2010; Sebaihia et al., 2006; Shan et al., 2012; 
Stabler et al., 2009). All of the C. difficile phages discovered so far have 
demonstrated lysogenic capacity and or contain typical elements associated 
with lysogeny control, including repressors, anti-repressors and integrases 
(Govind et al., 2006; Mahony et al., 1985; Nagy and Foldes 1991; Sell et al., 
1983; Shan et al., 2012). Goh et al (2005) carried out the first molecular 
characterisation of 4 temperate C. difficile phages, 3 of which were from the 
Myoviridae family (ΦC2, ΦC5 and ΦC8) and 1 Siphoviridae (ΦC6), obtained 
via mitomycin C induction of 56 clinical isolates of C. difficile. All 3 of the 
Myoviridae phages produced clear plaques when tested with sensitive C. 
difficile hosts. In 2007, Fortier and Moineau reported another 3 phages of the 
Myoviridae family, one of which was induced from the hypervirulent NAP1/027 
strain, and a further 5 Siphoviruses from other strains. Both Nagy and Foldes 
(1991) and Fortier and Moineau (2007) also observed numerous tail-like 
proteins in induced concentrated supernatants of C. difficile cultures when 
examined by TEM, even in the absence of intact phage particles. This may 
indicate a high incidence of phage elements in C. difficile genomes rather 
than complete prophages. The first C. difficile phage of the Siphoviridae family 
to be sequenced was by Horgan et al. (2010), and revealed many distinctions 
86 
 
relative to the genomes of Myoviridae phages (Goh et al., 2007; Govind et al., 
2006; Mayer et al., 2008).   
More recently a novel molecular approach has been taken for prophage 
screening in C. difficile (Shan et al., 2012). Using degenerate primers 
targeting the phage holin gene, 15 of 16 C. difficile strains were found to 
harbour a Myovirus prophage, 12 of which were confirmed by TEM analysis 
following prophage induction of the host. Two of these strains also contained 
a Siphovirus, both of which were confirmed by subsequent TEM analysis. 
Interestingly, both norfloxacin and mitomcycin C were used as inducing 
agents and the high frequency of recovery suggests that the use of multiple 
agents increases the chances of phage recovery by prophage induction in C. 
difficile. 
All of the C. difficile phages that have been fully characterised so far have 
been propagated in a sensitive host following a considerable screening effort 
to identify susceptible C. difficile strains. The scarcity of hosts and the 
apparent narrow range of phage activity has somewhat limited the pace of 
study, but by applying molecular screening techniques and sequencing 
technology that can utilise small amounts of target nucleic acid, we can begin 
to explore those that are as yet uncharacterised and correlate this data with 
the phenotypic and virulence traits of the host. 
Much of the interest in C. difficile phages has been concerned with phage 
encoded virulence factors since prophages, like all mobile genetic elements, 
help to drive the evolution of pathogens like C. difficile. The acquisition of 
phage elements can lead to the emergence of hypervirulent strains and 
threaten the efficacy of therapies designed to suppress or eliminate it.  
Identical prophages from inductions have been described in a range of 
hypervirulent NAP1/027 isolates (Fortier and Moineau, 2007), which were 
significantly different from other non-epidemic strains tested. This suggests 
that the carriage of certain prophages may be used to predict the clinical 
severity or pathogenicity of C. difficile strains (Shan et al., 2012) and that 
phage-encoded virulence factors are associated with different phenotypes, 
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despite failure to identify known virulence determinants in any of the C. 
difficile phage genomes.   
In the literature so far, there are no reports of exclusively lytic C. difficile 
phages despite significant efforts to isolate them (Goh et al., 2005; Shan et 
al., 2012). The apparent absence of phages with a solely lytic lifestyle could 
be due to the high incidence of prophages in C. difficile genomes, which may 
impart resistance to further infection refered to as phage immunity (Kutter and 
Sulakvelidze, 2005). Also, a lysogenic relationship is likely to be favoured 
when the host exists for long periods of time as spores, which are not 
amenable to phage infection, as is the case with C. difficile.  
3.2.1.1. ΦCD27 
Phage ΦCD27 was isolated by Mayer et al. (2008), after prophage induction 
of C. difficile NCTC 12727 with mitomycin C.  It has a long straight tail and an 
icosahedral capsid (Fig. 3.1), consistent with other viruses of the Myoviridae 
family (King et al., 2012; Mayer et al., 2008).  Four sensitive hosts (out of 38 
tested) were identified – NCTC 11204, NCTC 11205, NCTC 11207 and NCTC 
11209.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 TEM image of ΦCD27 (Mayer et al., 2008). 
 
 
100 nm 
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3.2.2. Manipulation of phage characteristics 
Some researchers have described mutagenic techniques that have 
successfully disabled the lysogenic capacity of phages. Ethylmethane 
sulphonate (EMS) is an alkylating agent that produces point mutations by 
nucleotide substitution (Masker et al., 1985). The ethyl group of the compound 
interacts with guanine nucleotides to form 06-methylguanine, to which 
polymerases will pair a thymidine rather than a cytosine (Coulondre and 
Miller, 1977). Mutants have previously been described following treatment 
with EMS, including Clostridium spp. (Bowring and Morris, 1985). The 
resulting phenotypes were highly varied across a range of bacterial species, 
(van der Vijver et al., 1975; Zablotny and Fraenkel, 1967). 
Hydroxylamine is another mutagenic agent that acts in a similar manner, 
altering cytosine nucleotides to uracil and resulting in guanine-cytosine 
residues becoming adenine-thymine residues (Levisohn, 1970). Mutations of 
phage using hydroxylamine have been described and include the reversion of 
T4 rII mutants (Levisohn, 1970).  
Sodium pyrophosphate (NaPP) is another agent which, despite extensive use 
in food products and no apparent mutagenic activity (Kim et al., 2010), has 
proved effective at producing deletions in phage genomes. Mutant phages of 
Bacillus subtillis, defective in their ability to lysogenise with their host, were 
identified as clear-plaque phenotypes following treatment with NaPP (Kroyer 
and Dean, 1979). Similarly, lytic derivatives of temperate phages of S. aureus 
and Lactobacillus spp. were isolated following sequential exposures to 100 
mM NaPP (García et al., 2007, 2009; Ladero et al., 1998). 
Mutations that give rise to changes in the bacteriophage components that 
confer specificity, such as the endolysin (Mayer et al., 2011) and tail proteins 
(Scholl et al., 2002) are known to alter host specificity. Phages that infect 
multiple strains, especially common clinical isolates, have greater therapeutic 
potential and this factor may represent a particular problem for C. difficile 
since all the phages described to date exhibit narrow host ranges (Goh et al., 
2007; Goh et al., 2005; Horgan et al., 2010; Mahony et al., 1985; Mayer et al., 
2008; Shan et al., 2012). Mutagenesis using hydroxylamine has previously 
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been successful at altering the host ranges of E. coli phages (Scholl et al., 
2001). 
3.3. Objectives 
 To demonstrate the activity of wild type ΦCD27 vs germinating spores 
of NCTC 11204 using time lapse microscopy 
 
 To mutate ΦCD27 using hydroxlyamine, EMS and NaPP, and to 
generate phenotypes defective in lysogeny. 
 To mutate ΦCD27 using hydroxlyamine, EMS and NaPP, and to 
generate phages with increased host range specificity. 
3.4. Materials and methods 
3.4.1. The potential of ΦCD27 to prevent C. difficile spore outgrowth 
The lytic activity of ΦCD27 can be observed by spot and overlay plaque 
assays (2.2.2). In this section, experiments were also set up to observe this 
action on germinating spores using time lapse microscopy as previously 
described for Clostridium botulinum (Stringer et al., 2005). Spores of C. 
difficile were prepared and purified by density separation using urografin 
(2.1.1.3). Twenty µL was placed onto a defined area of a Superfrost Plus 
electrostatically charged microscope slide and incubated at 2-8˚C for 30 min. 
Slides were then immersed in sterile distilled water to remove any unbound 
spores, air-dried and transferred to the anaerobic cabinet for at least 16 h 
before use. At the beginning of each experiment, 0.6% soft agar in 0.45 µm 
filtered BHI+C broth was melted and cooled to 45˚C. The soft agar was then 
mixed with ~ 1 x 106 PFU/mL ΦCD27 in BHI+C or blank BHI+C in the 
anaerobic cabinet. A coverslip was placed over the agar and was sealed with 
aluminium tape to prevent drying and to make the slide impermeable to 
oxygen. The slides were then transferred to an XZY stage (Marzhauser, 
Wetzlar-Steindorf, Germany) with a PE60 temperature controller held at 37°C 
(Linkham Scientific Instruments, UK) linked to a Leica DMRB optical 
microscope with a stage mounted peltier device (Linkham). Fields were 
observed by phase contrast microscopy using a Leica X40/0.70 numerical 
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aperture and a PL FLUOTAR objective. Stills were captured every 5 min using 
Image Pro Plus image analysis software (Media Cybernetics, USA) and a JVC 
KY-F70 coupled device digital camera. Images for each field were compiled to 
produce an animated sequence. The experiments were carried out 3 times, 
each with a control slide to verify the viability of the spores. 
3.4.2. Mutagenesis 
3.4.2.1. Ethylmethane sulphonate (EMS) 
The method was adapted from procedures previously described (Buxton, 
1976). Thirty µL EMS solution (1 M, Sigma), was added to 2 mL NCTC 12727 
(harbouring ΦCD27) in the exponential phase of growth. The mixture was 
incubated at 37˚C on a rotating platform for 2 h. The cells were harvested by 
centrifugation at 1500 x g for 10 min and washed twice with 10 mL pre-
reduced BHI+C before re-suspending in 2 mL pre-reduced BHI+C. The 2 mL 
of washed cells were added to 50 mL pre-reduced BHI + C, mixed gently and 
incubated for 3 h or until turbid. The culture was induced with mitomycin C as 
previously described (2.2.1) and the supernatant was serially diluted before 
testing in overlay plaque assays with NCTC 11204. Plaque assays with the 
wild-type ΦCD27 were carried out in parallel for comparison of plaque 
phenotype.  
3.4.2.2. Hydroxylamine 
The method used was obtained from The John Roth Laboratory Protocols 
(http://rothlab.ucdavis.edu/) with some modifications. Concentrated phage 
preparations (by PEG precipitation – 2.2.4) containing greater than 107 
PFU/mL re-suspended in suspension medium (SM) (2.5.28) were used for the 
mutagenesis. One mL of the concentrated bacteriophage suspension was 
combined with 2 mL phosphate buffer (0.45 M potassium phosphate and 5 
mM ethylene glycol tetraacetic acid (Sigma) adjusted to pH 5.5 with 
hydrochloric acid (Riedel-de Haën) and 1 mL of the hydroxylamine solution 
(0.35 g hydroxylamine hydrochloride (Sigma), 4.44 mL sterile water and 0.56 
mL of 4 M sodium hydroxide (Sigma)). Every 8 h, phage titres were 
determined by removing a 500 µL portion, centrifuging at 11,000 x g for 150 
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min, re-suspending in 500 µL SM buffer and allowing to re-suspend for a 
further 8 h at room temperature before making serial dilutions and performing 
overlay plaque assays with NCTC 11204. Enumerations were repeated 
approximately every 8 h to determine the point at which 1-1.5% of the original 
titre remain. Mutated phage from the appropriate time point, re-suspended in 
SM buffer, was added to an exponentially growing culture of NCTC 11204. 
After 8 h, the cultures were clarified and the supernatant was passed through 
a 0.45 µm filter. The filtrate was used to carry out overlay plaque assays with 
NCTC 11204 to check for the presence of clear-plaque phenotypes. Plaque 
assays with the wild-type ΦCD27 were carried out in parallel for comparison. 
3.4.2.3. Sodium pyrophosphate (NaPP) 
This method was carried as described previously (Ladero et al., 1998) with 
some modifications suggested by Dr. Pilar Garcia, Instituto de Productos 
Lácteos de Asturias (personal communication). NaPP (0.2 M) was made in 
Tris-HCl, pH 8. C. difficile NCTC 11204 was propagated in RCM broth and 
fresh inductions of ΦCD27 were made from NCTC 12727 grown in RCM 
broth. For these experiments, anaerobic jars were used for the incubations. 
The ΦCD27 preparation was enumerated and diluted to achieve a 
concentration of approximately 1 x 105 PFU/mL. ΦCD27 was exposed to 0, 
10, 25, 50, 75, 100 or 200 mM NaPP for 40 min. Concentrations beyond 200 
mM were not used due to poor solubility. A variety of different incubation 
temperatures were used, ranging from 37°C-51°C. Buffer-only controls were 
carried out with every test to ensure that any reduction in the PFU value was 
due to the NaPP and treatments that gave rise to 5-10% ΦCD27 survival were 
selected. Eight rounds of exposure were carried out, recovering phage by 
plate harvests (2.2.3.1) and enumerating the PFU value after each one. 
Plaque assays with the wild-type ΦCD27 were carried out in parallel for 
comparison. 
3.4.2.4. Identification of clear-plaque phenotypes 
Plaque assays of ΦCD27 were carried out following each round of 
mutagenesis with hydroxylamine, EMS and NaPP. Plates were incubated for 
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5 days and scrutinised using a 10 x magnification lens. Only plaques with 
absence of turbidity were followed up.  
3.4.2.5. Verification of disabled lysogenic capacity 
Clear plaques were excised using a glass Pasteur pipette and incubated in 1 
mL BHI with complements broth for 1 h at ambient temperature with 
occasional gentle mixing. The broth was passed through a 0.45 μM syringe 
filter and the entire filtrate was added to the centre of an agar plate seeded 
with C. difficile. Material from within the zone of lysis was subcultured onto 
BHI agar prior to culture in BHI plus complements broth and induction with 
mitomycin C (2.2.1). Supernatants were tested for the presence of induced 
phage by spot plaque assays (2.2.2.2). 
3.4.2.6. Verification that mutagen exposure gave rise to mutated 
genotypes 
Genomic DNA extracted from wild-type ΦCD27 and ΦCD27 post NaPP 
exposure (1.5 µg) was subjected to restriction digestion using NdeI and 
HindIII (NEB) using the protocol described in 2.3.8. The predicted fragment 
sizes based on the ΦCD27 genome are indicated in Table 3.1. Digestion 
profiles were visualised on a 0.8% agarose gel (65 V for 6.5 h) stained with 
ethidium bromide. 
 
Table 3.1 Predicted restriction profiles of wild-type ΦCD27. 
 
 
 
Restriction 
enzyme 
Number 
of sites 
Fragment sizes (bp) 
NdeI 12 8049, 4060, 5027, 1262, 40, 6345, 1238, 6246, 1451, 
1347, 9078, 6787. 
HindIII 46 755, 438, 65, 607, 992, 251, 307, 601, 33, 243, 472, 
91, 137, 249, 24, 113, 346, 24, 507, 735, 1491, 162, 
252, 138, 1276, 84, 3470, 946, 210, 54, 4315, 1803, 
178, 362, 7520, 5419, 214, 222, 349, 11, 502, 5689, 
639, 5057, 1762, 1815. 
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 3.4.2.7. Screening for mutated ΦCD27 with an extended host range 
 Mutated phage recovered from plate harvests were also tested neat in spot 
plaque assays with a selection of C. difficile strains that were not susceptible 
to wild-type ΦCD27. Strains R23 613 and R23 737 (clinical strains kindly 
provided by Dr. Jonathan Brazier, Anaerobe Reference Unit, University 
Hospital of Wales, Cardiff), DSMZ 12056, NCTC 12730 and environmental 
isolates NNUH-4, NNUH-7 and PIG-ENV (4.5.2) were tested.  
3.5. Results 
3.5.1. The potential of ΦCD27 to prevent C. difficile spore outgrowth 
Time lapse microscopy experiments of C. difficile spores in the presence and 
absence of ΦCD27 showed that the phage was able to prevent outgrowth of 
germinating cells. Examples of the still images obtained are shown in Fig. 3.2 
a-b but the animated sequence was able to show the un-coating of the spores 
just before the cells appeared to lyse.  
    
                  Frame 1 (5 min)                               Frame 200 (16.6 h) 
Figure 3.2 (a). Time lapse microscopy frames showing the germination 
of C. difficile NCTC 11204 spores over 16.6 h in the absence of ΦCD27 
treatment. 
    
                   Frame 1 (5 min)                               Frame 200 (16.6 h) 
Figure 3.2 (b). Time lapse microscopy frames showing no outgrowth of 
C. difficile NCTC 11204 spores over 16.6 h when treated with ΦCD27 (~1 
x 106 PFU). 
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3.5.2. Mutagenesis 
Random mutagenesis techniques on C. difficile NCTC 12727 containing 
ΦCD27 as a prophage were employed in addition to random direct mutation 
of ΦCD27 in the absence of bacterial cells. 
3.5.2.1. EMS 
Induced ΦCD27 from NCTC 12727 mutated with EMS produced plaques of 
varying morphology. These included clear-plaque phenotypes and plaques 
that appeared larger than normal, which were evenly distributed and therefore 
unlikely to be due to variations in the agar thickness. All were followed up but 
reverted to the standard plaque phenotype upon secondary propagation in all 
cases. The capacity for lysogeny was demonstrated by culture of C. difficile 
from the centre of lysis zones and the induction of phage that gave plaques 
with NCTC 11204.  No mutated ΦCD27 that were able to infect C. difficile R23 
613, R23 737, DSMZ 12056, NCTC 12730, NNUH-4, NNUH-7 or PIG-ENV 
were recovered. 
3.5.2.2. Hydroxylamine 
The viability of ΦCD27 decreased rapidly in the presence of hydroxylamine 
relative to the buffer-only control. The exposure time that gave rise to 1-1.5% 
of the original titres was approximately 21-28 h. Hydroxylamine mutagenesis 
was carried out 3 times, during which numerous query clear plaque 
phenotypes were followed up. Material that was cultured from the centre of 
the zones was found to contain C. difficile with inducible ΦCD27 in all cases. 
No mutated ΦCD27 that were able to infect C. difficile R23 613, R23 737, 
DSMZ 12056, NCTC 12730, NNUH-4, NNUH-7 or PIG-ENV were recovered. 
3.5.2.3. Sodium pyrophosphate 
During the first round of mutagenesis, ΦCD27 recovery notably decreased 
after treatment with sodium pyrophosphate at concentrations of 100 mM and 
above. The recovery rates for 100 mM and 200 mM treatments were similar 
(6% and 8.5% respectively) and ΦCD27 treated with 100 mM was selected for 
the second round of mutagenesis. It was expected that recovery rates for a 
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given concentration would increase with each round of treatment, so 50 mM, 
100 mM and 200 mM treatments were used for all 8 rounds and phage from 
the concentration that gave the most appropriate recovery rate was selected 
for the subsequent round (Table 3.2). The incubation temperature was also 
increased for some rounds and the incubation times were extended to up to 
80 min (Table 3.2). Lysogenic C. difficile was isolated from the centre of lysis 
zones confirming that the ability to lysogenize had been retained. No mutated 
ΦCD27 infecting C. difficile R23 613, R23 737, DSMZ 12056, NCTC 12730, 
NNUH-4, NNUH-7 or PIG-ENV were recovered. 
Round Concentration of 
NaPP 
Incubation 
temperature 
Incubation 
time 
Recovery of 
treated 
ΦCD27 
Recovery of 
untreated 
ΦCD27 
1 100 mM 37°C 40 min 6.00% 123.13% 
2 200 mM 42°C 40 min 17.00% 79.91% 
3 200 mM 48°C 40 min 3.30% 62.77% 
4 100 mM 37°C 45 min 2.00% 96.53% 
5 100 mM 37°C 30 min 2.02% 99.68% 
6 100 mM 40°C 45 min 2.77% 82.63% 
7 50 mM 40°C 60 min 3.80% 108.00% 
8 100 mM 40°C 80 min 1.80% 98.00% 
 
Table 3.2. ΦCD27 recovery over 8 rounds of sequential exposure to 
sodium pyrophosphate. 
 
3.5.2.4. Verification that mutagen exposure gave rise to mutated 
genotypes 
Differing restriction profiles were obtained for wild-type ΦCD27 and mutated 
ΦCD27 genomic DNA following digestion with NdeI and HindII (Fig. 3.3). For 
wild-type ΦCD27, many of the bands match predicted fragment sizes 
(detailed in Table 3.1) and many of these were not visualised in the mutated 
ΦCD27 DNA, hinting at multiple mutation sites (indicated in Fig. 3.4 a-b).  
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Figure 3.3. HindIII and NdeI restriction profiles for NaPP treated ΦCD27 
(M) and untreated ΦCD27 (WT) with Hyperladder I (HypI).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Diagrammatic representation of a) HindIII digests and b) NdeI 
digests of wild-type (WT) and NaPP treated (M) ΦCD27. Predicted 
fragments are in grey, with visualised predicted fragments in black. 
Potential sites of mutation are highlighted with a yellow star.  
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3.6. Discussion 
To date, exclusively lytic phages of C. difficile have not been described, and 
possible issues and changes relating to the novel phage isolation are 
discussed in Chapter 4. 
C. difficile spores represent a major challenge for healthcare providers – their 
abundance from patients suffering from CDI and their hardy nature require 
aggressive, continual cleaning to control their spread. In addition to use as a 
therapeutic agent, phages may also be useful as environmental 
decontaminants. The lytic activity of ΦCD27 on spores of NCTC 11204 was 
demonstrated by time lapse phase contrast microscopy and appeared to 
prevent the outgrowth of germinated cells in the 3 replicates tested. Although 
these spores were immobilised in agar and their behaviour may have been 
different in other situations, it can be suggested that phages in the 
environment may be a useful preventative agent against C. difficile outgrowth. 
Also, since the spores were observed to have germinated (rather than 
remained dormant) they would not be expected to be viable following this 
treatment. These observations may have useful applications for 
environmental decontamination in combination with agents that promote 
germination, such as sodium taurocholate (Paredes-Sabja et al., 2008; Sorg 
and Sonenshein, 2008), but also suggests that phage use may be effective in 
the prevention of C. difficile spore outgrowth following ingestion. 
Despite the lytic activity of ΦCD27 against NCTC 11204, lysogens were 
repeatedly isolated from the centre of lysis zones. This feature ultimately 
leads to phage resistance and C. difficile containing the ΦCD27 prophage 
quickly dominate susceptible strains. The mutagenic techniques applied to 
ΦCD27 did not yield any phages that were deficient in their capacity to 
lysogenise with their host. Despite the recovery of plaque phenotypes that 
appeared clear or larger than those previously obtained, secondary 
propagation gave rise to the standard phenotype and all of those investigated 
were able to form lysogens with NCTC 11204.  
Similarly, the mutagenic techniques did not yield any extension of host range 
that permitted infection of DSMZ 12056, NCTC 12730, the clinical strains R23 
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613 and R23 737 or the environmental isolates NNUH-4, NNUH-7 and PIG-
ENV. The decreases in ΦCD27 viability relative to the buffer-only controls, 
observed following treatment with hydroxylamine and sodium pyrophosphate 
were useful indicators of mutagenic action. The demonstration of differing 
restriction profiles of phages have been used by other researchers to confirm 
the presence of mutants (Ladero et al., 1998; McLaughlin et al., 1986), and 
clear differences were observed between wild-type and (sodium 
pyrophosphate) mutated ΦCD27 after NdeI and HindIII digestion, the extent of 
which suggests multiple point mutations following exposure to sodium 
pyrophosphate.  
Lytic mutants were screened for by looking for clear-plaque phenotypes, 
which is an approach taken by many researchers for the detection of phages 
deficient in their lysogenic abilities (Garcia et al., 2009; Kroyer and Dean, 
1979; Ladero et al., 1998; McLaughlin et al., 1986). However, this approach 
may have caused some lytic mutants to escape detection since the 
emergence of phage-resistant C. difficile, via mechanisms other than 
lysogeny, could have caused turbidity within the plaques and masked the lytic 
phenotypes. PCR-based methods to identify disrupted genes of interest may 
offer an alternative screening strategy. 
Due to licencing limitations it was not possible to take a directed mutagenesis 
approach, but this may have increased the likelihood of isolating suitable 
mutants. The regions associated with the establishment and maintenance of 
lysogeny have been well described. The immunity repressor, cI, causes 
suppression of genes associated with lytic growth when it binds to its 
promoter (Trun and Trempy, 2003). The pro-lytic protein, Cro, competes for 
the same promoter site. Other genes within the phage-encoded lysogeny 
‘cassette’ include cII, the product of which is readily degraded by the bacterial 
protease HflA and acts as an indicator of host nutritional status, promoting the 
production of cI (and therefore lysogeny) in times of nutritional depletion. Both 
cI and cII mutants have been identified or produced and are devoid of the 
ability to lysogenise with their host (Pedersen et al., 2010).  A phage-encoded 
integrase enzyme is also required for the establishment of lysogeny (Trun and 
Trempy, 2003) and similarly, mutations within this gene give rise to 
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exclusively lytic phenotypes (Durmaz et al., 2002). Other genetic elements 
that affect lysogeny have been described. Disruption of gene ‘d ’ of Bacillus 
subtilis by site-directed frameshift mutagenesis, gave rise to clear-plaque 
mutants. Interestingly, this gene also conferred host immunity when cloned 
into B. subtilis (McLaughlin et al., 1986).  
The successful disabling of lysogenic capacity, with extension of the host 
range to cover clinically relevant strains, would considerably increase the 
therapeutic potential of ΦCD27. Site-directed mutagenic techniques would 
permit minimal manipulation of the phage by affecting only key genes involved 
in lysogeny and or receptor binding, but practical use may still be limited by 
public resistance to genetically engineered viral particles.   
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Chapter 4 – In Search of Novel Phages 
4.1. Abstract 
Phages represent the richest and most diverse life form on earth and the 
majority of them are yet to be discovered and characterised. This chapter 
details the screening processes adopted and samples tested in an attempt to 
recover and identify new phages infecting C. difficile. No novel C. difficile 
phages were found but recovery methods were validated by isolation of 
phages infecting E. coli and a new phage infecting C. sporogenes was also 
discovered. Potential future modifications to C. difficile phage screening 
methods are discussed.  
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4.2. Introduction 
Phages represent the most abundant life-form known to man and are 
particularly plentiful in soil, rivers, lakes and sewage (Kutter and Sulakvelidze, 
2005). It would seem that only a fraction of bacteriophages that currently exist 
have been unearthed when the results of plaque assays are compared to the 
abundant phage-like particles that are seen using electron microscopy 
(Hendrix, 2002). This is a heartening thought for researchers and clinicians 
that advocate the use of phages for the prevention and remediation of 
bacterial infections, but does indicate that modifications to current isolation 
methods will be necessary to yield those that remain uncharacterised. Indeed, 
double-stranded DNA phages account for approximately 96% of phages that 
have been isolated (Serwer et al., 2004), which may suggest that the current 
methods being used for phage isolation are not appropriate for the detection 
of RNA phages. In addition, plaque assays will fail to identify filamentous, 
non-lytic phages. 
Many phages isolated and characterised to date have been obtained from 
environmental sources such as sewage effluent, sea water or clinical samples 
(Cantalupo et al., 2011; Imamovic et al., 2010; Morales et al., 2012). Up to 107 
phage particles per gram can be found in soil and the faeces of ruminants 
(Furuse et al., 1978) and hundreds of different phage genotypes have been 
obtained from the human gut (Breitbart et al., 2003). Enrichment techniques 
are often employed to amplify low numbers of phage prior to screening via 
spot plaque assays and this approach is recommended when searching for C. 
difficile phages due to the anticipated narrow host range (Nagy and Foldes, 
1991).  
Phages are often sensitive to extremes of pH, making them unsuitable for 
many of the reported virus isolation methods (Seeley and Primrose, 1982), 
but a pH neutral method for the recovery of mammalian viruses and phages 
from water samples using beef extract and ammonium sulphate to recover at 
least 83% of the original phage titre has been described (Shields and Farrah, 
1986). Many other elution buffers have been used, including sodium chloride 
(Ishihara et al., 2006), albumin (Ostle and Holt, 1979), glycine (Hurst and 
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Gerba, 1979) and beef extract (Guzman et al., 2007; Hurst et al., 1991; 
Williamson et al., 2003). 
Prophages can be induced from host bacterial strains (2.2.1), and thus 
provide another source of novel phages. All C. difficile phages characterised 
to date are derived from a host strain based on their lysogenic capacity 
(Fortier and Moineau, 2007; Goh et al., 2005, 2007; Govind et al., 2006; 
Horgan et al., 2010; Mahony et al., 1985; Mayer et al., 2008; Nagy and 
Foldes, 1991; Nale et al., 2012; Sell et al., 1983; Shan et al., 2012). Some 
cross-reactivity between Clostridial hosts has been observed. For example, 
phages of C. sordellii have previously been shown to infect C. difficile 
(Schallehn, 1985), and therefore efforts to find novel C. difficile phages should 
also include inductions from other closely related Clostridial species. Based 
on the phylogenetic relatedness of clostridial 16S rRNA (Collins et al., 1994), 
this should also include C. bifermentans (Fig 4.1).  
 
 
 
 
 
 
 
 
Figure 4.1. Dendrogram of the phylogenetic relatedness of clostridial 
species most similar to C. difficile based on 16S rRNA gene sequences 
(Collins et al., 1994). 
 
Despite the lysogenic capacity of these phages, induced prophages have 
been used successfully in experimental models to prevent and treat bacterial 
infections including C. difficile (Meader et al., 2010; Ramesh et al., 1999). The 
possibility of disabling their integrative ability as part of further development 
ensures them as worthy candidates for investigation. 
 
C. ghonii 
Eubacterium tenue 
C. sordellii 
C. bifermentans 
C. difficile 
C. mangenotil 
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4.3. Objectives 
 To compare the efficacy of a range of buffers for the elution of phage 
from environmental samples. 
 To isolate novel phages infecting C. difficile from a range of 
environmental samples. 
 To isolate novel phages infecting C. difficile from cultures of C. difficile, 
C. sporogenes and C. sordellii induced with mitomycin C. 
 
4.4. Materials and methods 
4.4.1. Sample sources utilised for phage isolation 
Environmental sources from which the isolation of C. difficile could be 
expected were chosen for phage screening. Faecal samples from humans 
and animals represented the majority of samples tested since phage yielded 
from this source would be more likely to survive the conditions of the gut and 
be suitable for therapeutic development. Table 4.1 shows the types and 
numbers of samples screened.  
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Sample type Location Number of  
samples 
Crude strained sewage Norfolk 1 
Crude settled sewage Norfolk 7 
Digested anaerobic sewage Norfolk 1 
Untreated sewage (hospital waste) Norfolk 6 
Water from a duck pond Norfolk 3 
Water from a duck pond Kent 1 
Giraffe faeces Norfolk 1 (pooled) 
Zebra faeces Norfolk 1 (pooled) 
Antelope faeces Norfolk 1 (pooled) 
Sheep faeces Norfolk 1 (pooled) 
Cat faeces Norfolk 1 (pooled) 
Chicken cecum content Yorkshire 5 (pooled) 
Horse faeces Norfolk 1 
Pig faeces and ceca Bristol 7 (pooled) 
Soil Norfolk 13 
Lake water Norfolk 9 
Human faecal samples Norfolk and Norwich 
University Hospital 
42 
Compost liquor Norfolk 2 
 
Table 4.1. Samples tested for the presence of C. difficile phages 
 
4.4.2. Isolation of new C. difficile strains and sample enrichment 
Solid environmental samples (approximately 20 g) were reconstituted using 
200 mL pre-reduced BHI broth with complements, (protecting phage from 
osmotic shock), and warmed to 37 C for 10 min prior to use to disaggregate 
particulate matter. Liquid samples (up to 250 mL) were re-constituted with 
pre-reduced BHI with complements (3 parts sample, 1 part quadruple strength 
BHI with complements to achieve the correct final concentration). Vigorous 
vortex mixing was avoided at all stages of processing as this is known to 
significantly reduce phage viability (Kutter and Sulakvelidze, 2005). Similarly, 
samples were kept out of direct sunlight during processing to preserve viability 
as much as possible.  
Untreated and alcohol shocked samples (2.1.1.3) were plated on pre-reduced 
CCEY agar to isolate C. difficile strains. In the latter stages of the 
environmental screening process, the CCEY agar was supplemented with 5 
mg/L lysozyme as this has been shown to enhance spore germination and 
recovery of C. difficile (Wilcox et al., 2000). Environmental samples were kept 
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in the anaerobic cabinet (Don Whitley Scientific) overnight to maintain 
anaerobic conditions and, where possible, separate aliquots were stored at 2-
8˚C. The following day the environmental samples were enriched with any 
putative C. difficile strains yielded from that particular source. In addition, 
strains NCTC 11204, NCTC 11207 (derived from neonatal meconium), DSMZ 
12056 (derived from the rumen of a lamb) and R23 613 (a clinical strain of 
ribotype 027 kindly donated by Jonathan Brazier, Anaerobe Reference Unit, 
University Hospital of Wales, Cardiff) were inoculated into each sample to be 
enriched. It has been documented that phages may not replicate if the 
population of host bacteria is below 103-105 cells per mL (Kutter and 
Sulakvelidze, 2005), and so environmental samples were inoculated with at 
least 106 CFU/mL C. difficile based on OD600 readings for NCTC 11204. It was 
estimated that an incubation period of 48 h should be sufficient to permit good 
growth of the host C. difficile strains, allow the phage to adsorb, infect and 
liberate the progeny (Kutter and Sulakvelidze, 2005).  
 
An overview of the methods used in an attempt to isolate novel phages is 
summarised in Fig. 4.2. 
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Figure 4.2. An overview of the methods used to isolate novel phages. 
 
4.4.3. Enhancing phage adsorption 
Following the inoculation of C. difficile enrichment strains, phage adsorption 
was enhanced by the addition of 10 mM calcium chloride and magnesium 
chloride to the environmental samples, as previously reported (Havelaar and 
Hogeboom, 1983). 
4.4.4. Elution of phages 
In order to determine the method that would elute the greatest proportion of 
phages from environmental samples, 12 g portions of soil were sterilised in 
Faeces (20 g) 
Add 1 part quadruple strength pre-
reduced BHI for every 3 parts sample 
Add elution buffer and mechanically agitate for 2-3 h 
 
Isolate C. difficile strains and culture in BHI  
Strains 
induced with 
mitomycin C 
in search of 
prophages 
Clarify by centrifugation and concentrate with PEG. Pass through a 0.45 
µm syringe filter 
Streak plate onto 
CCEYL agar 
Soil (20 g) Water 
(200 mL) 
Add 200 mL pre-reduced 
BHI  
  
Alcohol shock a 1 
mL aliquot 
  
Alcohol shock a 1 
mL aliquot 
    
  
  
Enrich samples with ~106 CFU/mL isolated C. difficile 
strains (plus selected C. difficile strains as detailed in 
4.4.1.2.) and incubate anaerobically for 48 h 
  
   
Test filtrate for activity against selected 
C. difficile strains via spot plaque assay. 
Analyse by TEM 
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Duran bottles and allowed to cool before being spiked with 2 mL of a 
suspension containing 1.275 x 106 PFU/mL of ΦCD27. The samples were 
then stored at 4°C for 24 h, and then equilibrated to ambient temperature for 
30 min. One hundred mL of each test elution buffer was added to the spiked 
soil samples, and the mixtures were left to agitate on a magnetic stirrer 
(medium speed) for 1 h 45 min at room temperature.  
Phage elution buffers documented in previous work were selected for 
comparison (listed in Table 4.2). Concentrated buffers were added to give the 
required final concentration and stirred gently with a magnetic stirrer or on a 
rotating platform for 1 h 45 min.  
The elution protocol for buffer 11 required sequential additions to bring about 
the formation of a floc (Shields and Farrah, 1986) rather than simple agitation 
and recovery. Beef extract (to give a final concentration of 2% w/v) was added 
followed by 2 volumes of saturated ammonium sulphate to give rise to a floc 
containing phage. Centrifugation was carried out to pellet the floc at 14,000 x 
g for 20 min (at 4˚C). The pellet was re-suspended in 20 mL sterile distilled 
water before PEG precipitation (2.2.4). 
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Elution 
buffer 
Buffer composition pH Reference Reported 
recovery 
rate 
1 0.025 M glycine 2 Modified from Hurst & Gerba, 1979 66% 
2 0.025 M glycine 7 This work NA 
3 0.025 M glycine 10 This work NA 
4 2% beef extract 7 Williamson et al., 2003*; Hurst et 
al., 1991 and Guzman et al., 2007 
26%* 
5 2% beef extract & 
0.025 M glycine 
7 This work based on the findings of 
Williamson et al., 2003 
NA 
6 Saline ND This work NA 
7 Sterile distilled water ND This work NA 
8 0.05 M magnesium 
chloride 
ND This work N/A 
9 0.05 M calcium 
chloride 
ND This work NA 
10 1% albumin  ND Modified from Ostle and Holt, 1979 0.2% 
11 10% beef extract & 
saturated ammonium 
sulphate 
7 Shields and Farah, 1986 >83% 
12 0.06 M ammonium 
acetate 
ND Modified from Ostle and Holt, 1979 0.2% 
13 0.001 M sodium 
chloride  
ND Modified from Ishihara et al., 2006 NA 
14 0.1 M sodium 
chloride  
ND Modified from Ishihara et al., 2006 NA 
15 0.5 M sodium 
chloride  
ND Modified from Ishihara et al., 2006 NA 
16 1 M sodium chloride  ND Modified from Ishihara et al., 2006 NA 
17 1.25 M sodium 
chloride  
ND Modified from Ishihara et al., 2006 NA 
18 2.5 M sodium 
chloride  
ND Modified from Ishihara et al., 2006 NA 
19 BHI + complements ND This work NA 
 
Table 4.2. Elution buffers used to evaluate ΦCD27 recovery. Samples 
were plated in triplicate using overlay plaque assays. ND: not 
determined. NA: not applicable. 
 
4.4.5. Recovery of eluted phages 
The samples were clarified by centrifugation at 1500 x g for 5 min, 
concentrated by PEG precipitation (2.2.4) in 20 mL aliquots and filtered using 
a 0.45 µm syringe filter before being tested undiluted in spot plaque assays.  
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In the latter stages of the environmental screening period, samples were also 
tested directly following clarification in spot plaque assays. For phage 
recovery and survival experiments, serial dilutions of the filtered supernatants 
were made to 10-4 in BHI + C, and 100 µL aliquots of these were used for 
PFU enumeration in an overlay plaque assay. 
In order to determine if there were any detrimental effects of PEG precipitation 
on phage viability, a 20 mL sample of ΦCD27 at a known titre (5 x 106 
PFU/mL) was subjected to PEG precipitation (2.2.4) and then reconstituted to 
20 mL in BHI + C broth. The viable titres of the original and PEG precipitated 
samples were determined by serial dilution and overlay plaque assays in 
triplicate. 
4.4.6. Survival and recovery of phages. 
In order to evaluate the likely survival rates of phages in sewage samples, 10 
mL aliquots of crude strained sewage, crude settled sewage and anaerobic 
digested sewage were spiked with ΦCD27 and mixed gently but thoroughly. 
One of each sample type was kept at room temperature. Plaque assays 
(overlay method) were carried out at time 0, 3 days, 1 week, 10 days and 2 
weeks post inoculation. These experiments were designed to ascertain an 
approximate maximum period of time that phages would remain viable during 
storage in the original sample.  
The pH stability of ФCD27 was determined by adjusting the pH of 10 SM 
aliquots to pH 1-10, adding 1 x 106 PFU ФCD27 and incubating at room 
temperature for 5 h. Aliquots were then tested for viable phage by triplicate 
overlay plaque assay (2.2.2.1).  
4.4.7. Validation of phage recovery methods 
In order to verify that the methods employed resulted in the isolation of viable 
phage from the environmental samples, the levels of E. coli phage (expected 
in abundance) were quantified in parallel with the screening tests using E. coli 
K12 (kindly provided by D. Hatziioanou). Samples that yielded no or very few 
E. coli phages were re-tested if possible. Environmental samples were not 
enriched with E. coli K12. 
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4.4.8. Induction of Clostridium species to search for novel prophages 
Strains of C. difficile from the culture collection and those isolated from 
environmental and clinical sources, were grown to mid-log phase and induced 
with mitomycin C (2.2.1). The resulting supernatants were concentrated by 
PEG precipitation, submitted for TEM analysis and tested for phage activity on 
lawns of C. difficile strains from the collection.  
Laboratory strains of C. sordellii ATCC 9715 and NCTC 13356 were also 
induced and included in the screening as it was considered that phages 
induced from closely related strains may infect C. difficile. In separate 
experiments which focused on screening for phage endolysin activity against 
a range of Clostridium spp, a strain categorised as C. sporogenes in the 
laboratory culture collection (C22-10) was found to be sensitive. This 
prompted the screening of induced supernatants of other C. sporogenes 
strains in search of phages that may cross-infect C. difficile. These comprised 
of strains BL81-04, BL84-18, BL84-17 and BL02-01. It was subsequently 
found, following 16S RNA sequencing, that C22-10 was in fact C. 
bifermentans.  
4.4.9. Enhancing plaque clarity and plaque size 
Calcium chloride (10 mM) and glycerol (5% v/v) were added to agar plates 
and soft top agar, used for environmental and prophage screening tests. It 
has previously been demonstrated that the addition of calcium chloride (10 
mM) increases the size and clarity of coliphage plaques in the overlay plaque 
assay method (Havelaar and Hogeboom, 1983). Similarly, the addition of 5% 
(v/v) glycerol to solid media has also been shown to increase the size of 
phage plaques, making them more clearly discernible (Santos et al., 2009). 
Although this study also reported that the use of sub-inhibitory levels of 
antibiotics could also improve plaque clarity and viral yield, it was decided not 
to adopt this approach as the sensitivity of environmental strains was 
undetermined and may be very low due to the lack of antibiotic exposure. 
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4.4.10. Ethical approval 
Since this study used human clinical faecal samples, advice as to whether this 
project required full ethical approval was sought from the Local and Regional 
Ethics Committee (LREC). As no information regarding the patients’ 
demographics or clinical history was used and the samples were discarded 
after the testing period, no approval was required. The LREC advice can be 
found in Appendix 2. 
4.5. Results 
4.5.1. Validation of phage isolation methods 
Environmental samples processed for the detection of novel C. difficile 
phages were first tested for the presence of phages infecting the E. coli strain 
K12 in order to verify that the sample contained viable phages. Phages 
infecting E. coli K12 were not isolated from all processed environmental 
samples. Two samples of lake water, two soil samples and one human faecal 
sample were subjected to repeat attempts at isolation but were not 
successful. Fig. 4.3 shows a typical K12 spot plaque assay and Fig. 4.4 
illustrates the range of recovery rates obtained from the environmental 
samples.  
 
Figure 4.3. Spot plaque assay of crude settled sewage samples using 
E.coli K12 as the indictor. 
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Figure 4.4. Mean recovery of E.coli K12 phages from environmental 
samples ± SD. Bars in black represent sources for which only one 
sample was tested. 
 
It is not clear if negative samples did not contain any K12 phages, or that the 
isolation methods used affected the viability of these phages. A processed 
crude settled sewage sample (negative for K12 phages) was submitted for 
TEM analysis and showed the presence of numerous phage particles (Fig. 
4.5).  
 
 
Figure 4.5. Phage particles seen in a processed sample of crude settled 
sewage 
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4.5.2. Recovery of C. difficile strains 
C. difficile strains were successfully isolated from alcohol shocked human 
faecal samples and pig faeces, as shown in Table 4.3. Their identity was 
confirmed by 16S rRNA gene sequencing and matching to the NCBI database 
using BLAST (Altschul et al., 1990; Zhang and Madden, 1997; Zhang et al., 
2000).  
C. difficile strain isolated Source 
NNUH-1 Human faecal sample 
NNUH-2 Human faecal sample 
NNUH-3 Human faecal sample 
NNUH-4 Human faecal sample 
NNUH-5 Human faecal sample 
NNUH-7 Human faecal sample 
NNUH-8 Human faecal sample 
PIG-ENV Pig faeces 
 
Table 4.3. C. difficile strains isolated from environmental and faecal 
samples 
 
4.5.3. Elution of phages from particulate matter 
Fig. 4.6 shows the results of the phage elution experiments using samples 
spiked with ΦCD27. This indicates that the overall recovery rate is low but 
generally better at neutral pH values. Sodium chloride (1 M) gave the greatest 
recovery level, with a mean yield of 65.1% (n=3). The elution experiment 
incorporating the use of beef extract and ammonium sulphate failed to yield a 
floc that could be harvested and was therefore not included in the elution 
results. 
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Figure 4.6. Elution of ΦCD27 from spiked soil samples with a range of 
elution buffers ± SD. 
4.5.4. Survival and recovery experiments 
Levels of ΦCD27 in spiked sewage samples decreased rapidly over 20 days 
relative to the control BHI with complements, with undetectable levels in crude 
settled sewage after this time period (Fig. 4.7). In the sewage samples, the 
mean recovery plummeted to 0.18% of the original titre by day 12. Although 
the purpose of these experiments was to assess viability of phage in these 
samples, it is not known to what extent the elutive capacity decreased over 
the 20 days.  
After 5 h at pH 1-2 no ФCD27 could be recovered, and only low recovery 
(mean 14.1%) was demonstrated at pH 3. At pH 4 81% of phage was 
recovered and 100% was recovered between the range 5-8. At pH 9-10, no 
ФCD27 could be isolated. These results are illustrated in Fig. 4.8. 
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Figure 4.7. Recovery of ΦCD27 from spiked sewage and BHI media over 
20 days at room temperature.          = Crude sewage,          =  crude 
settled sewage,          = anaerobically digested sewage,            = BHI. 
 
Figure 4.8. Recovery of ФCD27  between pH 1-10. Result are means of 
triplicate counts ± SD. 
4.5.5 Enhancement of plaque size and clarity 
The plaques that were observed after testing with 10 mM CaCl2 added to the 
molten agar in spot and overlay assays appeared larger and were of improved 
clarity relative to the other plaque assays. Concentrations above this caused 
precipitation in the media and actually obscured the visibility of lytic activity. 
The addition of 5% glycerol was also useful for enhancing the visibility of 
phage plaques. 
4.5.6. The effect of PEG precipitation on phage viability 
Concentration of phages by PEG precipitation was found to reduce the 
recovery and detection efficiency by 41.5% (± 8.3) (n=3). 
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4.5.7. Recovery of phages infecting C. difficile 
No free-living lytic phages specific for C. difficile NCTC 11204, NCTC 11207, 
DSMZ 12056, R23 737 or any of the environmental strains were recovered, 
although many putative plaques from spot assays of neat clarified 
environmental samples were followed up. Defined plaques were subsequently 
not identified in overlay plaque assays, and in all cases, any antimicrobial 
activity against C. difficile was nullified following neutralisation of the 
supernatant, indicating that any activity may be due solely to organic acids.  
4.5.8. C. difficile prophage inductions 
Table 4.4. shows the OD600 values of C. difficile cultures before and after 
induction with mitomycin C. The release of prophages was anticipated to 
cause a decrease in the OD600 due to lysis of the host cells as phage particles 
are liberated. With the exception of NCTC 12727, from which ΦCD27 of the 
Myoviridae family is derived (as shown in Fig. 4.9 a), no decreases were 
observed. NCTC 11307 (strain 630) has 2 known prophages described in the 
literature (Goh et al., 2007; Sebaihia et al., 2006), but did not show a 
decrease in OD600 following mitomycin C induction. Despite this, the level of 
growth post induction was minimal, indicated by an increase in OD600 of only 
0.02 and was consistent with the release of phage particles as shown by TEM 
analysis (Fig. 4.9 b). The phage particles observed are consistent with 
Myoviridae morphology, as previously described (Fortier and Moineau, 2007; 
King et al., 2012).  
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C. difficile strain OD600 before 
induction with 
mitomycin C 
OD600 2 hours 
post induction 
with mitomcyin C 
Electron microscopy 
observations 
12727 (1 known 
prophage) 
 
0.200 
 
0.110 
Phage particles seen 
11209 0.894 1.536 No phage particles 
12733 0.748 1.382 No phage particles 
11208 0.555 1.092 No phage particles 
12731 0.397 0.937 No phage particles 
12730 0.615 1.098 No phage particles 
11205 0.691 1.302 No phage particles 
12734 0.264 0.561 No phage particles 
11382 0.585 1.064 No phage particles 
11206 0.462 0.750 No phage particles 
12732 0.246 0.820 No phage particles 
12728 0.427 1.179 No phage particles 
12726 0.210 0.963 No phage particles 
12729 0.615 1.412 No phage particles 
 R23 720 0.711 1.378 No phage particles 
R23 635 0.233 0.890 No phage particles 
R23 524 0.395 1.040 No phage particles 
R23 613 0.380 1.022 No phage particles 
R23 521 0.346 0.908 No phage particles 
R23 621 0.545 1.239 No phage particles 
R23 639 0.337 0.964 No phage particles 
R23 614 0.655 1.169 No phage particles 
R23 642 0.385 0.972 No phage particles 
R23 737 0.186 0.756 No phage particles 
R23 732 0.651 1.05 No phage particles 
R23 727 0.671 1.118 No phage particles 
G83/07 0.211 0.757 No phage particles 
1787 0.107 1.193 No phage particles 
11207 0.320 1.111 No phage particles 
11223 0.145 0.812 No phage particles 
11307  
(2 known prophages) 
1.297 1.299  
Phage particles seen 
DSMZ 12056 0.324 1.341 No phage particles 
DSMZ 12057 0.467 1.111 No phage particles 
NNUH-1 0.366 0.722 No phage particles 
NNUH-2 0.450 0.620 No phage particles 
NNUH-3 0.450 0.869 NS 
NNUH-4 0.692 0.785 NS 
NNUH-5 0.332 0.963 NS 
NNUH-7 0.568 0.959 NS 
NNUH-8 0.566 0.758 NS 
PIG-ENV 0.411 0.771 NS 
 
Table 4.4. 0D600 values of C. difficile cultures before and after induction 
with mitomycin C. (Samples were diluted 1 in 10 prior to reading and 
corrected thereafter.) NS = not screened by electron microscopy. 
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Figure 4.9. Phage particle of the Myoviridae family observed by TEM 
after induction of a) C. difficile NCTC 12727 and b) C. difficile NCTC 
11307. 
 
4.5.9. Plaque assays using concentrated induced supernatants of C. 
difficile. 
Only ΦCD27 gave plaques when added to C. difficile NCTC 11204 (shown in 
Fig. 4.10), NCTC 11205, NCTC 11207 and NCTC 11209. No other 
susceptible hosts were identified. No phage activity in any other induced 
supernatants (including 11307) was observed when cross tested with all 12 C. 
difficile isolates in the collection.  
 
Figure 4.10. Plaques caused by ΦCD27 on a lawn on C. difficile NCTC 
11204. 
 
 
 
 
a b
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4.5.10. Prophage inductions from other Clostridium spp.  
4.5.10.1. C. sporogenes  
Table 4.5. shows the optical density results obtained when 5 C. sporogenes 
strains were induced with mitomycin C. As previously described, strain C22-
10 was found to be a C. bifermentans strain erroneously categorised as C. 
sporogenes.  
C. 
sporogenes 
OD600 before 
induction with 
mitomycin C 
OD600 2 h post-
induction with 
mitomycin C 
Electron microscopy 
observations 
BL81-04 1.1 1.478 No phage particles 
BL84-18 0.834 1.446 No phage particles 
BL84-17 1.074 1.474 No phage particles 
BL02-01 1.2 1.9 Phage particles seen 
 
Table 4.5. OD600 values of C. sporogenes strains before and after 
induction with mitomycin C. 
 
The phage yielded as a result of mitomycin C induction of C. sporogenes 
BL02-01 (ΦCS01) is shown in Fig. 4.11. The approximate length and width of 
the prolate particle head was 110 nm and 40 nm respectively. The tail 
appeared to be quite flexible with transverse striations, and measured 300 nm 
in length and 12 nm in width. This morphology indicates that the phage could 
be a member of the Siphoviridae family (Fortier and Moineau, 2007; King et 
al., 2012).  
 
Figure 4.11. TEM of ΦCS01, induced from C. sporogenes BL02-01. 
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Only ΦCS01 produced plaques when the induced supernatant was tested in 
plaque assays with C. sporogenes BL81-04. No phage activity was observed 
with any C. difficile strains in the collection. 
4.5.10.2. C. sordellii 
Two strains of C. sordellii were also induced in search of novel prophages that 
may infect C. difficile. The pre- and post-induction OD600 values are given in 
Table 4.6).  
C. sordellii OD600 before induction 
with mitomycin C 
OD600 2 hours 
post-induction 
with mitomycin C 
Electron microscopy 
observations 
ATCC 9715 0.679 1.983 N/A 
NCTC 13356 0.721 1.417 N/A 
 
Table 4.6. The OD600 values of C. sordellii strains before and after 
induction with mitomycin C. 
 
No phage activity was observed with any of the C. sordellii induced 
supernatants versus all of the C. difficile strains in the collection. 
 
4.5.10.3. C. bifermentans 
No phage particles were observed upon induction of C. bifermentans C22-10 
with mitomycin C (Table 4.7). 
 
C. bifermentans OD600 before 
induction with 
mitomycin C 
OD600 2 h post-
induction with 
mitomycin C 
Electron microscopy 
observations 
C22-10 1.2 1.350 No phage particles 
 
Table 4.7. The OD600 values of the C. bifermentans strain before and after 
induction with mitomycin C. 
 
No phage activity was observed with the C. bifermentans induced supernatant 
versus all the C. difficile strains in the collection. 
 
 
 
121 
 
4.6. Discussion 
C. difficile strains were successfully isolated from 7 out of 42 human faecal 
samples and 1 out of 7 pig faeces/cecum samples. This identification was 
initially based simply on the morphology of the colonies on CCEY to expedite 
processing in the interest of preventing significant sample deterioration, owing 
to the poor survival of phage demonstrated in separate experiments, but was 
later confirmed by 16S sequencing.  
Enrichment of environmental samples with selected laboratory strains and any 
strains derived from the sample itself was believed to be the best strategy for 
phage recovery, but no novel lytic C. difficile phages infecting any strain in the 
collection were isolated. Enrichment may not support all phages found in the 
environment, as previously observed (Ashelford et al., 2003). Some 
researchers omit any enrichment or purification step when searching for novel 
phages and simply introduce environmental samples directly into overlay 
plaque assays (Serwer et al., 2004). Despite some obscurity and ambiguity of 
plaques due to the particulate material, this approach proved successful for 
the isolation of phages infecting Bacillus subtilus and other bacterial genera, 
whilst the same sample tested by liquid culture enrichment yielded no phages 
(Serwer et al., 2004). This finding, together with the poor survival rates 
demonstrated for phage in sewage samples (which also validate the need for 
expedited testing), suggests that unprocessed samples used promptly in 
screening assays may have yielded better results. However, to date no non-
lysogenic phages infecting C. difficile have been described in the literature, 
which does seem to suggest scarcity, absence, extremely narrow host ranges 
or the need to modify isolation techniques.  
In the majority of cases, the processing and concentration of environmental 
samples yielded viable phage, as demonstrated by the detection of E. coli 
K12 phages. The isolation of K12 phages was not successful in all cases, 
even despite repeat attempts. This may reflect a genuine absence of this type 
of phage or highlight a problem with the isolation methods applied to the 
sample, therefore invalidating negative C. difficile phage screening results. 
Indeed, the recovery experiments indicate that despite best efforts, only 
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65.1% of phage from spiked samples could be recovered, and this may be 
further lessened in samples for which strong interactions between phage and 
particulate material have occurred. Significant batch to batch variations in the 
reagents used for phage recovery have previously been demonstrated 
(Katzenelson et al., 1976; Payment et al., 1984; Shields and Farrah, 1986). In 
particular, the use of some batches of beef extract did not result in the 
formation of a floc, while with other batches a thick floc rich in bacteriophages 
could be observed (Shields and Farrah, 1986). The beef extract used to 
reproduce this work did not give rise to a floc and may therefore be explained 
by this observation. In addition to reagent variability, it was not feasible to 
agitate (gently on a rotating platform) the enriched environmental samples 
during incubation due to the limited electrical supply inside the anaerobic 
cabinet used for these experiments. By introducing sample agitation, the 
chances of phage-host interaction may have been increased and with it the 
possibility of isolating a novel phage. Changes to the method of phage 
concentration such as extending the PEG incubation period to 12-15 h may 
also have improved phage yield (Kutter and Sulakvelidze, 2005).  
Several other observations relating to environmental screening techniques 
have come to light that may go some way to explain the lack of C. difficile 
phage recovery. In addition to the inefficiencies of elution, filtration has been 
shown to reduce the yield of phage by up to 20% (personal communication 
with Chloe James, University of Liverpool). Similarly, a closer look at the 
effect of PEG precipitation indicated that a reduction of up to 45.1% in the titre 
of viable phage could be seen. Future tests should also include a chloroform 
(and/or an ether) exposure step to break open infected cells in case the 
conditions of the environmental sample are not permissive to lysis (Kutter and 
Sulakvelidze, 2005). This step would also reveal any phages that trigger an 
abortive infection system, instructing bacterial cell death in response to 
infection, which may have hidden positive results in the screening tests. Some 
groups have shown that, depending on the conditions, infecting phage 
particles may not be able to lyse and release new phage particles (Kutter and 
Sulakvelidze, 2005). Although this adaptation would sacrifice phages 
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containing a lipid envelope, these would be of negligible use in a gut 
environment.  
The environmental screening was carried out from October 2007 to March 
2008. The proportion of phage particles relative to the levels of bacteria in 
environmental samples has been shown to vary depending on the season, 
with up to ten-fold fewer in winter (Kutter and Sulakvelidze, 2005). This may 
be due to the induction of prophages in summer as a result of the UV light. 
Despite the abundance of phage in environmental sources such as soil, these 
samples are comprised of multiple microenvironments, which vary depending 
on the level of rainfall, temperature and the presence of different biofilms and 
binding agents such as clay. No evaluation as to the presence or abundance 
of such compounds was undertaken but may have influenced phage recovery.  
The environmental screening methods were phenotypic and so quite time 
consuming. If it were possible to identify the presence of phage genes 
permitting attachment to (and subsequent infection of) C. difficile hosts based 
on sequence similarity to known C. difficile phages, the screening rate could 
be considerably increased.  
In addition to environmental sampling, induced strains of C. difficile were 
concentrated and examined by electron microscopy for evidence of phages, 
plus they were screened against the entire laboratory collection of C. difficile 
strains for signs of lytic activity. This approach was successful in obtaining a 
prophage of C. sporogenes (ΦCS01) which infects C. sporogenes BL81-04 
but no phages infecting C. difficile were detected, despite the high incidence 
of prophages in C. difficile genomes (Fortier and Moineau, 2007; Goh et al., 
2005; Govind et al., 2006; Horgan et al., 2010; Mahony et al., 1985; Mayer et 
al., 2008; Nagy and Foldes, 1991; Nale et al., 2012; Sell et al., 1983; Shan et 
al., 2012). Successful alternative inducing agents have been described 
including UV light (Rambler and Margulis, 1979) and norfloxacin (Shan et al., 
2012). Other studies have used temperature, pressure (Kutter and 
Sulakvelidze, 2005) and even plant extracts (Erskine, 1973). Reports show 
that by using a variety of inducing agents, different profiles of phages can be 
induced from the same collection of host strains (Shan et al., 2012).  
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Adaptations to the sample processing protocol prior to analysis by electron 
microscopy could have aided the screening process and increased the 
chances of finding novel phages. Wash steps using ammonium acetate 
followed by centrifugal sedimentation has been recommended by Kutter and 
Sulakvelidze (2005). This may have reduced the background artefacts, which 
may have impeded clear identification of phage particles. It may also be 
possible that unusual phage morphologies could have been missed in the 
screening process.  
In summary, no novel phages infecting C. difficile were discovered despite 
testing a large number of samples from different sources and attempts to 
improve phage isolation protocols. This work has highlighted the need for new 
approaches to environmental screening for C. difficile phages and the 
incorporation of alternative inducing agents when searching for prophages.  
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Chapter 5 – Modelling phage therapy of C. difficile infection using batch 
fermentations. 
5. 1. Abstract 
An in vitro batch fermentation model of acute C. difficile infection was used to 
evaluate the effect of a prophylactic and a remedial bacteriophage treatment 
regime. It was demonstrated that the prophylaxis regime was effective at 
restraining the growth of C. difficile (p = <0.001) and considerably suppressed 
the production of toxins A and B. The remedial treatment regime caused a 
less profound and somewhat transient decrease in the number of viable C. 
difficile cells (p = <0.0001), but still resulted in a lower level of toxin production 
relative to the control. The numbers of commensal bacteria including total 
aerobes and anaerobes, Bifidobacterium spp., Bacteroides spp., Lactobacillus 
spp., total Clostridium spp. and Enterobacteriaceae suffered no detrimental 
effect as a result of phage therapy, whereas significant decreases were 
observed following metronidazole treatment, the current recommended 
treatment for uncomplicated C. difficile infection.  
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5. 2. Introduction 
The human gut hosts a rich, diverse population of organisms and disruption of 
these complex communities is associated with the onset of C. difficile infection 
plus a wide range of other pathologies including allergies and colorectal 
cancer (Prakash et al., 2011). The dynamics and functionality of these 
organisms are imperative to the health of the human host and evidence on 
specific groups and their associated benefits is mounting (Chassard et al., 
2008; Freeman et al., 2003; Hopkins and Macfarlane, 2002; Parkes et al., 
2009; Rehman et al., 2012). These functions include vitamin synthesis 
(Chassard et al., 2008) and immunomodulatory effects (Schiffrin et al., 1995) 
and are described in more detail in 1.7.4. It is therefore crucial to assess the 
impact of any proposed therapeutic agent on the commensal microbiota and 
this is particularly poignant for CDI, in which the diseased state arises 
following antimicrobial treatment and the subsequent disruption to the gut 
flora. It is also essential to assess the activity of therapeutic agents and their 
effect on the target pathogen in conditions simulating those in vivo as the 
abundance of microbial flora, associated metabolites, neutralising proteins 
and surfactants may impede or inhibit activity. 
Batch fermentations offer a simple preliminary in vitro model system for 
observing the performance of therapies in the distal colon (Possemiers et al., 
2005; Salminen et al., 1998). Culture of the major bacterial groups from these 
models has been used to enumerate the effects of interventions on the 
microbiota (Olano-Martin et al., 2000), the prebiotic effects of some functional 
foods (Mandalari et al., 2007, 2008; Saulnier et al., 2008; Stewart et al., 2008) 
and also the fate of enteric pathogens such as Salmonella spp. (Martin-
Pelaez et al., 2008; Meimandipour et al., 2009). They have also been used 
previously to represent CDI and to investigate potential therapeutic agents. 
(Rea et al., 2007). This group used simple faecal fermentations in an 
anaerobic chamber to determine the activity of the lantibiotic lacticin 3147 
against C. difficile strains, and demonstrated a decrease to below the limit of 
detection by culture. They also monitored the effect on the commensal 
microbiota by culture and recorded a 3 log10 decrease in the numbers of 
Bifidobacterium spp. and Lactobacillus spp. as a result of the lacticin 
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treatment. These groups are thought to confer colonisation resistance against 
C. difficile (Freeman et al., 2003) and so these results are not conducive to 
the prevention of CDI recurrence. No pH control was included in these 
fermentations and since clostridia are known not to grow well in acidic 
conditions (Gibson and Roberfroid, 1995) and the growth of lactic acid 
bacteria would be expected to cause a reduction in the pH, this may have 
contributed somewhat to the inhibition of C. difficile under these conditions.  
ФCD27 is a bacteriophage of the Myoviridae family, which produces semi-
clear plaques on a lawn of C. difficile NCTC 11204 (2.2.2; Mayer et al., 2008). 
Despite having lysogenic capacity, the lytic activity of ФCD27 has therapeutic 
potential and is amenable to investigation using a batch fermentation model of 
C. difficile infection. The batch fermentation culture models were designed to 
represent a short window of active C. difficile infection, during which 
vegetative cells are producing high levels of toxins A and B.  
There is a clinical need for the selective elimination of gut pathogens without 
compromising the integrity of the microbiota. The specificity of phage therapy 
warrants investigation as to its ability to infect and kill target hosts in the gut 
environment. Due to the nature of CDI onset, prophylactic agents could be 
strategically instigated alongside any course of antimicrobial therapy that is 
likely to lead to the suppression of normal commensals and subsequent 
germination of C. difficile. Various studies have also demonstrated differing 
efficacies depending on the dosing intervals, and with these factors in mind, a 
prophylactic phage regime was tested in addition to a remedial schedule. 
5. 3. Objectives: 
 To determine the relative efficacy of a prophylactic and a remedial 
phage therapy schedule to treat CDI. 
 To determine any significant changes to commensal gut microbiota as 
a result of phage therapy, relative to an un-treated control and a 
metronidazole-treated control. 
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5. 4. Methods 
5. 4. 1. Bacteriophage propagation 
Clostridium difficile strain 11204, obtained from the NCTC culture collection, 
was used for the batch fermentation experiments. Culture conditions and 
media details are described in 2.5.14. 
Bacteriophage ФCD27 was induced from a turbid culture of C. difficile NCTC 
12727 using mitomycin C at 3 μg/mL as described in 2.2.1. In an attempt to 
minimise the concentration (and possible effects of) mitomycin C from the 
phage preparation, lysates were prepared from plate harvests (2.2.3.1).  
5. 4. 2. Bacterial culture 
5. 4. 2. 1. Clostridium difficile inoculum 
C. difficile was cultured as described (2.1.1.1) and material from the second 
subcultures was used to inoculate the batch fermentation vessels. Growth 
curves were used to determine the inoculum volume required in advance, and 
this was confirmed by colony counts of serial dilutions post inoculation. 
5. 4. 2. 2. Enumeration of gut bacteria 
Five mL samples from the batch fermentation vessels were taken at each time 
point and enumerations of C. difficile and a range of gut bacteria were made 
(2.1.2). Growth curves were plotted and the area under the curve was 
calculated to represent the overall level of growth. After processing, samples 
were stored at -20°C. 
5. 4. 3. The batch fermentation system 
The batch fermentations were carried out over 48 h according to the 
procedure described previously (Mandalari et al., 2007). The apparatus is 
pictured in Fig. 5.1. Culture media was prepared as described previously 
(2.5.14). Aliquots of 135 mL were dispensed into the fermentation vessels, 
which were then autoclaved at 121°C for 15 minutes. The pH of each vessel 
was adjusted and maintained at 6.8 ± 0.2. Oxygen-free nitrogen was bubbled 
through the sterile batch fermentation vessels overnight to create anaerobic 
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conditions prior to the inoculation of fresh faecal slurry. Ten percent slurry was 
made with freshly voided faecal sample from a volunteer aged under 60 
years, diluted with pre-reduced PBS. Fifteen mL of this slurry was then used 
to inoculate each vessel (230 mL capacity). At time 0, approximately 2 x 106 
cells of C. difficile NCTC 11204 from an overnight culture, were added to 
vessels 2 and 3. No C. difficile was added to vessel 1, which served as a 
control. Vessel 4 received a dose of ФCD27 at 0, 6, 24 and 36 h, and was 
challenged with approximately 2 x 106 cells of C. difficile culture at 6 h. The 
dosing schedule is summarised in Table 5.1, and was designed to represent a 
snapshot of acute C. difficile infection.  
 
Figure 5.1.The batch fermentation system. Each vessel (A) is pH 
controlled (B), maintained at 37°C using water jackets (C) and kept 
anaerobic via a continuous nitrogen purge (D). 
 
Vessel 0 h 6 h 24 h 36 h 48 H 
Control  - - - - - 
Control  
C. difficile 
 
C. difficile 
added 
- - - - 
Remedial 
regime 
C. difficile 
added 
ФCD27 added ФCD27 
added 
ФCD27 
added 
ФCD27 
added 
Prophylactic 
regime 
ФCD27 
added 
C. difficile and 
ФCD27 added 
ФCD27 
added 
ФCD27 
added 
ФCD27 
added 
 
Table 5.1. The dosing schedules for batch fermentation vessels. 
 
A 
B 
C 
D 
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Phage preparations were stored in sterile BHI broth plus complements, and 
dosed at a multiplicity of infection (MOI) value of 7 in the first experiment and 
10 in the two subsequent repeats. The dose volume was 10 mL. Vessel 3 
received phage treatment at 6, 24 and 36 h. Samples for analysis were taken 
at 0, 6, 24, 36 and 48 h. At the sampling time points, 5 ml of sample was 
extracted using a Pasteur pipette, and transferred immediately to the 
anaerobic cabinet for enumeration of commensal bacterial groups (5.4.2.2) 
Samples were then used for toxin quantification (2.1.3).  
In the prophylactic schedule, ΦCD27 dosing began prior to the addition of 
vegetative C. difficile cells. It was therefore necessary to exclude the 
possibility that it could replicate in faecal flora and subsequently compromise 
the ability of the experiment to fairly evaluate both the prophylactic and 
remedial regime in parallel. Three bottles of 25 ml batch culture media were 
pre-reduced in the anaerobic cabinet overnight after which 10 g freshly voided 
faecal sample was added to each. The same faecal sample was also used for 
the 3rd batch fermentation experiment. ΦCD27 was harvested from a semi-
confluent plaque assay (2.2.3.1) and 1 ml was added to each of the faecal 
cultures before returning to the anaerobic incubator. At time 0, 24 h and 48 h 
the cultures were mixed well and a 1 ml sample removed for ΦCD27 
enumeration by overlay plaque assay. 
In a separate experiment demonstrating the effect of metronidazole on C. 
difficile and other microflora in the batch fermentations, the antibiotic doses 
were based on the normal human therapeutic dose of 500 mg every 8 h and 
the approximate volume of the human colon (0.5 L).  The total volume 
contained in each batch vessels was 150 mL, meaning that 150 mg 
metronidazole powder comprised each dose.  
5. 4. 4. Fluorescence in situ hybridisation (FISH) 
A fluorescence in situ hybridisation (FISH) probe (Bloedt, et al., 2009), 5’-
CATCCTGTACTGGCTCAC-3’ labelled with Cy5, was tested in an attempt to 
achieve specific C. difficile detection with a sensitivity level superior to that of 
culture.  
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Samples were prepared from an 8 h culture of C. difficile NCTC 11204, 
centrifuged for 2 min at 500 x g to remove particulate debris. The supernatant 
(375 μl) was added to 1125 μl pre-chilled 4% paraformaldehyde solution in a 
1.5 ml microcentrifuge tube and kept at 4°C overnight to fix. After this the fixed 
samples were centrifuged at 500 x g for 5 min and the supernatant removed 
and replaced with 1 ml PBS (filtered through a 0.45 μm syringe filter and 
subsequently autoclaved). After another centrifugation step and removal of 
the supernatant, the pellet was washed again with another 1 ml of sterile 
filtered PBS. When this supernatant was removed, the pellet was thoroughly 
resuspended in 150 μl sterile filtered PBS containing 2 mg/ml lysozyme and 
50 U/ml mutanolysin. Next, 150 μl of ethanol (96%) was added. The sample 
was mixed well and stored at -20°C for at least 1 h.  
For hybridisation, 16 μL of the prepared cells were added to 264 μl of filtered 
hybridisation buffer (40 mM Tris-HCl pH 7.2; 1.8 M NaCl and 2% SDS), pre-
warmed to 50°C. In a separate microcentrifuge tube, 15 μl of the probe at a 
concentration of 50 ng/μl was added. Immediately, 135 μl of the hybridisation 
mix was added to the probe mix at a ratio of 1:10, vortex mixed and placed in 
a 50°C oven for 15 h to hybridise. To wash, 5 ml of washing buffer (pre-
warmed to 50°C), was added to a sterilin tube, followed by 20 μl of 4,6-
diamidino-2-phenylindole. Next, 100 μl of the hybridised sample was added 
and the tubes were returned to the 50°C oven for 30 min.  
Filter apparatus was assembled with wet filters (0.2 μm diameter) matt side 
facing upwards. The sample mixtures were poured onto the filters and a 
vacuum pump was used to draw the liquid through. The sample tube was 
rinsed with warmed washing buffer and passed through the filter, which was 
then removed and placed onto a glass slide. A drop of SlowFade  
(Invitrogen) was added to the filter prior to placing a coverslip over the slide. 
The slides were then transferred to the dark room for analysis.  
The Nikon Eclipse 90i fluorescent microscope was used to analyse the FISH 
samples. First the UV light was used to visualise 4,6-diamidino-2-
phenylindole-stained bacteria. Next the green light filter was used to visualise 
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C. difficile cells. Fifteen fields of view were counted, and the mean of these 
(corrected for the dilution) denoted the quantity.  
5. 4. 5. C. difficile toxin detection 
Samples from the batch fermentation vessels were stored at 4°C for up to 2 
days following the bacterial enumerations, and tested for C. difficile toxin 
using the Premier Toxins A & B assay kit (Meridian Bioscience Incorporated, 
Ohio, USA) according to the manufacturer’s instructions and as described in 
2.1.3.  
5. 4. 6. Statistical analysis of data 
Data from the bacterial enumerations at each sampling interval were plotted 
as growth curves and the area under the curve was calculated. Repeats were 
grouped together and tested for significant differences relative to the control 
tests by means of a one-way ANOVA using a Tukey’s Honestly Significant 
Difference post-hoc test. 
5.4.7. Measuring the effect of C. difficile toxins and lysed C. difficile cells 
on commensal faecal bacteria. 
Enumerations were carried out from cultures of faecal sample inoculated with 
C. difficile NCTC 11204 (a toxigenic strain) and NCTC 12726 (a non-toxigenic 
strain) to ascertain possible effects of C. difficile toxins on the growth of 
common groups of commensal bacteria. Ten g of fresh faeces was 
suspended in 100 ml pre-reduced PBS and transferred to the anaerobic 
cabinet. One mL was added to pre-reduced BHI plus 200 μL from an 
overnight culture of the relevant C. difficile strain. Experiments were carried 
out in replicates of 3.  After 24 h, the numbers of Bifidobacterium spp., total 
Clostridium spp., Lactobacillus spp., Bacteroides spp., total anaerobes, total 
aerobes, Enterobacteriaceae and Gram-positive cocci were enumerated by 
culture as described in 2.1.2. and 5.4.2.2. 
Faecal cultures with and without lysed C. difficile cells were carried out to 
investigate the possible benefits of liberated nutritional compounds to other 
groups of bacteria. An overnight culture of C. difficile NCTC 11204 was 
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autoclaved and bead beaten 4 times with glass beads <106 μm (Sigma) for 
30 s with 10 min rests on ice between each (Fast Prep 120 BIO 101 Thermo). 
One ml was added to a 1% faecal fermentation (in pre-reduced batch 
fermentation media – 2.5.14) and incubated overnight. One mL of an 
overnight C. difficile culture and 1 mL of PBS (not pre-reduced) served as 
controls. Experiments were carried out in replicates of 3. After 24 h, the 
numbers of commensal gut bacteria were enumerated by culture (2.1.2). 
5. 5. Results 
5. 5. 1. Bacterial culture 
A batch fermentation system was used to model the effect of ΦCD27 phage 
therapy on the levels of viable C. difficile, toxins A and B, and a range of 
faecal organisms. Two different treatment schedules were tested – remedial 
and prophylactic. Levels of C. difficile in the remedial schedule were on 
average less than 1 log10 lower than the untreated control but still reached 
levels greater than 1 x 106 CFU/mL after initiation of phage treatment. When 
the mean area under the curve values are considered, the reduction was 
significant (p = <0.0001). The prophylactic treatment schedule resulted in a 
greater than 4 log10 reduction in the numbers of C. difficile relative to the 
control when an MOI of 7 was used (experiment a), and suppression to below 
the limit of detection by culture at 48 h when an MOI of 10 was used 
(p=<0.0001; experiment b and c). These results are shown in Fig. 5.2.  
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Fig 5.2. a-c. The effect of phage therapy on levels of C. difficile. Figures 
represent plate counts of C. difficile from replicate experiments of 4 
vessels. No cells were detected in the control vessel with no C. difficile.      
          = control vessel (plus C. difficile),          = remedial phage treatment 
schedule vessel and          = prophylactic phage treatment schedule 
vessel. Values are the means of triplicates ± SD.  
 
The possible adverse effect of phage therapy on other commensal gut 
bacteria was also monitored in this batch model by viable enumerations at 
each sampling point. No significant reduction in the number of Bifidobacterium 
spp., total anaerobes, Bacteroides spp., Lactobacillus spp., or total 
Clostridium spp. was observed in the phage treated vessels relative to the 
control vessels. There was however, a 0.79 log10 increase in the number of 
total aerobes (p = 0.017) and a 1.43 log10 increase in Enterobacteriaceae (p = 
0.021) (Fig. 5.3-5.10). 
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Figure 5.3. a-c. The effect of phage therapy on Bifidobacterum spp. 
Figures represent plate counts of replicate experiments of 4 vessels. 
         = control (no C. difficile) vessel,          = control (plus C. difficile) 
vessel,        =  remedial phage treatment schedule vessel and        = 
prophylactic phage treatment schedule vessel. Values are means of 
triplicates ± SD 
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Fig 5.4. a-c. The effect of phage therapy on levels of total Clostridium 
spp. Figures represent plate counts from replicate experiments of 4 
vessels.        = control (no C. difficile) vessel,         = control (plus C. 
difficile) vessel,       =  remedial phage treatment schedule vessel and       
= prophylactic phage treatment schedule vessel. Values are the means 
of triplicates ± SD. 
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Fig 5.5. a-c. The effect of phage therapy on levels of Lactobacillus spp. 
Figures represent plate counts from replicate experiments of 4 vessels.         
= control (no C. difficile) vessel,        = control (plus C. difficile) vessel,        
= remedial phage treatment schedule vessel and         =  prophylactic 
phage treatment schedule vessel. Values are the means of triplicates ± 
SD. 
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Fig 5.6. a-c. The effect of phage therapy on levels of Bacteroides spp. 
Figures represent plate counts of replicate experiments of 4 vessels.        
= control (no C. difficile) vessel,         = control (plus C. difficile) vessel,          
= remedial phage treatment schedule vessel and     = prophylactic phage 
treatment schedule vessel. Values are the means of triplicates ± SD. 
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Fig 5.7. a-c. The effect of phage therapy on levels of total anaerobes. 
Figures represent plate counts of replicate experiments of 4 vessels.        
= control (no C. difficile) vessel,          = control (plus C. difficile) vessel,          
= remedial phage treatment schedule vessel and        = prophylactic 
phage treatment schedule vessel. Values are means of triplicates ± SD. 
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Fig 5.8. a-c. The effect of phage therapy on levels of total aerobes. 
Figures represent plate counts of replicate experiments of 4 vessels.         
=  control (no C. difficile) vessel,          = control (plus C. difficile) vessel,        
= remedial phage treatment schedule vessel and        = prophylactic 
phage treatment schedule vessel. Values are means of triplicates ± SD. 
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Fig 5.9. a-c. The effect of phage therapy on levels of Enterobacteriaceae. 
Figures represent plate counts of replicate experiments of 4 vessels.        
=  control (no C. difficile) vessel,         = control (plus C. difficile) vessel,          
= remedial phage treatment schedule vessel and        = prophylactic 
phage treatment schedule vessel. Values are means of triplicates ± SD. 
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Fig 5.10. a-c. The effect of phage therapy on levels of total Gram-positive 
cocci. Figures represent plate counts of 4 replicate experiments of 4 
vessels.        = control (no C. difficile) vessel,        = control (plus C. 
difficile) vessel,       = remedial phage treatment schedule vessel and          
=  prophylactic phage treatment schedule vessel. Values are means of 
triplicates ± SD. 
 
The batch fermentation system was also used to model the effect of 
therapeutic doses of metronidazole on C. difficile and the gut flora over 48 h 
(Fig.5.11-19). The results show eradication of C. difficile after addition of the 
antibiotic, but also demonstrate a profound detrimental effect on some of the 
other bacterial populations. These findings are in agreement with those 
described previously (Freeman et al., 2007). Levels of total Clostridium spp. 
were undetectable by viable counts after the first dose of metronidazole (given 
at 6 h after inoculation), and at the end of the fermentation (48 h) were at least 
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2 log10 lower than in the control vessel (p = <0.0001). Lactobacillus spp. were 
reduced by between 1 and 2 log10, with Bacteroides spp. and 
Enterobacteriaceae being completely eliminated from the system (p = < 
0.0001). The level of total anaerobes decreased by approximately 1 log10 
throughout the 48 h fermentation compared to the controls, while aerobic 
populations were increased by about 1 log10 (p = <0.0001). Gram-positive 
cocci, which were present only transiently in the control vessels (and at 1 x 
104 CFU/mL at most), showed a marked increase and finished at levels of 1 x 
107 CFU/mL. Statistically, this increase was highly significant (p = <0.0001). 
 
 
Fig 5.11. Effect of metronidazole therapy on levels of C. difficile. Figures 
represent plate counts of 2 replicate experiments of 2 vessels         = 
control (plus C. difficile) vessel and         = metronidazole treated vessel. 
Values are the means of triplicates ± standard deviation. 
 
Fig 5.12. The effect of metronidazole therapy on levels of 
Bifidobacterium spp. Figures represent plate counts of 2 replicate 
experiments of 3 vessels.        =  control (no C. difficile) vessel,         =  
control (plus C. difficile) and        =  metronidazole treated vessel. Values 
are means of triplicates ± SD. 
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Fig 5.13. The effect of metronidazole therapy on levels of total 
Clostridium spp.  Figures represent plate counts of 2 replicate 
experiments of 3 vessels        =   control (no C. difficile) vessel,         =  
control (plus C. difficile) vessel and          =  metronidazole treated 
vessel. Values are means of triplicates ± SD. 
 
 
Fig 5.14. The effect of metronidazole therapy on levels of Lactobacillus 
spp.  Figures represent plate counts of 2 replicate experiments of 3 
vessels         =   control (no C. difficile) vessel,        =  control (plus C. 
difficile) vessel and        =  metronidazole treated vessel. Values are 
means of triplicates ± SD. 
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Fig 5.15. The effect of metronidazole therapy on levels of Bacteroides 
spp.  Figures represent plate counts of 2 replicate experiments of 3 
vessels.          =   control (no C. difficile) vessel,         =  control (plus C. 
difficile) vessel and          =  metronidazole treated vessel. Values are 
means of triplicates ± SD. 
 
Fig 5.16. The effect of metronidazole therapy on levels of total 
anaerobes. Figures represent plate counts of 2 replicate experiments of 
3 vessels.         =   control (no C. difficile) vessel,         =  control (plus C. 
difficile) vessel and         =  metronidazole treated vessel. Values are 
means of triplicates ± SD. 
 
Fig 5.17. The effect of metronidazole therapy on levels of total aerobes.  
Figures represent plate counts of 2 replicate experiments of 3 vessels.        
=   control (no C. difficile) vessel,         =  control (plus C. difficile) vessel 
and         =  metronidazole treated vessel. Values are means of triplicates 
± SD. 
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Fig 5.18. The effect of metronidazole therapy on levels of 
Enterobacteriaceae. Figures represent plate counts of 2 replicate 
experiments of 3 vessels.        =   control (no C. difficile) vessel,         =  
control (plus C. difficile) vessel and        =  metronidazole treated vessel. 
Values are means of triplicates ± SD. 
 
Fig 5.19. The effect of metronidazole therapy on levels of Gram-positive 
cocci. Figures represent plate counts of 2 replicate experiments of 3 
vessels.        =   control (no C. difficile) vessel,         =  control (plus C. 
difficile) vessel and         =  metronidazole treated vessel. Values are 
means of triplicates ± SD. 
 
5. 5. 2. C. difficile toxin production 
The production of C. difficile toxins A and B were measured during replicate 
experiments 2 and 3 (Fig 5.20). As expected, no toxins were detected at any 
point in the experiment in the control vessel that was not inoculated with C. 
difficile. In the control vessel inoculated with C. difficile positive toxin results 
were obtained after 24 h fermentation, remaining until the end of the 48 h 
fermentation. Samples of batch fermentations from the remedial therapy 
schedule taken at 6 h onwards were all weakly positive for C. difficile toxin. In 
the prophylactic therapy schedule, toxin levels remained below the cut-off 
value of the assay throughout the experiment.  
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Figure 5.20. C. difficile toxin measurements during phage treatment 
(experiments 2 and 3).        = Control (no C. difficile) vessel,        = control 
(plus C. difficile) vessel,       = remedial phage treatment schedule vessel 
and        = prophylactic phage treatment schedule vessel. Values are 
means of triplicate readings ± SD. The dashed line represents the cut-off 
value of the assay. 
 
In the metronidazole-treated fermentations, toxin production decreased 
following the commencement of the therapy but remained weakly positive 
throughout the experiment (Fig. 5.21). 
 
 
Figure 5.21. C. difficile toxin measurements during metronidazole 
treatment.       = Control (no C. difficile) vessel,        = control (plus C. 
difficile) vessel and        = metronidazole treated vessel. Values are 
means of triplicate readings ± SD. The dashed line represents the cut-off 
value of the assay. 
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5.5.3. The effect of toxin and lysed C. difficile cells on commensal 
microbiota.  
The numbers of faecal commensal bacterial groups isolated in the presence 
of a toxigenic strain of C. difficile and a non-toxigenic strain of C. difficile are 
shown in Fig. 5.22. A significantly higher number of Lactobacillus spp. were 
isolated 24 h after growth in a faecal fermentation containing non-toxigenic C. 
difficile relative to a toxigenic strain (p = 0.003), although this difference was 
less than 1 log10. A decrease of greater than 1 log10 was observed for total 
Clostridium spp. (p = 0.002) in the toxigenic culture. The group that seemed 
most sensitive to the C. difficile toxins was Bacteroides spp., for which a 
greater than 2 log10 reduction was recorded. These results suggest that C. 
difficile toxins may have a degree of antimicrobial activity, which has not been 
previously reported in the literature. 
 
Figure 5.22. Growth of major bacterial groups grown in the presence of 
toxigenic C. difficile (         ) and non-toxigenic C. difficile (          ). Values 
are means of 3 replicates ± SD. 
 
There were no significant differences in the numbers of commensals 
recovered from a 24 h faecal fermentation in the presence of live C. difficile 
cells, lysed C. difficile cells and PBS. These results are shown in Fig. 5.23. 
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Figure 5.23. Growth of major bacterial groups grown in the presence of 
PBS (         ), live C. difficile cells (        ) and lysed C. difficile cells (        ). 
Values are means of 3 replicates ± SD. 
 
 
5.5.4. Tests for lysogeny 
In order to investigate the possible risk of the bacteriophage switching to a 
lysogenic life cycle during the treatment, 5 isolates of C. difficile from each 
batch fermentation vessel (in which C. difficile could be recovered), were 
induced using mitomycin C and tested for the presence of the phage. No 
phage could be found in the parent strain of C. difficile NCTC 11204 used for 
initial colonisation of the batch vessels. In all of the phage treatment vessels, 
100% of the C. difficile strains isolated were found to contain ФCD27 as a 
prophage (after mitomycin C induction). This rendered the C. difficile resistant 
to further treatment with ФCD27, and is a likely explanation for the regrowth of 
C. difficile following the initial decline at the beginning of the treatment.  
5.5.5. Phage replication in faecal samples 
In order to verify that the ΦCD27 was not replicating in other faecal bacteria, 
approximately 1 x 107 PFU/ mL was added to a 10% suspension of faecal 
sample in batch fermentation broth and incubated anaerobically for 48 h. 
Enumeration of ΦCD27 throughout this period confirmed that there had been 
no significant increase or decrease in the phage titre (Fig. 5.24). 
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Figure 5.24. Enumerations of ΦCD27 recovered from a spiked faecal 
sample. Values are means of triplicate plaque assays ± SD. 
 
5.5.6. Fluorescence in situ hybridisation 
Cells of C. difficile labelled with the specific probe were visible under the 
fluorescent microscope in the neat culture suspension but not in any of the 
dilutions. This sensitivity was not acceptable for the purposes of the study and 
not superior to that of culture. It was therefore not pursued further.    
5.6. Discussion 
In this study we used an in vitro batch fermentation model to test the efficacy 
of specific bacteriophage treatment regimes in controlling the levels of C. 
difficile. Our results demonstrate that a prophylactic phage treatment regime 
resulted in a significant reduction in the levels of viable pathogens recovered. 
In addition, this reduction in C. difficile cell numbers also resulted in the 
suppression of toxin production. To a lesser extent, phages may help in the 
remediation of C. difficile-associated disease as this treatment regimen 
resulted in a less profound decrease in viable C. difficile and weak toxin 
production relative to an untreated control. It was interesting to note that 
metronidazole-treated vessels also retained weak toxin production throughout 
the therapy. Patients suffering from acute C. difficile infection are reported to 
excrete up to 104 to 107 organisms per gram of faeces (Rea et al., 2007), 
although to our knowledge, there are no published reports of the levels 
expected within the colon. Enumerations from the control vessels show that 
levels surpassed 107 CFU/mL, indicating that these results have some clinical 
relevance, however, the perceived success of ФCD27 in the reduction of C. 
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difficile numbers in the prophylactic regime may have been due to the 
changes in the growth phase and or gene expression as it adjusts to the batch 
fermentation media and fermentation by-products. The burden of C. difficile 
spores has not been investigated here (and this was also omitted from 
previous investigations of lacticin 3147 using batch fermentations (Rea et al., 
2007)). This is an important consideration as the presence of spores permits 
recrudescence of disease. 
The actively growing C. difficile cells were added to a culture of faecal flora 
with no prior antibiotic treatment. The onset of C. difficile infection is normally 
preceded by the effects of a broad-spectrum antibiotic and so the numbers 
and proportions of commensal flora did not truly represent those of the 
diseased state. As with previous batch fermentation studies, the donor faecal 
sample was also from a healthy adult under the age of 65 years and therefore 
not in the risk group for development of CDI. This factor may have enhanced 
any therapeutic action of the phage, since normal commensal flora is itself 
associated with CDI resolution. The batch fermentations are maintained at pH 
6.8 ± 0.2 and do not incorporate the acidic and proteolytic conditions of the 
upper gastrointestinal tract, which can be expected to have a detrimental 
effect on the viability of phages (Ryan et al., 2011). Advances in 
microencapsulation (Cook et al., 2012) and also the administration of 
neutralising agents may help to address this problem and aid delivery of the 
phage to the lower gastrointestinal tract. In vitro pH tolerance tests (4.5.4) 
have shown no reduction in the viability of ΦCD27 at pH 5 to 8, which 
encompasses the range encountered in the human gastrointestinal tract from 
the duodenum to the rectum (Fallingborg, 1999). 
In both the prophylactic and remedial treatment models, the efficacy of phage 
treatment was improved by increasing the phage infection dose from 7 to 10 
MOI. Integration of ΦCD27 into C. difficile NCTC 11204 was demonstrated for 
5/5 of the C. difficile colonies isolated from the phage treated batch 
fermentations at the end of the experiment, when an MOI value of 7 was 
used. At higher MOI values no C. difficile was recovered at 48 h and therefore 
possible lysogens could not be observed. The lysogenic switch renders the 
host bacteria resistant to further phage treatment and this probably explains 
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the observed re-growth of the pathogen in the remedial treatment regime. The 
presence of a prophage may also protect the host from infection by other 
different phages (Serra-Moreno et al., 2006). The ability of phages to 
lysogenise with bacterial hosts is a major disadvantage with regards to their 
therapeutic potential, and these data demonstrate evidence of this. 
Conversely, the rapid release of antigenic determinants and endotoxins 
brought about by in vivo lysis of pathogenic bacteria can sometimes initiate an 
overwhelming systemic immune response. This is known as the Jarisch-
Herxheimer reaction and has been observed following antibiotic treatment of 
syphilis (Kobayashi et al., 2011), Q fever (Aloizos et al., 2008), Leptospirosis 
(Leblebicioglu et al., 2003) and group B Streptococcal infection (Rac et al., 
2010). There is concern about the risk of similar reactions in the context of 
phage therapy (Dixon, 2004) and some efforts have focused on the 
production of lysis-deficient phages for therapeutic use (Hagens and Blasi, 
2003; Paul et al., 2011) with encouraging results. However, studies using lytic 
phages to treat canine ear infections caused by Pseudomonas aeruginosa 
have not reported any systemic reactions (Hawkins et al., 2010). An 
alternative explanation for the incomplete elimination of C. difficile from the 
treatment vessels is the emergence of resistance to phage infection, as 
observed in other previous studies (Atterbury et al., 2007; 1.9.5). It is probable 
that different phages and their bacterial hosts have a diverse range of optimal 
dosing schedules, and consideration should also be given to possible 
adherence of the phage to non-specific matter and how this affects the 
dynamics and interactions between phage and host.  
Despite dosing with the same number of plaque-forming units, the 
prophylactic and remedial treatment routines used in this study gave 
dissimilar results in terms of the recovery of viable C. difficile and the 
production of toxin. In further support of the prophylactic regime, it should be 
considered that, in vivo, the increase in C. difficle numbers post-germination 
would actually be more gradual than the large inoculum of rapidly growing 
cells that was added to the vessels. In vivo, resolution of C. difficile would also 
be aided by inflammatory reactions and antibody responses to immunogenic 
determinants.  
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As expected, due to the relatively high host-specificity, the C. difficile phage 
did not have any significant detrimental effect on any of the other measured 
commensal bacterial populations. However, based on the large diversity of 
bacterial species in the human gut it can be expected that the growth and 
survival of many bacterial groups were not supported by the batch 
fermentation culture media. It should also be noted that many low G-C 
organisms have been found to be under-represented in in vitro incubations 
(Macfarlane and Macfarlane, 2007) and despite continuous nitrogen purges, 
no anaerobic indicator was used in the vessels. Also, it is not known to what 
extent the immunomodulators produced in CDI could be expected to have a 
suppressive effect on commensal flora, but this is another factor to consider 
when interpreting in vitro data. (Also see 6.6.4 for further discussion of in vitro 
testing). 
In the phage-treated batch fermentations, significant increases in the numbers 
of Enterobacteriaceae and total aerobes were recorded but despite this the 
magnitude of deviation from the control was less than 1 log10 based on the 
mean counts. This extent of variation has been observed between sequential 
replicates of the batch fermentation models (5.5) and for other bacterial 
counts using these models (Gibson and Wang, 1994, Olano-Martin et al., 
2000). Differences may have been brought about by the liberation of 
nutritional factors from lysis of the C. difficile cells although this effect was not 
reproduced in separate experiments (Fig. 5.24). A reduction in competition for 
nutrients in the enclosed batch system could also have been a factor which 
may not occur in vivo. Separate studies have suggested a significant 
antimicrobial effect of the C. difficile NCTC 11204 toxin on Lactobacillus spp, 
total Clostridium spp. and Bacteroides spp. but not Enterobacteriaceae or 
total aerobes (Fig. 5.23). The apparent antimicrobial activity of the toxins may 
be due to strain-specific factors such as bacteriocins. 
In comparison to the effects of phage on commensal microbiota, the levels in 
the metronidazole treated batch fermentations were significantly reduced, 
presumably due to its broad antibacterial spectrum. The dramatic rise in 
Gram-positive cocci observed in metronidazole-treated vessels may have 
serious implications for patients colonised with vancomycin-resistant 
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Enterococcus spp. and may predispose to associated diseases and 
nosocomial spread (Al-Nassir et al., 2008; Sethi et al., 2009).  
Other studies have used FISH to quantify components of the microbiota 
(Chassard et al., 2008; Hidalgo et al., 2012; Mandalari et al., 2007, 2008), 
which also detects non-viable organisms. Detection of C. difficile by FISH was 
attempted but gave levels of sensitivity inferior to that of culture. This may 
have been due to lack of cell penetration due to ineffective lysozyme action or 
complete disruption of cell integrity due to over-treatment. Probe permeation 
is notoriously problematic in Gram-positive organisms (Franks et al., 1998) 
but cell association with masking proteins, hybridisation temperature or strain 
specificity may have also prevented detection. 
Batch fermentations have significant temporal limitations as these are closed 
systems and the nutritional value of the media is spent within 48 h. In the 
distal bowel however, substrate availability is limited and the conditions are 
similar to that of a batch culture (Macfarlane and Macfarlane, 2007). While 
these models lack the effects of metabolic, secretory and immunological 
factors of the gut, the media and conditions are carefully controlled and these 
studies are generally less variable than in vivo experiments, allowing 
associations and effects of interventions to be more easily identified.  
Pre-emptive selective treatments such as phage therapy could dramatically 
reduce the burden of C. difficile-associated disease in health care settings, 
with no disruption to patients’ normal gut microbiota and therefore no 
anticipated predisposition to secondary complications. The high specificity of 
phage therapy however, is a limiting factor in terms of the range of C. difficile 
strains that are affected. Bacteriophage cocktails could be used to defend 
against multiple strains and resistant bacteria, plus there is the possibility of 
synergistic use with other agents to enhance current treatment strategies.  
In summary, this work has shown that: (i) prophylactic bacteriophage therapy 
resulted in a significant decrease in the number of viable C. difficile cells and 
gave negative toxin results (ii) remedial treatment of a colonised system 
resulted in a short-lived reduction in the number of viable C. difficile CFU’s 
and reduced toxin production (iii) integration of ΦCD27 into the genome of C. 
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difficile NCTC 11204 was demonstrated after it was used for therapeutic 
treatment; (iv) ΦCD27 treatment did not detrimentally affect the abundance 
and proportions of selected groups of commensal flora, whereas (v) treatment 
of C. difficile with metronidazole in the batch fermentation system caused 
significant reductions in total Clostridium spp., Lactobacillus spp., Bacteroides 
spp. and Enterobacteriaceae plus a significant increase in the proportion of 
Gram-positive cocci relative to an untreated control. Supplementary studies 
also suggested that (vi) C. difficile toxins may exhibit some antibacterial 
activity. 
Many of the limitations in this study have been addressed in subsequent 
experiments using a three-component continuous model colon.   
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Chapter 6 – Modelling phage therapy of C. difficile infection using an in 
vitro colon model 
6.1. Abstract 
The potential of ΦCD27 as a prophylactic agent was investigated using a 
three-component human colon model of C. difficile infection. This work builds 
on previous batch fermentation studies, which suggested that a prophylactic 
approach was more effective than a remedial regime. Phage treatment 
resulted in elimination of vegetative C. difficile cells in 2 of the 3 experiments, 
with clinically relevant suppression of toxin production relative to an untreated 
control in all experiments. No detrimental effect on commensal flora as 
measured by culture and molecular profiling techniques was observed. 
Despite this, an increase in the number of C. difficile spores was recorded as 
well as a strong predilection for phage integration, demonstrating the potential 
for recrudescence and acquisition of virulent genetic elements.  
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6.2. Introduction 
Phage therapy has the potential to offer a highly specific method of reducing 
the burden of vegetative C. difficile cells. In batch fermentation models of CDI 
(Chapter 5), it was demonstrated that prophylactic treatment with ФCD27 (as 
opposed to a remedial-based approach) resulted in a significant reduction of 
viable C. difficile cells and a reduction in toxin production with no detrimental 
impact on the main bacterial groups comprising commensal gut flora (Meader, 
et al., 2010). These models were designed to represent a short window of 
acute CDI but in order to better evaluate the efficacy of a prophylactic phage-
treatment regime, a more representative and temporally relevant experiment 
that can model the disease from colonisation through to active disease was 
required. Many in vitro and in vivo models of CDI development have been 
described to date: 
6.2.1. The golden Syrian hamster model 
This model is widely accepted as an accurate representation of human CDI 
and has been used extensively in the evaluation of promising therapeutic 
agents since it was first described (Small, 1968). Both male (Bartlett et al., 
1977) and female (Dvoskin et al., 2012; Goulding et al., 2009) hamsters have 
been used and are pre-treated with clindamycin at 15 mg/kg by subcutaneous 
injection (Freeman et al., 2005) or oral gavage (Goulding et al., 2009). After 
24 h a spore suspension of 1 x 102-1 x 107 CFU/mL is administered by oral 
gavage and it is from this time that therapeutic agents are often given. 
Untreated animals typically develop diarrhoea (wet tail) and become moribund 
between 30-50 h post inoculation, at which point they are sacrificed. 
Histological evidence of inflammation in the ceca and colons can be observed 
post mortem (Goulding et al., 2009), although disease predominantly affects 
the cecum (Abrams et al., 1980). Using this model, different strains of C. 
difficile have shown significant variations in the severity and pathogenesis of 
disease (Goulding et al., 2009). 
The results of hamster model generally correlate well with data from clinical 
trials, as demonstrated by recent work on the novel therapeutic agent OPT-80 
(Louie, et al., 2009 a, 2009 b) although some agents have proved not to be 
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efficacious despite promising results in hamster models, as was the case with 
the toxin–binding protein, Tolevamer (Baines et al., 2009). Hamsters also lack 
a cytokine response. In humans, particular cytokines, such as interleukin 1β, 
tumour necrosis factor α and interleukin 8 are released in response to C. 
difficile toxins and contribute to the pathogenesis of CDI. Differences in the 
profiles of these cytokines can have a considerable effect on the severity of 
disease in humans (Kelly and Kyne, 2011).  
6.2.2. The mouse model 
Murine models have also been used extensively to reproduce CDI and have 
the advantage of affecting both the cecum and colon of the animals, which is 
more representative of human disease. They also allow the generation of 
cytokine profiles, although there have been some differences between murine 
levels and the results of human studies with regards to levels of tumour 
necrosis factor alpha (TNFα) and interferon gamma (IFN- ) (Ishida et al., 
2004; Pawlowski et al., 2010), both important mediators of inflammation.  
Various murine lines have been used including gnotobiotic C57BL/6 mice, 
CF1 and CD1 mice. In the majority of studies, animals are pre-treated with an 
antibiotic cocktail, typically including kanamycin, gentamicin, colistin and 
metronidazole (Kang et al., 2011) before clindamycin, given intraperitoneally 
(Jarchum et al., 2011; Kang et al., 2011), or by subcutaneous injection (Jump 
et al., 2011). In some studies, no pre-treatment with antibiotics was employed 
(Pawlowski et al., 2010).  
Mice can also be used for a relapse model of CDI (Sun et al., 2011) as the 
infection is less likely to be lethal, the severity being dependent on the dose of 
C. difficile with co-administration of antibiotics. Mice that recover suffer further 
episodes when subsequently challenged with antibiotics (although C. difficile 
was not proven as the cause in all cases) and antibiotics plus a C. difficile 
spore inoculum. Immunosuppressed patients are at a greater risk of severe 
and relapsing CDI, which has also been demonstrated in this model by adding 
dexamethasone to the drinking water. The results of this study indicate that 
neutralising antibodies to toxins A and B protect against CDI relapse and this 
has also been shown to be the case in humans (Kelly and Kyne, 2011).  
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6.2.3. Piglet models 
The anatomical similarities between human and swine organs make them 
ideal candidates for models of human disease. Swine are also susceptible to 
CDI and it is regarded as an important aetiological agent of porcine neonatal 
diarrhoea (Post et al., 2002; Songer, 2004; Waters et al., 1998; Yaeger et al., 
2002). Pseudomembraneous colitis can also be induced in piglets following 
antimicrobial therapy (Steele et al., 2010). Porcine models are not frequently 
used to evaluate novel therapies but have been used in competitive exclusion 
experiments where pre-colonisation with a non-toxigenic strain of C. difficile 
ameliorated the growth retardation associated with CDI in piglets after 
challenge with a toxigenic strain (Songer et al., 2007).  
Murine, hamster and piglet models all permit the assessment of stool 
consistency – an important marker of CDI in humans. 
6.2.4. Guinea pig models 
One of the first studies of antibiotic-associated enterocolitis, which provided 
evidence of a toxin-mediated effect, used guinea pigs that were given 
clindamycin with no prior inoculation of C. difficile (Knoop, 1979). Similar 
effects were observed with penicillin treatment (Lowe et al., 1980), but these 
models were not subsequently used to the same extent as hamster or mouse 
models. 
6.2.5. Ligated ileal loop models 
Ileal loop models using rabbits and mice have previously been adopted for the 
study of C. difficile toxins and potential toxin antagonists (Carneiro et al., 
2006; Ketley et al., 1987; Warren et al., 2012). Ileums are typically flushed 
with PBS before loops are created with double ties. Toxin A with and without 
test agents is injected into the loops, which are then returned to the abdominal 
cavity. Further treatments are generally given by the intravenous route and 
assessments are typically achieved via toxin quantification of samples and 
detection or observation of inflammatory markers.  
With these in vivo models, only the short-term effects on cells can be 
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investigated, whilst implications on the gut microbiota remain undetermined. 
Long-term effects cannot be evaluated and experiments may not even exceed 
the proposed treatment duration. Clearly, all model systems offer both 
advantages and disadvantages and the use of a range of models is required 
to demonstrate therapeutic potential and highlight some possible limitations.  
6.2.6. The 3-stage continuous in vitro colon model 
The 3 stage continuous system represents conditions in the large intestine 
from the proximal to the distal bowel. It was validated using human intestinal 
contents from the cecum/ascending colon and the sigmoid colon from 2 
patients who died suddenly from coronary heart disease (Macfarlane et al., 
1998). The pH of these regions was measured and microbiological profiles 
were generated by culture of commensal bacterial groups. These continuous 
colon model systems correlate well with results from in vivo and human 
studies (O'May et al., 2005 a, 2005 b) and have previously been used to 
evaluate the efficacy of therapeutic agents to eradicate intestinal pathogens 
such as Campylobacter jejuni and Salmonella enterica (Fooks and Gibson, 
2003; Zihler et al., 2010). 
The colon model system was validated to model CDI (Freeman et al., 2003). 
This group investigated the effect of various antimicrobial agents in relation to 
the risk of CDI onset (Baines et al., 2005, 2006, 2009; Saxton et al., 2009), 
the efficacy of current treatment strategies (Baines et al., 2009, 2011; 
Freeman et al., 2007) and novel therapeutics (Baines et al., 2009). The model 
was shown to maintain a diverse microbial community throughout the 
experimental period, concordant with those from an in vivo Syrian golden 
hamster model (Freeman et al., 2005) and serves as an excellent forerunner 
to animal experiments. It may be regarded as more temporally relevant to 
human disease, since the onset of toxin production and C. difficile proliferation 
in both the colon model and patients is generally 5-10 days after clindamycin 
therapy has ceased as opposed to 2 days in the animal models. This model 
has also been shown to correlate with clinical trials better than the hamster 
model in some cases (Baines et al., 2009). Further to successful preliminary 
in vitro studies, hamster model results and phase II clinical trials of Tolevamer 
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(a toxin binding styrene derivative), the phase III clinical trials demonstrated 
inferiority to vancomycin. This poorer efficacy was subsequently 
demonstrated in the colon model and the reduced activity was proposed to be 
due to binding interference from the particulate matter (Baines et al., 2009).    
The colon model offers an excellent simulation of the gut environment and it is 
of paramount importance to assess the activity of novel therapeutic agents in 
such conditions where the action of digestive enzymes, metabolites, 
surfactants or simply the abundance of bacterial flora can render a drug 
ineffective despite the results of promising in vitro tests, as demonstrated in a 
study of the lantibiotic lacticin 3147-producing Lactococcus lactis (Dobson et 
al., 2011).  
6.3. Objectives 
 To determine the efficacy of a prophylactic phage treatment regime in 
the prevention of CDI using a 3-stage continuous culture in vitro model. 
 To determine any significant changes to commensal gut microbiota as 
a result of phage therapy relative to an untreated control by culture and 
molecular profiling. 
6.4. Methods 
6.4.1. C. difficile strains and bacteriophage induction. 
C. difficile strains 11204 and 12727 were obtained from the NCTC culture 
collection and maintained in Robertson’s cooked meat media (SGL, Corby) at 
room temperature and grown anaerobically at 37°C in pre-reduced BHI 
(Oxoid, UK) with complements (2.5.2). Spore preparations of NCTC 11204 
and NCTC 12727 were made as previously described (2.1.1.3). 
Bacteriophage ФCD27 was induced from C. difficile NCTC 12727 using 
mitomycin C and phage stocks were propagated by recovering phage 
particles from semi-confluent plaque assays (2.2.3.1). For the phage-free 
control broth, 15 mL BHI with complements was added to uninfected lawns of 
C. difficile, incubated and harvested in the same way as phage stocks.  
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6.4.2. The Colon Model 
6.4.2.1. Apparatus 
The colon model is a three-component continuous system designed to 
replicate the spacial, temporal, nutritional, physiochemical and microbiological 
composition of the human large intestine and is shown in Fig 6.1. Each model 
system was comprised of 3 linked vessels positioned in a cascade 
arrangement, pH controlled to 5.5, 6.2 and 6.8 respectively (  0.2) to simulate 
conditions in the ascending, transverse and descending sections of the colon. 
The capacity of vessel 1 was 280 mL and the capacity of vessels 2 and 3 was 
300 mL. Nitrogen was continuously bubbled through each vessel to maintain 
an anaerobic environment. Media was fed into vessel 1 at a constant rate, to 
give a retention time of approximately 66.7 h and waste from the last vessel 
was collected in an additional receptacle.  
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Figure 6.1. The colon model system. A. Vessel 1 (representing the 
ascending section). B. Vessel 2 (representing the transverse section). C. 
Vessel 3 (representing the descending section). Each vessel was pH 
controlled (D), maintained at 37°C using water jackets (E) and kept 
anaerobic via a continuous nitrogen purge. Media (F) is fed in to vessel 
1 and waste is collected at the end of the system (G). 
 
Freshly voided faeces from the same male volunteer aged over 60 years, was 
used to prime the system in each replicate experiment. Each experiment was 
comprised of 2 model systems – one to serve as a control and one to receive 
the prophylactic phage therapy and replicate experiments were carried out 
sequentially. The intervention points are indicted on the timeline below (Fig. 
6.2). In the prophylactic phage treated system, phage preparations were 
A 
B 
C 
D 
E 
F 
G 
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dosed at an MOI of 10 (calculated on the basis of the initial C. difficile 
inoculum) and were dispensed into vessel one (ascending section) every day 
for 42 days. The same volume of phage-free broth was administered to the 
control system. Samples (5 mL) were taken from all vessels of each system 
approximately every 3 days. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Timeline of colon model interventions. 
 
6.4.2.2. Antibiotic treatments 
Colon model systems were treated with 33.9 mg/L clindamycin every 6-8 h 
between day 14 and day 21 to disrupt the normal levels of faecal bacteria and 
thus permit the germination and outgrowth of C. difficile. The doses simulated 
the concentration expected in the human gut after a 600 mg oral dose (Baines 
et al., 2008). 
To ensure the correct concentration of clindamycin was reaching each part of 
the system, bioassays were carried out on filtered supernatants on day 1, 3 
and 7 of the antibiotic course, using FI10640 Micrococcus luteus (kindly 
provided by D. Hatziioanou) as the indictor strain. Assays were performed in 
duplicate. 500μL of colon model samples were centrifuged for 2 min at 12,000 
x g to remove bacterial cells and debris.  The supernatant was removed, 
diluted in PBS and filter sterilised before adding 50 μL to a bored-out well in 
an MRS agar plate seeded with M. luteus (100 μL overnight liquid culture per 
100 mL agar). Standard concentrations of 0.64, 1.25 and 1.56 μg/ml 
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(undiluted) of clindamycin were also tested with each batch of samples. Plates 
were kept upright for 15 min to allow the liquid to be absorbed and then 
incubated aerobically overnight. Zones of clearing around the wells were 
measured the next day and clindamycin concentrations were estimated using 
a calibration curve obtained from the known standards.  
6.4.2.3. Enumeration of C. difficile cells and spores 
Triplicate samples of 20µL from the colon model vessels were serially diluted 
to 10-7 in PBS and bacterial enumerations were carried out (2.1.1.2.2.1).  
Growth curves were plotted and the area under the curve was used to 
represent the overall level of growth for the purposes of statistical analysis.  
All replicates of the control and the phage treated system were tested by 
means of a one-way ANOVA using a Wilcoxon Rank Sum test. 
Spores of C. difficile were enumerated on CCEY as previously described 
(2.1.1.3.2). 
6.4.2.4. Toxin quantification 
Premier Toxins A & B enzyme immunoassay kits (Meridian Bioscience 
Incorporated), used according to the manufacturer’s instructions were used to 
quantify the production of toxin in each vessel of each system. The method is 
described in 2.1.3.  
6.4.3. Denaturing gradient gel electrophoresis (DGGE) 
Bacterial population profiles from the control and phage-treated systems were 
obtained using DGGE, as previously described (Muyzer et al., 1993) with 
some modifications. A range of methods to extract nucleic acid (2.3.2) were 
tested to determine the most suitable protocol. 
6.4.3.1. Amplification of 16S rDNA 
Primers targeting the V3 region of 16S rDNA (forward (including a GC clamp): 
5’-CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGGCCTA 
CGGGAGGCAGCAG-3’ and reverse: 5’-ATTACCGCGGCTGCTGG-3’) were 
used. The composition per 50 μL reaction was as follows:  35.8 μL Sterile 
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water, 5 μL 10 x Hot Master Buffer, 4 μL dNTPs (2.5 Mm each), 1 μL each 
primer (10 μM), 0.2 μL Hot Master Taq Polymerase (5 PRIME), 1 μL BSA (10 
mg/ml) and 2 μL DNA template. The presence of a product was confirmed by 
visualising on a 0.8% agarose gel.  
6.4.3.2. Gel preparation, running conditions and investigation of 
discordant bands. 
The BioRad D Code Universal Mutation Detection System was used to run 
the DGGE gels. PCR samples and DNA ladders (made from pooled amplified 
PCR products from a faecal sample) were applied directly to 8% (wt/v) 
polyacrylamide gels containing a gradient from 40% to 60% formamide (v/v) 
plus 0.08% (wt/v) ammonium persulphate (Sigma) and 0.14% NNN’N’-
tetramethylethylenediamide (Fisher Scientific). Electrophoresis was carried 
out in 0.5 x TBE buffer (Fisher Scientific) at 59°C at a constant voltage of 80 
V. The DNA molecules are immobilised at differing points in the gel depending 
on domain with the lowest melting temperature, as partial separation of the 
DNA strands prevents further migration. After 14 hours the gels were stained 
using SYBR Green (Invitrogen) for 30 min, rinsed with distilled water and 
visualised using the BioRad Pharos FX Plus Molecular Imager with an 
external laser at 65% voltage. Images were captured using Quantity One 
software and exported to Phoretix 1D Pro for band profile analysis. PAST 
software (version 2.14) was used to make statistical comparisons (Hammer et 
al., 2001).  
A representative sample of well-separated, discrepant bands (those present in 
the control vessels and absent in the phage-treated vessels or those present 
in the phage-treated vessels but not the control vessels) were excised using a 
UV transluminator (Dark Reader, Clare Chemical Research Ltd), re-amplified 
and re-run on a further 3 DGGE gels to obtain pure bands. Amplicons were 
cleaned using SureClean Plus (Bioline) (2.3.7), sub-cloned into pCR2.1 
vectors using the TA cloning kit (Invitrogen) (2.3.11) and sequenced with the 
forward M13 primer (2.3.10). Good quality sequences were submitted to the 
Ribosomal Database Project 10 (Cole et al., 2009), to obtain probable 
identities of the bacterial species corresponding to the band.  
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6.5. Results 
A continuous colon model system was used to investigate the effect of phage 
therapy on C. difficile growth and toxin production. 
6.5.1. Validation of colon model performance 
Bioassays were carried out to determine the concentration of clindamycin in 
each colon model vessel. The use of M. luteus and clindamycin standards 
permitted the calculation of clindamycin concentration as shown in Fig. 6.3 a-
b. The system required adjustments and extra doses to achieve levels 
approximating 33.9 mg/mL within the treatment timeframe as indicated in 
Table 6.1. The growth of C. difficile and commensal gut bacteria may have 
been affected by differing exposures to clindamycin despite efforts to control 
the concentration.  
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Figure 6.3 a) Example of bioassay results from experiment 2 and b) 
Calibration line made using measurements from the clindamycin 
bioassays. 
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 Vessel 72 h 
(mg/mL) 
Adjustment 118 h 
(mg/mL) 
Experiment 1 Ascending 0.0616 Decrease retention time 
(increase pump speed). 
48.2 
 Transverse 0.00575 None 29.9 
 Descending 0.00075 Extra 9.4 mg dose 35.6 
Experiment 2 Ascending 25.6 Extra 5 mg dose 29.3 
 Transverse 5.6 Extra 5 mg dose 30.9 
 Descending 1.2 Extra 5 mg dose 34.2 
Experiment 3 Ascending 37.3 Extra 5 mg dose 35.9 
 Transverse 16.7 None 32.3 
 Descending 31.9 None 29.9 
 
Table 6.1. Assessment and modulation of clindamycin concentrations of 
the colon model. 
 
6.5.2. Reproducibility of results in the absence of phage treatment. 
In each control system, vegetative C. difficile growth was detected after the 
clindamycin treatment. In order to determine the significance of reductions in 
C. difficile numbers due to phage therapy, it was necessary to establish the 
natural variability of the control systems observed in replicate experiments. In 
the ascending section (vessel 1), a significant difference in the numbers of C. 
difficile vegetative cells was recorded. A significant difference was also 
observed in the numbers of C. difficile spores from the ascending and 
transverse vessels, as shown in Table 6.2.  
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 P values (student’s t test) 
Experiment 
1 and 2 
Experiment 
1 and 3 
Experiment 
2 and 3 
C. difficile (vegetative) recovered 
from the ascending vessel 
 
0.026437 
 
0.062758 
 
0.002754 
C. difficile (vegetative) recovered 
from the transverse vessel 
 
0.067053 
 
0.15196 
 
0.021408 
C. difficile (vegetative) recovered 
from the descending vessel 
 
0.132195 
 
0.210368 
 
0.151343 
C. difficile (spores) recovered from 
the ascending vessel 
 
0.011598 
 
0.003135 
 
0.011245 
C. difficile (spores) recovered from 
the transverse vessel 
 
0.007132 
 
0.075667 
 
0.002219 
C. difficile (spores) recovered from 
the descending vessel 
 
0.03411 
 
0.016097 
 
0.033666 
 
Table 6.2: Extent of variation in C. difficile numbers between replicate 
control experiments. P values were calculated from total numbers 
throughout the experiment (area under the curve). 
 
The numbers of C. difficile cells that were recovered are similar to the 
quantities that can be isolated from patients with active CDI and therefore 
have some clinical relevance (Mutters et al., 2009). The pattern of germination 
post clindamycin treatment is comparable with the work of previous groups 
that have used the colon model to simulate CDI and the enumerations of 
vegetative C. difficile cells are also similar (Freeman et al., 2003, 2007). 
Spore numbers differed significantly between replicate experiments (Table 
6.2) and were generally present at levels approximately 1 log10 lower than 
previous reports (Freeman et al., 2003, 2007). 
6.5.3. Efficacy of phage therapy 
 A significant decrease in the total number of C. difficile vegetative cells was 
recorded in the phage-treated systems relative to the untreated controls (p = < 
0.001). In the first replicate, phage treatment precluded the growth of C. 
difficile whereas in the control system, high numbers (>105 CFU/mL) were 
recorded less than 24 h after the clindamycin treatment ceased (Fig.6.4 a, 6.5 
a and 6.6 a). The absence of vegetative C. difficile cells in the phage-treated 
systems was confounded by the significant increase in the number of spores 
relative to the control (p = < 0.001) (Fig. 6.7 a, 6.8 a and 6.9 a). In replicate 2, 
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phage treatment was not successful at preventing growth of C. difficile and 
levels comparable to that of the control system were recorded between days 
24 and day 28 (Fig 6.4 b, 6.5 b and 6.6 b). Interestingly, on this occasion the 
phage-treatment yielded significantly fewer spores relative to the control 
system (p = <0.001) (Fig. 6.7 b, 6.8 b and 6.9 b). In the third replicate, phage 
treatment again precluded the proliferation of C. difficile while in the control 
system, vegetative C. difficile was detected at levels greater than 107 CFU/mL 
from day 28 (Fig. 6.4 c, 6.5 c and 6.6 c). As with replicate 1, the successful 
suppression of vegetative cells in the phage-treated system gave way to a 
significant rise in the overall levels of spore counts (p = <0.001) (Fig. 6.7 c, 
6.8 c and 6.9 c).  
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Figure 6.4 a-c. Vegetative C. difficile cell counts from the ascending 
vessels of the colon model replicates 1-3 respectively. Figures represent 
the means of triplicates ± SD. 
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Figure 6.5 a-c. Vegetative C. difficile cell counts from the transverse 
vessels of the colon model replicates 1-3 respectively. Figures represent 
the means of triplicates ± SD. 
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Figure 6.6  a-c. Vegetative C. difficile cell counts from the descending 
vessels of the colon model replicates 1-3 respectively. Figures represent 
the means of triplicates ± SD. 
 
 
 
0
1
2
3
4
5
6
7
8
9
10
0 3 7 11 14 17 21 24 28 32 35
Lo
g 1
0 
C
FU
/m
L  
Day 
1
2
3
4
5
6
7
8
9
10
0 3 7 11 14 17 21 24 28 32 35
Day 
0
1
2
3
4
5
6
7
8
9
10
0 3 7 11 14 17 21 24 28 32 35
 L
o
g 1
0 
C
FU
/m
L  
Day 
0
1
2
3
4
5
6
7
8
9
10
0 3 7 11 14 17 21 24 28 32 35
Day 
0
1
2
3
4
5
6
7
8
9
10
0 3 7 11 14 17 21 24 28 32 35
Lo
g 1
0 
C
FU
/m
L  
Day 
1
2
3
4
5
6
7
8
9
10
0 3 7 11 14 17 21 24 28 32 35
Day 
a 
Control Phage-treated 
b 
c 
175 
 
 
 
 
 
 
 
Figure 6.7 a-c. C. difficile spore counts from the ascending vessels of 
the colon model replicates 1-3 respectively. Figures represent the 
means of triplicates ± SD. 
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Figure 6.8 a-c. C. difficile spore counts from the transverse vessels of 
the colon model replicates 1-3 respectively. Figures represent the 
means of triplicates ± SD. 
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Figure 6.9 a-c. C. difficile spore counts from the descending vessels of 
the colon model replicates 1-3 respectively. Figures represent the 
means of triplicates ± SD. 
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6.5.4. Toxin measurements 
Toxin production in the control system was strongly positive approximately 10 
days following the cessation of clindamycin therapy (Fig. 6.10) and this 
correlated well with the spike in C. difficile numbers at this time. In the phage-
treated systems however, toxin levels remained below the cut-off value of the 
enzyme immunoassay throughout the experiment, despite the presence of 
vegetative C. difficile at levels exceeding 108 CFU/mL.  
 
Figure 6.10: Mean toxin results from the descending sections of the 
control and phage-treated vessels ± SD. The cut-off value of the 
Meridian toxins A and B assay is indicated by the dashed line.         = the 
control systems and        = results from the phage-treated systems. 
 
In order to investigate the high levels of vegetative C. difficile cells detected in 
experiment 2 (phage-treated), ten C. difficile colonies isolated from the 
transcending section of the phage-treated system were taken on day 35. 
Ninety percent of these were shown to harbour ΦCD27 as a prophage. The 
transition to a lysogenic life cycle is a likely explanation for the survival of C. 
difficile throughout the treatment and was investigated further by producing a 
lysogenic strain of NCTC 11204 in vitro by sub-culturing material from within 
lysis zones on a spot plaque assay, growing in BHI broth and confirming the 
presence of a prophage after mitomycin C induction. Relative to the wild-type 
strain, the lysogen produced less toxin in vitro (Fig. 6.11). The mean 
absorbance values (450 nm) of the toxin assay for 10 cultures of the lysogens 
and 10 cultures of the wild type were 0.75 (± 0.12) and 1.32 (± 0.19) 
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respectively (p = <0.001). C. difficile cells were not recoverable from 
experiments 1 and 3 at day 35 and could therefore not be examined for 
evidence of lysogeny. 
 
Figure 6.11: Toxin assay results of the supernatants of wild type and 
lysogenic cultures. Values are means of 10 replicate cultures ± SD. 
 
6.5.5. The effect of phage treatment on commensal flora. 
The effect of phage treatment on commensal flora was investigated by 
bacterial culture and molecular profiling using DGGE analysis. The culture 
results revealed no detrimental effect of phage therapy on any of the groups 
that were measured, but did show a significant increase in the number of 
Bacteroides spp. (p = 0.011) (Fig. 6.12-6.14), total aerobes (p = 0.001) (Fig. 
6.15-6.17), and Enterobacteriaceae (p = 0.009) (Fig. 6.18-6.20) in the phage-
treated vessels. A significant increase in the numbers of Lactobacillus spp. 
were also observed following phage treatment (p = 0.05), but this deviation 
seems to be due to the results of one replicate of the control system, in which 
numbers of Lactobacillus spp. had fallen to below the limit of detection by day 
35 (Fig. 6.21-6.23). The figures illustrating the numbers of Bifidobacterium 
spp., total anaerobes, Clostridium spp. and Gram-Positive cocci (for which no 
significant changes were observed) can be found in Appendix 3. 
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Figure. 6.12. Bacteroides spp. recovered from the control (a) and the 
phage-treated (b) ascending sections of the colon model.        = replicate 
1        = replicate 2 and         = replicate 3.  
 
 
 
Fig. 6.13. Bacteroides spp. recovered from the control (a) and the phage-
treated (b) transverse sections of the colon model.        = replicate 1        
= replicate 2 and        = replicate 3 
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Fig. 6.14. Bacteroides spp. recovered from the control (a) and the phage-
treated (b) descending sections of the colon model.      = replicate 1        
= replicate 2 and        = replicate 3 
 
 
 
Figure 6.15. Total aerobes recovered from the control (a) and the phage-
treated (b)  ascending sections of the colon model.       = replicate 1        
= replicate 2 and        = replicate 3 
0
2
4
6
8
10
0 3 7 11 14 17 21 24 28 32 35
Lo
g 1
0 
C
FU
/m
L  
Day 
0
2
4
6
8
10
0 3 7 11 14 17 21 24 28 32 35
Lo
g 1
0 
C
FU
/m
L  
Day 
0
2
4
6
8
10
0 3 7 11 14 17 21 24 28 32 35
Lo
g 1
0 
C
FU
/m
L  
Day 
0
2
4
6
8
10
0 3 7 11 14 17 21 24 28 32 35
Lo
g 1
0 
C
FU
/m
L  
Day 
b 
a 
a 
b 
182 
 
 
 
Figure 6.16. Total aerobes recovered from the control (a) and the phage-
treated (b) transverse sections of the colon model.        = replicate 1        
= replicate 2 and        = replicate 3 
 
 
 
Figure 6.17. Total aerobes recovered from the control (a) and the phage-
treated (b) descending sections of the colon model.      = replicate 1        
= replicate 2 and        = replicate 3 
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Figure 6.18. Enterobacteriaceae recovered from the control (a) and the 
phage-treated (b) ascending sections of the colon model.        = replicate 
1        = replicate 2 and        = replicate 3 
 
 
 
Figure 6.19. Enterobacteriaceae recovered from the control (a) and the 
phage-treated (b) transverse sections of the colon model.        = replicate 
1        = replicate 2 and        = replicate 3 
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Figure 6.20. Enterobacteriaceae recovered from the control (a) and the 
phage-treated (b) descending sections of the colon model.      = replicate 
1         = replicate 2 and         = replicate 3 
 
 
 
Figure 6.21. Lactobacillus spp. recovered from the control (a) and the 
phage-treated (b) ascending sections of the colon model.         = 
replicate 1        = replicate 2 and        = replicate 3 
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Figure 6.22. Lactobacillus spp. recovered from the control (a) and the 
phage-treated (b) transverse sections of the colon model.        = replicate 
1        = replicate 2 and         = replicate 3 
 
 
 
Figure 6.23. Lactobacillus spp. recovered from the control (a) and the 
phage-treated (b) descending sections of the colon model.      = replicate 
1        = replicate 2 and        = replicate 3 
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6.5.6. Nucleic acid extraction efficiencies. 
In order to determine the optimal method for nucleic acid extraction, the 
Qiagen Stool mini kit, the Boom method and the modified phenol chloroform 
method in addition to freeze-thaw disrupted samples were compared. The 
nucleic acid yields from samples of C. difficile NCTC 11204 vegetative 
cultures, NCTC 11204 spores and faeces were determined. The PCR 
products from these extracts were also compared by using V3 primers 
(6.4.3.2) minus the GC clamp (since it was found that C. difficile NCTC 11204 
could not be amplified using the V3 primers with the GC clamp present). The 
highest and most consistent yields were obtained following freeze-thaw 
disruption (Table 6.3). 
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Extraction 
method 
Sample DNA yield 
(μg/mL) 
V3 PCR 
product 
DGGE 
profile 
 
Qiagen 
Stool 
Mini kit 
C. difficile cells (vegetative) 34  None 
C. difficile (spores) 9 
 
None 
Faecal sample 1 
 
None 
Faecal sample spiked with C. difficile 
cells (vegetative) 
0.043  None 
V3 PCR positive control (ladder) 29  Good 
 
Boom 
method 
C. difficile cells (vegetative) Cannot 
measure 
due to use 
of silica 
matrix 
 Not 
tested C. difficile (spores)  
Faecal sample  
Faecal sample spiked with C. difficile 
cells (vegetative) 
 
V3 PCR positive control (ladder) 29  N/A 
 
Modified 
phenol 
chloroform 
method 
C. difficile cells (vegetative) 13 
 
None 
C. difficile (spores) 21 
 
None 
Faecal sample 9  None 
Faecal sample spiked with C. difficile 
cells (vegetative) 
13 Not 
tested 
None 
V3 PCR positive control (ladder) 29  Good 
 
Freeze-
thaw 
extraction 
C. difficile cells (vegetative) Not 
measured 
 
Good 
C. difficile (spores)  Good 
Faecal sample  Good 
Faecal sample spiked with C. difficile 
cells (vegetative) 
 Good 
V3 PCR positive control (ladder) 29 
 
Good 
 
Table 6.3. Comparison of 4 methods of nucleic acid extraction/cell 
disruption from faecal samples and C. difficile NCTC 11204 vegetative 
cells and spores. 
6.5.7. Density gradient gel electrophoresis (DGGE) analysis 
In the analysis of band profiles generated by DGGE, a comparison of the 
Shannon Diversity Indices of the control and phage-treated vessels (Fig. 6.36) 
show no significant differences (p = 0.07; correlation coefficient 0.56). Despite 
this, some clear discrepancies were observed in the banding patterns on the 
DGGE gels. Twenty-five well isolated bands, unique to either the control or 
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phage-treated samples (Fig. 6.37), were picked and sub-cloned. Three 
replicates of each were sequenced and good quality sequences were 
submitted to the Ribosomal Database Project 10 to obtain probable identities. 
The replicate picks gave highly variable results with all 3 picks giving different 
identifications in some cases. For those that gave 2 or more identifications in 
agreement with each other, 3 further picks were sequenced. The results are 
shown in Table 6.4 with the ‘seqmatch’ score. This is the number of unique 7-
base oligomers shared between the sequence and the given RDP sequence 
divided by the lowest number of unique oligomers in either of the two 
sequences (Cole et al., 2009). Only bands 2, 8, 16, 19, 22 and 25 gave 
identities that were in agreement.  
All these identified bacteria represented normal commensal flora with the 
exception of band 2 (control vessel). Five of 6 sequences for these clones 
gave a >0.721 seqmatch score for Veillonella spp. No species discrimination 
was achieved and although this group comprises normal mammalian 
commensals, it should be noted that Veillonella spp. are sometimes reported 
as human pathogens (Houston et al., 1997).  
 
Figure 6.24: Comparisons of the Shannon Diversity Indices obtained 
from DGGE profiles ± SD. Higher scores represent higher bacterial 
population biodiversity. Black patterns illustrate the control systems (C). 
Grey patterns illustrate the phage-treated systems (P). Horizontal lines = 
ascending vessels; vertical lines = transverse vessels and chequered 
squares = descending vessels. 
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Band 
number 
Control/ 
Phage- 
treated  
system 
Length 
(bp) 
Closest match RDP 10. 
Seqmatch 
score 
1 Phage-
treated 
168 
173 
Prevotella spp. 
Roseburia spp. 
0.956 
0.795 
2 Control 189 
173 
170 
169 
162 
Veillonella spp. 
Veillonella spp. 
Veillonella spp. 
Veillonella spp. 
Prevotella spp. 
1.000 
0.942 
0.721 
0.969 
0.949 
3 Control 138 
142 
162 
Parabacteroides spp. 
Anaerovorax spp. 
Bacteroides spp. 
0.700 
0.881 
0.784 
4 Phage-
treated 
359* 
185 
211 
415* 
518* 
*Double 
insert 
Faecalibacterium spp. 
Lachnospiracea spp. 
Bacteroides spp. 
Alistipes spp. 
Bacteroides spp. 
 
0.595 
0.892 
0.717 
0.569 
0.398 
 
5 Control 268 
216 
195 
E.coli 
Megasphaera spp. 
Megasphaera spp. 
No other query transformants on plate 
0.799 
0.907 
0.894 
6 Control 195 
224 
215 
Bacteroides spp. 
Lactobacillus gasseri 
Clostridium hathewayi 
0.471 
0.917 
0.901 
7 Phage -
treated 
219 
175 
221 
Prevotella spp. 
Clostridium hathewayi 
Veillonella spp. 
0.939 
0.941 
0.980 
8 Control 330 
220 
180 
279 
220 
Enterococcus faecalis 
Enterococcus faecalis 
Shigella sonnei 
Enterococcus faecalis 
Enterococcus faecalis 
0.955 
0.949 
1.000 
0.876 
0.954 
9 Control 267 
194 
Prevotella spp. 
Lactobacillis gasseri 
0.827 
0.962 
10 Control No sequences returned 
11 Control 228 
224 
190 
Megasphaera spp. 
Enterococcus faecalis 
Megasphaera spp. 
0.869 
0.877 
0.703 
12 Control 195 
169 
215 
Clostridium hathewayi 
Laconifactor spp. 
Lactobacillus casei 
0.855 
1.000 
0.961 
13 Control 189 
169 
246 
Prevotella spp. 
Anaerostipes spp. 
Lactobacillus gasseri 
0.873 
0.982 
0.887 
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14 Control 189 
169 
189 
Prevotella spp. 
Clostridium hathewayi 
Bacteroides spp. 
0.994 
0.884 
0.929 
15 Phage-
treated 
169 Laconifactor spp. 
(Remaining clones gave poor quality 
sequences). 
0.878 
16 Phage 
treated 
227 
194 
194 
164 
171 
Enterococcus faecalis 
Enterococcus faecalis 
Enterococcus durans 
Lactobacillus gasseri 
Enterococcus faecalis 
0.937 
1.000 
1.000 
0.615 
1.000 
17 Phage-
treated 
225 
85 
270 
E.coli/Shigella spp. 
Sarcina maxima 
Dorea spp. 
0.923 
0.762 
0.801 
18 Phage-
treated 
169 
165 
180 
Clostridium spp. 
Enterobacter cloacae 
Prevotella spp. 
0.931 
0.956 
0.989 
19 Phage 
treated 
163 
189 
189 
168 
148 
Bacteroides spp. 
Bacteroides spp. 
Bacteroides spp. 
Bacteroides spp. 
Dorea spp. 
0.956 
1.000 
1.000 
1.000 
0.951 
20 Phage-
treated 
189 Prevotella spp. 0.917 
21 Phage-
treated 
95 
194 
187 
Enterobacter spp. 
Lactobacillus casei 
Prevotella spp. 
0.744 
0.904 
0.665 
22 Control 413 
245 
189 
210 
Bacteroides spp. 
Bacteroides fragilis 
Bacteroides fragilis 
Lactobacillus gasseri 
(Poor sequence returned for 5th pick) 
0.777 
0.852 
0.880 
0.696 
23 Control 237 
218 
254 
242 
Lactobacillis gasseri 
Bacteroides spp. 
Bacteroides spp. 
Candidatus megasphaera 
micronucliformis 
(Poor sequence returned for 5th pick) 
0.862 
0.909 
0.902 
0.770 
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24 Phage-
treated 
177 
195 
195 
Dialister invisus 
E.coli/Shigella spp. 
Candidatus megasphaera 
micronucliformis 
0.799 
0.847 
0.588 
25 Phage 
treated 
281 
113 
241 
193 
150 
Lactobacillus caesei 
Lactobacillus caesei 
Lactobacillus caesei 
Lactobacillus casei 
Lactobacillus casei 
0.912 
0.972 
0.901 
0.941 
0.942 
 
Table 6.4. Results of the unique band identities according to the 
Ribosomal Database Project 10. Green shading highlights bands for 
which a majority agreement was observed and further picks were 
sequenced to confirm the designation. 
6.6. Discussion 
6.6.1. Efficacy of phage therapy to treat CDI.  
This study has shown that prophylactic phage treatment of C. difficile in an in 
vitro colon model can result in a significant reduction in the number of viable 
C. difficile cells relative to an untreated control, and suppresses toxin 
production to below levels that are regarded as clinically significant by current 
diagnostic tests. The number of C. difficile cells recovered from the control 
systems were comparable to reported levels in other studies that have used 
the colon model to assess pathogenesis of C. difficile strains and the efficacy 
of treatment regimens (Baines et al., 2009; Freeman et al., 2007) and are also 
clinically relevant (Mutters et al., 2009). The levels of C. difficile vegetative 
cells isolated from phage–treated systems however, were highly variable 
between replicate experiments despite the highly controlled conditions. Phage 
treatment was sufficient to suppress the levels of vegetative cells of C. difficile 
to below the limit of detection by culturing (60 μL plated undiluted) in 2 of the 3 
experiments. In 1 replicate however, levels of C. difficile approached those of 
the untreated system, although these samples were negative for C. difficile 
toxins A and B. It was hypothesised that lysogeny between the NCTC 11204 
host and ΦCD27 gave rise to phage resistance in the host and rendered 
treatment with ΦCD27 ineffective in terms of cell lysis. It might be that a 
component of the faecal inoculum affected the phage activity although no 
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major differences in the numbers of commensal bacteria were recorded. This 
observation highlights the delicate balance of the microbiota and its 
significance with regards to therapeutic outcome. The suppression of toxin 
production was presumed to be a result of lysogeny between the C. difficile 
strain and ФCD27 and this was also shown in previous batch fermentation 
models of CDI (5.5.4;(Meader et al., 2010)) Lysogenisation of phage with the 
host has also been demonstrated in vivo during remedial therapy in a hamster 
model when a single dose of ΦCD119 was added 1 h after C. difficile 602 
challenge (Govind et al., 2011). It was found that despite recovering reduced 
numbers of C. difficile cells and recording suppressed levels of toxin 
production in lysogens produced both in vitro and in vivo, all phage-treated 
hamsters died within 5 days. Also, all C. difficile strains were shown to contain 
ΦCD119 as a prophage and were resistant to further infection. The outcome 
may have been improved with additional phage doses but this demonstrates a 
significant pitfall of using bacteriophages that have the capacity to lysogenise 
with their host, especially since all C. difficile phages isolated to date have this 
ability (Goh et al., 2005; Govind et al., 2006; Horgan et al., 2010; Mahony et 
al., 1985; Mayer et al., 2008). The effect of a prophylactic phage treatment 
regime is yet to be investigated in vivo.  
The relative increase in the number of C. difficile spores in the phage-treated 
colon model systems is a cause for concern. This observation has been 
recorded previously in vitro and in hamster models of vancomycin-treated CDI 
(Freeman et al., 2005). Relapse rates of CDI in humans exceed 70% in some 
studies (Kamboj et al., 2011) and the persistence of spores following 
treatment permits the recurrence of CDI at any time. With regards to phage 
treatment, these spores may harbour the therapeutic phage as a prophage 
and so future rounds of preventative or remedial therapy could have little or 
no effect. Transmission to other patients via spore ingestion would also still be 
possible and these factors represent considerable restraints on the potential 
therapeutic use of phages against C. difficile and possibly other spore-forming 
organisms. 
Despite efforts to minimise the influence of variables in the experiments, some 
aspects to consider when interpreting this data include the possible different 
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antimicrobial effects of a phage-infected C. difficile culture supernatant (used 
to harvest the phage particles) and an un-infected C. difficile supernatant 
(used for the control systems). Changes in gene expression in response to 
phage infection may have given rise to chemical factors that could have 
affected the growth of C. difficile in the colon model. The colon model system 
lacks the influence of metabolic (Freeman et al., 2003), secretory (Yadav et 
al., 2011) and immunological factors (Modi et al., 2011) that are likely to play 
an important role in CDI.  
6.6.2. Characteristics of ΦCD27 during treatment.  
Phage repressor proteins produced during lysogeny can directly regulate toxin 
production in C. difficile (Govind et al., 2011; Govind et al., 2009) and 
although manipulation at this level could be an avenue to pursue for 
therapeutic benefit, this finding has considerable bearing on the safety of 
phage therapy, particularly since the acquisition of phages by C. difficile does 
not always give rise to a reduction in the amount of toxin produced. Sekulovic 
and colleagues (2011) noted a 1.6- fold increase in the amount of toxin A 
production and a 2.1-fold increase in the quantity of toxin B as a result of 
ΦCD28-2 integration. Phage proteins may also interact with other bacterial 
genes in its target host and bacteria in the surrounding environment with 
unknown consequences for normal commensal organisms. Aside from the 
effect on bacterial genes, the integration of phages into their target host also 
has the potential to introduce new virulent genetic elements, indeed some 
significant virulence genes of C. difficile are themselves thought to be phage-
derived (Canchaya et al., 2002; Goh et al., 2005).  
Toxin C is an ADP-ribosylating binary toxin present in some hypervirulent 
strains of C. difficile (Davies et al., 2011), which has been associated with an 
increased CDI fatality rate (Bacci et al., 2011). NCTC 11204 is not known to 
produce toxin C, but the effect of phage-therapy on this virulence factor is an 
important factor to consider as any increase could enhance the severity of 
CDI. 
A significant advantage of the colon model is that these systems are less 
prone to the natural variations often seen with in vivo models as the retention 
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time, which is known to have a considerable effect on colonic bacteria 
(Cummings et al., 1979) and nutritional components can be controlled. It was 
particularly beneficial to be able to use the same donor inoculum for each 
experiment, but should be considered that the efficacy of phage treatment 
could be quite different if faecal material from another donor was used to 
prime the model, as individual variations in microbiota composition, 
metabolites and nutritional factors can be expected to impact on resilience 
against C. difficile colonisation and proliferation. 
6.6.3. Impact of ΦCD27 therapy on commensal bacterial populations. 
Due to the specificity of the phage, no detrimental impact on commensal 
bacteria was expected and indeed no statistically significant decreases in 
these groups or overall diversity were observed relative to controls by culture 
or DGGE. The use of molecular profiling permitted the inclusion of bacterial 
genera and species that cannot be cultured, however, these methods are not 
without issue. PCR inhibition, contamination and differing template affinities 
would give rise to variation in the profiles generated. A variety of nucleic acid 
extraction methods were tested in preparation for DGGE, which gave highly 
variable results with generally very poor yields. The decision to process 
samples for PCR following a single freeze-thaw cycle was made in order to 
achieve more consistent and reproducible results but has associated flaws. Of 
particular concern is the possibility of under-representing the Gram positive 
organisms that may require a rigorous lysis step to liberate associated nucleic 
acid. It is possible that material from non-viable or decaying organisms might 
comprise much of the DNA that is available for PCR.  
Considerable variations in the results of unique band identification were 
observed and this highlights reproducibility issues of the DGGE method and 
difficulties in the determination of unique bands. 
Phage treatment gave rise to significantly higher numbers of Lactobacillus 
spp., Bacteroides spp., aerobes and Enterobacteriaceae by culture relative to 
the controls. Only an increase in numbers of Enterobacteriaceae and aerobic 
bacteria in the phage-treated system was observed during our previous study 
of CDI in a batch fermentation model (Meader et al., 2010). The apparent 
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antimicrobial effect of C. difficile toxins also has some support from 
supplementary studies, which show significantly poorer recovery of 
Lactobacillus spp., Bacteroides spp. and also total Clostridium spp. growing in 
the presence of a toxigenic C. difficile strain versus a non-toxigenic strain 
(5.5.3). The promotion of these bacterial groups is of unknown clinical 
significance but can be expected to be of benefit to the host. In similar colon 
model studies of antibiotics that are active against C. difficile, major groups of 
commensal bacterial including Bacteroides spp, Bifidobacterium spp. and 
Lactobacillus spp. were reduced to levels below the limit of detection by 
culture (Freeman, et al., 2005). In a study by Rea et al. (2011), which used a 
similar colon model to investigate C. difficile therapy using Lacticin 3147 (a 
lantibiotic produced by Lactococcus lactis) and employed solely molecular 
methods to enumerate commensal bacteria, significant reductions in the 
Firmicutes and Bacteroidetes phyla were reported. As part of the same work, 
this group also reported that the novel lantibiotic, Thuricin CD, achieved a 3 
log10 reduction in the burden of C. difficile with no significant detrimental effect 
on commensals. Despite the impact on C. difficile, no significant increases in 
the proportions of commensal bacterial were reported. 
This work has concentrated on the importance of quantifying bacterial profiles, 
but other studies have focused on assessing shifts in the metabolic activity 
within bacterial populations in response to nutritional factors and pathogens 
(Nuenen et al., 2003). Some short chain fatty acid products of fermentation 
are damaging to human health and are associated with the onset of AAD, liver 
problems (Mortensen and Clausen, 1996) and cancer (Gill and Rowland, 
2002). Further models of CDI interventions should consider this as an 
additional measure to assess the safety of novel therapies, but it should be 
taken into account that due to the model’s lack of mucosal absorption, these 
profiles are not likely to represent in vivo levels.  
The colon model is not expected to accurately reproduce the biofilms 
observed in the lumen and coating food particles (Macfarlane and Macfarlane, 
2007). It is unknown to what extent this would affect the clinical relevance of 
the study, but the adherence of Bifidobacterium spp. to intestinal mucus has 
been documented (Ouwehand et al., 1999) meaning that these groups may 
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have been under-represented in the model. Bifidobacterium spp. are regarded 
as protective against C. difficile colonisation, and so it is possible that these 
conditions were more permissive to C. difficile growth than in vivo conditions. 
The addition of mucin to future colon models may help to address this issue. 
6.6.4. Conclusion 
This work has shown that in a human colon model, prophylactic phage 
therapy of CDI can considerably reduce the burden of C. difficile vegetative 
cells and caused a clinically relevant decrease in toxin production. 
Disappointingly, the phage has also shown a strong predilection for 
integration with its host, demonstrating the risk of virulence gene acquisition 
and prevention of C. difficile elimination. In this system, integration led to 
reduced levels of toxin production, but this may have the opposite effect in 
other strains. This, together with the observed increase in spore production, 
illustrates the possibility of CDI recrudescence post phage treatment. Further 
work into the use of phages to prevent and treat CDI should include phages 
with disabled capacity for lysogeny and those with a greater range of 
susceptible C. difficile strains. The specificity of phage therapy, benign nature 
and ease of production still maintains their worth as candidates for alternative 
therapeutic agents and co-treatments in the battle against CDI. 
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Chapter 7 - The effect of lysogeny on C. difficile toxin production  
7.1. Abstract 
The integration of bacteriophages into C. difficile host chromosomal DNA has 
previously been shown to affect the expression of toxin A by the action of 
phage repressor proteins. Differential toxin production was determined in 4 
wild-type C. difficile strains and their lysogenic counterparts showing a clear 
decrease in phenotypic toxin production upon lysogeny in 3 strains but an 
increase in the fourth strain. Transcriptional analysis of toxin and toxin 
regulatory genes was also carried out and showed apparent weaker 
expression of toxin A in lysogens relative to their wild-type counterparts. A 
putative repressor of ΦCD27, encoded in open reading frame (ORF 44), was 
shown to be expressed in the lysogenic state, but the affinity of the purified 
protein to promoters regions for C. difficile toxins and toxin regulatory genes 
could not be demonstrated by Electrophoretic Mobility Shift Assay. The 
integration site of the phage was determined and found to be the same in all 4 
laboratory-made lysogens and the host from which the prophage derives. 
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7.2. Introduction 
After infection, bacteriophages can either adopt a lytic life cycle or become 
lysogenic (Kutter and Sulakvelidze, 2005; Lamont et al., 1993). The 
integration of phage elements into host DNA during lysogeny is beneficial to 
both the phage and the host bacterium. In lysogenic infection the phage can 
replicate at the rate of the bacterial strain and persist until the end of its life, 
before releasing progeny that can go on to infect other cells. Genetic 
elements encoding virulence factors such as toxins and antibiotic resistance 
are often embedded in phage DNA (Chen et al., 2011; Frobisher and Brown, 
1927), and acquisition can impart significant competitive advantages enabling 
the host bacterium to survive in changing environments. In some clostridial 
species, toxins are also encoded by phage sequences (Eklund et al., 1971) 
and in the genome of C. difficile some putative phage elements have also 
been identified including the toxin A gene, tcdA, a negative regulator of toxin 
A, tcdC (Goh et al., 2005) and the tcdE gene homologous to holins (Tan et al., 
2001).  
Phage genes may encode regulatory factors that enhance or repress the 
expression of some elements, such as the repression of Shiga-toxin 
production in E. coli by Stx prophages (Serra-Moreno et al., 2008) and the 
impairment of DNA repair systems in Streptococcus pyogenes due to the 
influence of the SF370.4 prophage (Scott et al., 2008), which gives rise to 
increased mutation rates in competitive conditions. Studies have also 
demonstrated the effect of prophage-encoded repressors on the expression of 
toxin and regulatory genes located in the PaLoc region of the C. difficile 
genome. Phenotypic observations and transcriptional analysis of C. difficile 
containing ФCD119 as a prophage revealed a reduction in the expression of 
tcdA, tcdB, tcdR, tcdE and tcdC relative to the phage-free counterparts 
(Govind et al., 2009). This was also observed in vivo following experimental 
treatment of susceptible C. difficile with ΦCD119 in a hamster model (Govind 
et al., 2011). Upon examination of the ФCD119 genome a putative repressor 
denoted as repR was identified and found to be expressed in all the lysogenic 
strains (Govind et al., 2009). Purified, recombinant repR protein showed 
binding affinity for the promoter region of the positive tcdA (toxin A) regulator, 
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tcdR, in gel shift assays, thus offering an explanation for the observed 
reduced toxigenic phenotype of the lysogens, since this protein is an RNA 
polymerase sigma factor that augments toxin A production (Mani and Dupuy, 
2001). Phage infection does not always lead to a reduction in toxin 
production. It was found that levels of toxin B were significantly increased in 4 
of 6 C. difficile strains after phage integration and an increase in toxin A in one 
strain was also reported (Goh et al., 2005). This was demonstrated not to be 
via acquisition of further copies of phage-encoded toxin genes but 
hypothesised to be due to the action of phage-encoded regulators.  A similar 
study (Sekulovic et al., 2011) demonstrated increased extracellular toxin A 
and B in NAP1/027 strains containing a ΦCD38-2 prophage relative to strains 
without the phage. Up-regulation of all PaLoc genes was noted, in particular 
tcdE, indicating that toxin export was facilitated by the production of this gene. 
The authors note varying effects on toxin production when the same phage 
infected different C. difficile strains.  
Apart from the genes of the PaLoc region, other constituents of the C. difficile 
genome have been associated with the control of toxin production. The known 
global gene expression regulator and energy sensor CodY, has been shown 
to reduce the expression of C. difficile toxins A and B by binding to the 
promoter region of tcdR to cause down regulation (Dineen et al., 2007). The 
affinity for DNA binding is evidenced by the helix-turn-helix region of this 
dimeric protein (Brennan and Matthews, 1989). In addition, CodY has also 
been shown to interact directly, albeit with a low affinity, with the promoters of 
tcdA (toxin A) and tcdB (toxin B). For reasons that remain unclear, binding to 
the promoter region of tcdC (a negative regulator of toxin production) can also 
be observed (Dineen et al., 2007). In a similar manner the transcription factor, 
CcpA, can act as both a positive and negative regulator (Kim et al., 2002; 
Lorca et al., 2005; Moir-Blais et al., 2001; Moreno et al., 2001) and has 
previously been implicated in the regulation of enterotoxin production in C. 
perfringens (Varga et al., 2004) and the repression of C. difficile toxins A and 
B in the presence of high glucose concentrations (Antunes et al., 2011). A 
protein encoded by a gene responsible for the initiation of sporulation, Spo0A, 
has also been shown to reduce toxin production by more than 90% 
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(Underwood et al., 2009) as demonstrated by a knock-out model of C. difficile 
630. This down regulation is hypothesised to occur at the level of toxin 
transcription or translation in a similar manner to Clostridium perfringens, 
where Spo0A is thought to bind to a region upstream of the toxin gene to up 
regulate production (Huang et al., 2004; Underwood et al., 2009).  
The genome of ΦCD27 has been sequenced previously (Mayer et al., 2008). 
When this genome was scrutinised, several genes that were homologous to 
known phage repressor protein genes were identified – orf44, orf45 and orf72, 
as shown in Table 7.1. The DNA binding potential of the translated proteins 
was recognised by the helix-turn-helix domains with homology to the XRE 
family of repressors (Brennan and Matthews, 1989), as seen with other 
transcriptional regulators such as repressors of phage lambda (Jordan and 
Pabo, 1988) and the trp repressor of E. coli (Otwinowski et al., 1988). 
ORF Location on 
genome 
Homology of translated protein (NCBI E 
value on 29.7.12)  
NCBI Accession 
number 
44 35729-35274 
reverse 
Phage repressor of C. difficile 630 (6e-105) YP_001089466.1 
45 35883-36104 Phage repressor of C. difficile 630 (5e-44) YP_001089465.1 
72 48448-49611 Phage DNA-binding protein of C. difficile 
630 (0.0). 
YP_001089442.1 
 
Table 7.1. Putative phage repressors of ΦCD27 
The identification of transcriptional regulators that inhibit the production of 
toxin from C difficile could lead to a novel therapeutic approach in which such 
proteins are administered in vivo to specifically repress the virulence of the 
infecting pathogen without the risk of a Jarisch-Herxheimer reaction (1.9.2) or 
disruption of the commensal flora. 
7.3. Objectives 
 To establish differential expression of the toxin-encoding genes of C. 
difficile (tcdA and tcdB), and other elements concerned with regulation 
of these genes (tcdC, tcdE, tcdR, CodY, CcpA and Spo0A) in wild 
types and laboratory-made lysogenic strains of C. difficile NCTC 
11204, 11205, 11207 and 11209. 
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 To express a putative repressor protein of ФCD27 and investigate the 
affinity of the purified protein to promoter regions of the C. difficile 
PaLoc genes tcdA, tcdB, tcdC, tcd E and tcdR. 
 To determine the integration site of ФCD27 into susceptible C. difficile 
strains NCTC 11204, 11025, 11207 and 11209 to investigate potential 
disruption of putative toxin regulatory genes. 
7.4. Methods 
7.4.1. Measuring differential toxin production 
Lysogens of C. difficile NCTC 11204, 11205, 11207 and 11209 were 
produced as previously described (2.2.2.3). Triplicate liquid cultures were 
made in BHI broth with complements and grown for 10 h. Supernatants were 
harvested and immediately tested using the Meridian Bioscience C. difficile 
Tox A and B assay (2.1.3). The toxin assay results of the wild type strains 
relative to the lysogenic strains were compared and statistically analysed 
using a Student’s t test.  
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Table 7.2. Primers used to assess differential expression of PaLoc 
genes and other regulatory elements. 
 
 
Gene Primer sequences (melting 
temperatures) 
Product 
size 
Reference 
16S F: 5’-CCT ACG GGA GGC AGC AG-3’ 
(60°C) 
R: 5’-ATT ACC GCG GCT GCT GG-3’ 
(57.6°C) 
193 bp (Muyzer et 
al., 1993) 
Toxin A (tcdA) F: 5’- GCA GCT ACT GGA TGG CAA 
AC -3’ (64.7 C) 
R: 5’- ATC TCG AAA AGT CCA CCA GC 
-3’ (63.2 C) 
1783 bp (Govind et 
al., 2009) 
Toxin B (tcdB) F: 5’ - GCA GTT GAA TAT AGT GGT 
TTA G -3’ 
R: 5’ – TCA CTA ATT GAG CTG TAT 
GAG – 3’ 
538 bp This work 
Negative regulator 
of toxin A 
production 
(tcdC) 
F: 5’- GTT CAA AAT GAA AGA CGA C -
3’ (54.5 C) 
R: 5’- CTA TCC CTG GTA TGG TTA TT 
-3’ (54.5 C) 
385 bp This work 
Positive regulator of 
toxin A production 
(tcdD/R) 
F: 5’- TCA AAG TAA GTC TGT TTT 
TGA GGA A -3’ (61.9 C) 
R: 5’- TGC TCT ATT TTT AGC CTT ATT 
AAC AGC -3’ (62.6 C) 
177 bp (Govind et 
al., 2009) 
Protein of unknown 
function, showing 
homology to phage 
holins (tcdE) 
F 5’- TGG AGG AAT CAG AAA AGT 
AGC A -3’ (62.6 C) 
R 5’- CAT TTC ATC TGT CAT TGC ATC 
T -3’ (61.5 C) 
273 bp (Govind et 
al., 2009) 
Gene responsible 
for the initiation of 
sporulation (Spo0A) 
F 5’-GCTAAGGATGGAATTGAAGCA-3’ 
(51.7 C) 
R 5’-GCTCCTAGATTTATTGCGCTTT-3’ 
(54.0 C) 
181 bp This work 
Known 
transcriptional 
regulator (CcpA) 
F 5’-GTGATGAGGCTGCCATAGGT-3’ 
(53.5 C) 
R 5’-TTGCTACTGCTCCCATATCGT-3’ 
(54.3 C) 
144 bp This work 
Known 
transcriptional 
regulator (CodY) 
F 5’-GGAAGCGGTCAAAGATTAGG-3’ 
(51.4 C) 
R 5’-GCTTCAAGCTCGGAGTAGGA-3’ 
(55.0 C) 
186 bp This work 
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7.4.2. Determination of differential toxin production and regulatory gene 
expression in C. difficile between wild types and lysogens. 
Total RNA from stationary phase cultures (approximate OD600 1.5) of NCTC 
C. difficile 11204, 11205, 11207 and 11209 and the corresponding lysogenic 
strains were extracted using the SV Total RNA Extraction System and treated 
with Turbo DNase as described previously (2.3.2.2). Complementary DNA 
copies of the RNA were made using the Invitrogen Superscript Reverse 
Transcriptase kit (2.3.2.2.2) and these products were used as templates for 
PCR using primers for toxin and regulatory genes as shown in Table 7.2. The 
PCR products (5 µL) were analysed by electrophoresis on a 1.5% agarose gel 
as previously described (2.3.4.2). After staining with ethidium bromide the 
band intensities were visually determined and used to estimate differential 
expression. 
7.4.3. Production of a putative repressor of ФCD27 
Using the sequence information of orf44, primers were designed to amplify a 
product covering the coding region and flanking sequence, with some 
mismatches to incorporate an NdeI restriction site (in the forward primer) and 
XhoI (in the reverse primer), as shown in Fig. 7.1. 
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5’TATTTTATAGAGGTGATAAATTTGAATACTGAAAATGA-3’  
 ORF44_NdeI: 5’-GGTGATACATATGAATACTGAAAATGA-3’ 
Figure 7.1. (a) Original ФCD27 sequence (blue font) and forward primer 
(black font) with NdeI site highlighted in yellow and base-pair 
mismatches highlighted in red font. Start site of orf44 is underlined. 
 
5’-TTTCATAACTATTCATAAGTTCACCTACCTATTTTACCAATAGACG-3’ 
  ORF44_XhoI:  5’-TTCTCGAGTTCACCTACCTATTTTAC-3’ 
Figure 7.1. (b) Original ФCD27 sequence (blue font) and forward primer 
(black font) with XhoI site highlighted in yellow and base-pair 
mismatches highlighted in red font. Stop site of orf44 is underlined. 
Total nucleic acid from ФCD27 was extracted from lysates of phage 
propagated in BHI broth plus complements using the Qiagen Lambda Mini kit 
(2.3.2.1.5). Concentrations of 50 ng and 100 ng were used as a template for 
PCR with Phusion Polymerase (2.3) and the ORF44_NdeI and ORF44_XhoI 
primers as detailed above (Fig. 7.1). Five cycles of PCR with an annealing 
temperature of 49°C were carried out first to permit extension of the 
mismatched bases, with 20 cycles at 64°C thereafter.  
PCR products from putative phage repressors were digested with NdeI and 
XhoI (2.3.8) and subcloned for protein expression into the restricted, 
dephosphorylated pET15b vector, placing the sequence downstream of the 
T7 promoter, the IPTG-inducible lac operator, and an in-frame 6xHis tag. The 
estimated size of the 6xHis-tagged product was 19.63 kDa, as predicted from 
the translated sequence (EditSeq 5.06, DNA STAR Inc). The pET15b-orf44 
ligated products were used to transform E. coli TOP10 cells for sequence 
confirmation then E. coli B21(DE3) cells for expression (2.3.11.3). Positive 
transformants were confirmed with T7P2 and T7_T primers (2.3.5.1) and 
protein inductions were carried out using 0.5 mM IPTG to determine the 
optimum harvest time. E.coli cells with empty vector controls were also 
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induced and extracted in parallel. Two buffers for protein extraction were tried 
in order to optimise the yield: Tris buffer (20 mM Tris, 50 mM NaCl, pH 7.5) 
and sodium phosphate buffer (50 mM sodium phosphate, 300 mM NaCl, 20 
mM imidazole, pH 8). The protein concentration was estimated using a 
Bradford assay (2.4.3) and the crude extracts were run on a 10% NuPage 
Bis-Tris Mini Gel (2.4.4), stained using SimplyBlue Safe Stain (2.4.5). Putative 
ORF 44 protein was identified as an additional band (relative to the empty 
vector control) in the expected position. The presence of the ORF44 protein 
was confirmed by Western blot, utilising labelled anti-His antibodies to 
visualise the product (2.4.6). 
Once expression had been confirmed, protein inductions were carried out for 
the purposes of downstream applications, and proteins were extracted using 
the Qiagen Qiaexpress Ni-NTA FastStart Kit (2.4.2.2). Aliquots of each elution 
and wash flow-through were applied to an SDS-PAGE protein gel to assess 
purity. Dialysis was used to further purify the protein (2.4.7.1) and 
concentration (when necessary) was via ultra-centrifugal filters (Amicon) 
(2.4.8).  
7.4.4. Identification of toxin gene promoters and amplification of PaLoc 
intergenic regions. 
Promoter regions of PaLoc genes were estimated by submitting intergenic 
region sequences to the Softberry BPROM Bacterial Sigma 70 Promoter 
Recognition Programme. Primers were designed to give a product that 
spanned these predicted regions and as much of the intergenic region as 
possible in less than 600 base pair fragments, to ensure suitability for use in 
the electrophoretic mobility shift assays (EMSAs). PCR products were 
subcloned into pCR2.1 (2.3.11) and confirmed by sequencing (2.3.10). 
7.4.5. Purification of PCR products of intergenic regions by gel 
extraction 
The Qiagen QIAEX gel extraction kit was used according to the 
manufacturer’s protocol. All reagents were kit components unless otherwise 
stated. PCR products of the subcloned intergenic regions were applied to a 
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1.5% agarose gel as described previously (2.3.4.2) with some modifications. 
Extra wide gel combs were used to allow up to 30 µL to be loaded into each 
well and a one lane gap separated each sample. Bands were visualised on a 
UV transilluminator and excised from the stained gel with a clean scalpel. 
Three times the volume of QX1 buffer (relative to the weight of the band) was 
added and the band was re-suspended by vortex mixing. QIAEX II solution 
was added (30 µL) and the tubes were incubated for 10 min at 50ºC to 
dissolve the agar and bind the DNA. Tubes were vortex mixed every 2 min 
and centrifuged for 30 s at 13,000 x g after incubation. The supernatant was 
carefully removed and 500 µL of buffer QX1 was added. The tubes were 
vortex mixed to re-suspend the pellet, centrifuged for 30 s at 13,000 x g and 
the supernatant was carefully removed. Pellets were washed twice with buffer 
PE in the same way and the pellet was air-dried for 15 min. The DNA was 
eluted by adding 20 µL of nuclease-free water, vortex mixing and incubating 
at ambient temperature for 5 min. This elution was transferred to a new 
microtube to allow a second elution with a further 20 µL incubated at 50ºC for 
5 min. The yields of the 2 separate elutions were compared by gel 
electrophoresis. 
7.4.6. Electrophoretic mobility shift assays (EMSAs) 
Molecular Probes Electrophoretic Mobility Shift Assay (EMSA) kits from 
Invitrogen Detection Technologies were used to assess the binding affinity of 
a putative phage repressor protein, ORF 44, to toxin and regulatory gene 
promoters in the PaLoc region of C. difficile NCTC 11205 and 11209. 
Reagents were kit components unless otherwise stated. Concentrations of 
proteins used were similar to those used in previous studies of phage 
repressor protein interactions and are considered to be physiologically 
relevant (Govind et al., 2009). Binding reactions were comprised of 50-500 ng 
protein (170-1700 nM) with dilutions made in sterile ultra-pure water if 
necessary. The binding buffer (50 mM Tris, pH 7.8, 100 mM KCl, 12.5 mM 
MgCl2, 1 mM EDTA, 20% glycerol stored at -20°C) was selected from 
previous published studies of EMSAs using a phage repressor protein 
(Govind et al., 2009) and 3 µL of this was added to the reactions with 40 ng of 
DNA. DNA-only controls and protein controls of the highest concentration 
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were also tested. Calf thymus DNA (Sigma) at 40 ng was used to check for 
non-specific binding (added before the promoter-containing DNA). Binding 
reactions were incubated for 20 min at ambient temperature and 2 µL of 6 x 
EMSA gel loading buffer was added to each before applying the whole 
volume to wells of a 6% Novex TBE polyacrylamide gel (Invitrogen) mounted 
in the XCell SureLock module. Gels ran in 0.5 x TBE buffer for 35-60 min 
(depending on the DNA fragment size) at 100 V (12-15 mA start, 6-15 mA 
end) and were stained by submerging in TBE buffer (2.5 x) containing 5 µL 
10,000 x SYBRGreen, with gentle rocking on a rotating platform (Stuart, 30 
rpm) for 20 min. 
7.4.7. Determination of the site of ФCD27 integration.  
It was considered that integration of the phage into the host genome could 
disrupt a gene involved in the regulation of toxin production. The site of 
integration (the attB site) was determined and compared between C. difficile 
NCTC 12727 (the original host of the ФCD27 prophage) and each lysogenic 
strain that was studied. Genomic DNA extractions from ФCD27, NCTC 12727 
and the 11204LYS (NCTC 11204 containing ФCD27) were made (2.3.2.1.3). 
Approximately 700 ng of genomic DNA and 600 ng of the plasmid vector 
pUC19 were separately digested with HindIII and SacI restriction enzymes at 
37˚C for 1-3 h. Genomic DNA was also digested with Sau3AI under the same 
conditions and pUC19 digestion with BamHI was also carried out. Two µL 
aliquots were visualised on a 1.5% agarose gel to confirm that digestion had 
occurred, prior to inactivation of the restriction enzymes. The digested DNA 
(approximately 500 ng) was ligated into pUC19 vectors (approximately 100 
ng) using T4 DNA ligase (NEB) for 2-15 h at 16˚C (2.3.11.2).  
Ligation reactions (2.5 μL) were used as templates for PCR reactions with 
primers designed to amplify pUC19 and regions up/down stream of identified 
HindIII, SacI and Sau3AI restriction sites to give products for which the 
expected size (for phage-only DNA) could be calculated based on the ФCD27 
sequence. Red Mix (Bioline) containing Taq polymerase, reaction buffer, 
dNTPs and ions was used according to manufacturer’s instructions. 
Templates 1-6 (Table 7.3) were each tested with primer pairs A-H (Table 7.4) 
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to give a total of 48 reactions, plus 1 control without template for each primer 
pair. Primer sequences are shown in Table 7.5. 
Template 
designation 
Vector Genomic DNA 
source 
Restriction enzyme 
used 
1 pUC19 12727 HindIII 
2 pUC19 11204LYS HindIII 
3 pUC19 12727 SacI 
4 pUC19 11204LYS SacI 
5 pUC19 12727 BamHI/Sau3AI 
6 pUC19 11204LYS BamHI/Sau3AI 
 
Table 7.3. Details of ligation mixtures used as PCR templates for the 
identification of the attB site 
 
Primer combination designation Primer 1 Primer 2 
A pCC1F ORF41_F 
B pCC1R ORF41_F 
C pCC1F ORF42_R 
D pCC1R ORF42_R 
E pCC1F ORF42_F 
F pCC1R ORF42_F 
G pCC1F ORF43_R 
H pCC1R ORF43_R 
 
Table 7.4. Primer combinations used with ligation mixture templates for 
the identification of the attB site. 
 
Primer Sequence (melting temperature) 
ORF42_R AAT ATA ACT GAA GAA CAG GAG AGT C (57.7°C) 
ORF42_F TAA CGC CAC GAC TTA GTC TAT C (59.9°C) 
ORF41_F GAA ATG AGC GAA TTT TTA CTA GG (59.7°C) 
ORF43_R GGC TTA CAA CAA GTT AAT TGG TC (60.3°C) 
pCC1F GGA TGT GCT GCA AGG CGA TTA (56.3°C) 
pCC1R CTC GTA TGT TGT GTG GAA TTG (50.0°C) 
 
Table 7.5. Sequences of the primers used for the identification of the 
attB site. 
Products of a larger than expected size were estimated to contain genomic 
DNA from the bacterial host genome and these fragments were submitted for 
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sequencing with the appropriate ORF primer to elucidate the site of phage 
integration in the host genome.  
The inferred site was then confirmed by designing specific primers flanking 
this integrated region, incorporating both phage and host sequence. 
Amplification was carried out with GoTaq (2.3.5.1) with an annealing 
temperature of 60°C, a 30 s extension and 25 cycles. C. difficile NCTC 11204, 
11205, 11207 and 11209 were tested with the corresponding lysogenic 
strains. The identity of the fragments was confirmed by subcloning the 
products (2.3.11) and sequencing using Big Dye version 3.1 (2.3.10). 
7.5. Results 
7.5.1. Differential toxin production in wild type and lysogenic strains 
When the mean absorbance values of the toxin assay were considered, the 
lysogenic strains of C. difficile NCTC 11204, 11205 and 11209 produced 
considerably less toxin than their wild type counterparts (p = < 0.05). For 
11207 however, a significant increase relative to the wild type was observed 
(p = < 0.05). These results are shown in Fig. 7.2. The toxin measurements 
were made from cultures when they reached an OD600 of 1.5 (approximately 1 
x 108 CFU/mL) and it was noted that lysogenic strains required an incubation 
time of 1-3 h longer than wild types in order to reach this cell density.  
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Figure 7.2. Differential toxin production in wild type (WT) and lysogenic 
(LYS) strains of C. difficile. Values are means of 5 replicate cultures ± 
SD. 
 
7.5.2. Expression of PaLoc and regulatory genes in wild-type and 
lysogenic strains of C. difficile 
Genomic DNA extractions (2.3.2.1.3) of all C. difficile strains were used as 
positive controls for all the primers designed to amplify the genes indicated in 
Table 7.3. Synthesis of cDNA was carried out on DNase-treated total RNA 
extracted samples and was used as a template for PCR to assess the 
differential expression of genes involved in C. difficile toxin regulation. 
Expression of putative phage repressor proteins was also investigated. After 
DNase treatment, no PCR products were obtained in amplification reactions 
of the control target (16S DNA), indicating that all genomic DNA in the 
samples had been degraded. After cDNA synthesis, amplification using 
primers for the 16S region was positive in all extracts and similar in terms of 
band intensity (Fig. 7.3 and Table 7.6). Toxin A (tcdA) expression was found 
to be slightly lower in lysogenic strains compared to corresponding wild-types 
with the exception of NCTC 11209, which was higher in the lysogenic strain 
(Fig. 7.3). For toxin B (tcdB), no expression was observed in NCTC 11204 or 
11207, wild types and lysogens. Weak expression was observed for the wild 
type of NCTC 11205, which was absent in the lysogen. Very weak tcdB 
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expression was recorded for the wild type of NCTC 11209, which was slightly 
stronger in the lysogen (Fig. 7.3). No expression of tcdC was seen in any 
strains, wild types and lysogens (Fig. 7.3), which was to be expected since 
cultures were harvested in the stationary phase (corresponding to peak levels 
of toxin production). For tcdE, no expression was observed in NCTC 11204 
and 11207, wild types and lysogens. Strong expression in the wild type NCTC 
11205 was observed, with no expression recorded for the lysogenic strain. In 
NCTC 11209 however, expression was stronger in the lysogenic strain 
relative to the wild-type (Fig. 7.3). For CodY, expression was essentially equal 
apart from a slight reduction in 11207LYS compared to 11207 wild-type (Fig. 
7.3). CcpA, which was not expressed at all in 11204LYS or wild-type, showed 
similar expression in 11205LYS and 11205 wild-type. For 11207 and 11209 
wild-types, no expression was detected but their lysogenic counterparts 
demonstrated weak expression (Fig. 7.3). Finally, Spo0A expression was 
generally lower in lysogens relative to wild-types, but no expression was 
detected in either 11207LYS or 11207 wild-types (Fig. 7.3).  
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  16S DNA pre cDNA synthesis* 
16S DNA post cDNA synthesis 
tcdA 
tcdB 
tcdC 
tcdR 
tcdE* 
CodY 
Ccpa* 
SpoA 
orf44* 
orf45 * 
orf72* 
 
* The negative 
control was pooled 
with others in a 
separate lane on 
this gel.  
 
Figure 7.3. Band 
intensity of amplified 
cDNA for wild-type and 
lysogenic strains of C. 
difficile. 11204LYS 
genomic DNA was used 
for the positive control. 
Sterile ultra-pure water 
was used for the 
negative control.  
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Positive  
control 
+++ ++ + ++++ + +++ (+) + ++ +++ 
Negative 
control 
- - - - - - - - - - 
11204 - ++ ++ - - - - (+) - ++ 
11204LYS - ++ + - - - - (+) - + 
11205 - ++ +++ + - ++ + + + +++ 
11205LYS - ++ ++ - - (+) (+) + + ++ 
11207 - ++ ++ - - - (+) + - - 
11207LYS - ++ + - - - - (+) (+) - 
11209 - ++ ++(+) (+) - (+) (+) + - +++ 
11209LYS - ++ +++ - - + + + + ++ 
 
Table 7.6. Differential expression of PaLoc genes and toxin regulatory 
genes of C. difficile in wild type strains and lysogens (- = no expression; 
(+) = very weak; + = weak; ++ = strong and +++ = very strong).* PCR 
product was diluted 1 in 10 prior to electrophoresis due to high band 
intensity. 
 
7.5.3. Putative repressors of ΦCD27 
The expression of phage repressors is required to maintain the lysogenic 
state of prophages (Kutter & Sulakvelidze, 2005). The results of putative 
phage repressor gene expression in the wild-type and lyosgenic C. difficile 
strains are shown in Fig. 7.3 and Table 7.7. No PCR products were obtained 
with orf44, orf45 or orf72 primers when used to test wild-type genomic DNA, 
confirming absence of ΦCD27, and genomic DNA from lysogenic strains 
(containing ΦCD27) was used for the positive controls. Mitomycin C induction 
of ФCD27 from all lysogenic strains was demonstrated. 
Expression of orf44 was observed in all lysogenic strains. Negligible 
expression of orf45 was observed. Orf72 was expressed in 11205LYS but no 
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other lysogenic strains. These results point to orf44 as the candidate ФCD27 
repressor. 
 orf44 orf45 orf72 
Positive control (genomic DNA of corresponding 
lysogens) 
++ ++ ++ 
Negative control (genomic DNA of wild-type strains) - - - 
11204 - - - 
11204LYS ++ - - 
11205 - - - 
11205LYS ++ - ++ 
11207 - - - 
11207LYS ++ - - 
11209 - - - 
11029LYS ++ - - 
 
Table 7.7. Expression of putative phage repressor genes in wild type 
and lysogenic strains of C. difficile (- = no expression; ++ = strong 
expression). 
 
7.5.4. Purification of a putative repressor protein of ФCD27 
The orf44 gene was amplified (2.3.5.2), subcloned (2.3.11.2.2) and expressed 
(2.4.1.2) and the His-tagged protein was purified as previously described 
(2.4.2.2). All fractions obtained from the Qiagen Ni-NTA columns (3.25 µL 
samples) were run on a protein gel (Fig. 7.4 a) and the presence of a 6xHis 
tagged product was confirmed by Western blot (Fig. 7.4.b). 
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Figure 7.4. Protein gel after Ni-NTA column extraction (a) and Western 
blot (b). SeeBluePlus2 marker (1), lysate (2), column flow-through (3), 
wash 1 (4), wash 2 (5), elution 1 (6), elution 2 (7) and elution 3 (8). The 
arrows highlight the ORF44 protein. 
The first and second elutions contained many other protein bands in addition 
to ORF44. The third elution had fewer visible secondary products and so was 
selected for dialysis (2.4.7.1)and concentration by ultra-centrifugal filtration 
(2.4.8). A protein gel (Fig. 7.5) and a Bradford assay were carried out to verify 
the product size and estimate the concentration prior to use in the EMSAs. 
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Figure 7.5. 
Dialysed ORF44 
protein extracts. 
SeeBluePlus2 
ladder (1), elution 
1 (2) and 
concentrated 
elution 3 (3). 
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7.5.5. Amplification and preparation of PaLoc intergenic regions. 
Intergenic regions (IGR) were successfully amplified and the recovery post 
QIAex gel extraction gave yields suitable for EMSA testing as shown in Fig. 
7.6. Quantities were estimated based on band intensity relative to bands of 
the Hyperladder I. 
 
 
Figure 7.6. PCR products of PaLoc intergenic regions Hyperladder I, 5 
μL (1 & 12), hyperladder I, 1 μL (2 &11), PCR product from IGR 1 
containing NCTC 11205 promoter for tcdD (3). PCR products from IGR 2 
containing NCTC 11205 promoter region of tcdA (4-5). PCR products 
from IGR 1 containing NCTC 11209 promoter region of tcdD (6-8) and 
PCR products from IGR 2 containing NCTC 11209 promoter region of 
tcdA (9-10). 
7.5.6. Electrophoretic Mobility Shift Assays (EMSAs) 
ORF44 purified protein at concentrations of 50-500 ng (above the 30 ng 
sensitivity limit of the EMSAs) was tested with 40 ng DNA from C. difficile 
NCTC 11205 and 11209 (containing promoter regions of PaLoc genes). DNA 
bands were visualised with SYBRGreen but for unknown reasons no protein 
bands could be detected after staining with SYPRO Ruby. This was 
investigated with a series of repeat tests and modification of conditions 
(protein concentration, run duration and binding buffers used), but with no 
success. Only non-denatured products were tested by EMSA as the protein 
was required to be in its native state to study the DNA binding affinities. 
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Denatured products from the same preparation could be visualised on a 10% 
NuPage Novex Bis-Tris gel, with no indication of dimer formation. The 
observation was presumed to be a result of retro-phoresis due to the intrinsic 
nature of the protein, which has an isoelectric point of 6.193 (and therefore a 
net negative charge at pH 7). The interpretation of the EMSAs was 
confounded by this inability to visualise protein since protein-DNA complexes 
would also be subjected to retro-phoresis. Weakening of bands with increased 
protein concentration may indicate the formation of complexes, but only in the 
absence of non-specific interactions (judged by results of calf thymus DNA-
containing samples) 
7.5.6.1. Intergenic regions containing the promoter for tcdD. 
No band retardation was observed following binding reactions with the ORF44 
protein and the intergenic region upstream of tcdD (11205 and 11209 regions 
were tested as shown in Fig. 7.7). 
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Figure 7.7. EMSA of ORF44 protein with 40 ng tcdD promoter containing 
DNA. DNA ladder Alpha Innotech, 1µL (1), 273 ng ORF 44 only (2), 40 ng 
DNA (11205) only (3), DNA (11205) plus 50 ng protein (4), DNA (11205) 
plus 100 ng protein (5), DNA (11205) plus 250 ng protein (6), DNA (11205) 
plus 273 ng protein (7) and 273 ng protein plus 40 ng calf thymus DNA 
(8); DNA (11209) plus 50 ng protein (9), DNA (11209) plus 100 ng protein 
(10), DNA (11209) plus 250 ng protein (11) and DNA (11209) plus 273 ng 
protein (12).  
 
7.5.6.2. Intergenic regions containing the promoter for tcdA. 
Despite an apparent weakening in the intensity of the band observed with 
tcdA-promoter containing DNA from C. difficile NCTC 11205 and 250/500 ng 
ORF 44 protein relative to 50 ng, no actual shift in the position of the band 
was observed and this weakened intensity could also be observed in the 
presence of calf-thymus DNA (Fig. 7.8). Similarly, no shift was observed with 
DNA of this region from NCTC 11209.  
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Figure 7.8. EMSA of ORF44 protein with 40 ng tcdA promoter containing 
DNA. DNA ladder Alpha Innotech, 1µL (1), 500 ng protein only (2), 40 ng 
DNA (11205) only (3), 40 ng DNA (11209) only (4), DNA (11205) plus 50 ng 
protein (5), DNA (11205) plus 250 ng protein (6), DNA (11205) plus 500 ng 
protein (7), 40 ng calf thymus DNA plus 500 ng protein and DNA (11205) 
(8); DNA (11209) plus 50 ng protein (9), DNA (11209) plus 250 ng protein 
(10), DNA (11209) plus 500 ng protein (11) and 40 ng calf thymus DNA 
plus 500 ng protein and DNA (11209) (12).  
 
7.5.6.3. Intergenic regions containing the promoter for tcdE. 
No significant mobility shifts or weakening in the intensity of the bands were 
seen following binding reactions with increasing concentrations with ORF44 
and putative tcdE promoters, as shown in Fig. 7.9. 
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Figure 7.9. EMSA of ORF44 protein with 40 ng tcdE promoter containing 
DNA. DNA ladder Alpha Innotech, 1µL (1), 500 ng protein only (2), 40 ng 
DNA (11205) only (3), 40 ng DNA (11209) only (4), DNA (11205) plus 50 ng 
protein (5), DNA (11205) plus 250 ng protein (6), DNA (11205) plus 500 ng 
protein (7), 40 ng calf thymus DNA plus 500 ng protein and DNA (11205) 
(8); DNA (11209) plus 50 ng protein (9), DNA (11209) plus 250 ng protein 
(10), DNA (11209) plus 500 ng protein (11) and 40 ng calf thymus DNA 
plus 500 ng protein and DNA (11209) (12).  
 
7.5.7. Phage integration site 
Restriction digestions of genomic DNA from the lysogenic strains were 
successful. These digests were ligated into pUC19 and used as templates for 
PCR. The resulting fragments of the primer and target combinations (from 
Tables 7.2-7.4) are illustrated in Fig. 7.10 and show the presence of products 
of the expected size (Table 7.5) and some that are larger than expected from 
phage DNA alone (Table 7.6), indicating the presence of bacterial DNA. 
These latter fragments were sequenced to identify the integration site 
(2.3.10).  
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HindIII Restriction 
site on ΦCD27 
genome 
Expected size of 
fragment (bp) 
Expected size of 
ligated fragment (bp) 
Seen on 
gel 
34670  
214 
 
417 
 
No 
34884 
 
222 
 
425 
 
No 35106 
 
349 
 
552 
Yes (C1, 
Fig. 7.10) 
35455 
 
11 
 
214 
Yes (GI, 
Fig. 7.10). 
35466 
SacI restriction 
site on ΦCD27 
genome 
Expected size of 
fragment (bp) 
Expected size of 
ligated fragment (bp) 
Seen on 
gel 
10526  
2203 
 
2406 
 
N/A 
12729 
 
Table 7.5. Expected fragment sizes of ligated restriction digests. No 
Sau3AI restriction sites can be found on the ΦCD27 genome. 
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Figure 7.10. PCR products from templates of a HindIII digest of C. 
difficile NCTC 12727 (1), HindIII digest of 11204LYS (2), SacI digest of 
12727 (3), SacI digest of 11204 LYS (4), Sau3AI digest of 12727 (5) and 
Sau3AI digest of 11204LYS (6) amplified with pCC1_F & ORF41_F primer 
pairs (A), pCC1_R & ORF41_F primer pairs (B), pCC1_F & ORF42_R 
primer pairs (C), pCC1_R & ORF42_R primer pairs (D), pCC1_F & 
ORF42_F primer pairs (E), pCC1_R & ORF42_F primer pairs (F), pCC1_F 
& ORF43_R primer pairs (G), pCC1_R & ORF43_R primer pairs (H). The 
fragments of unexpected size are highlighted by the blue boxes. 
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Designation  (Lane and sample number, Fig. 7.10) Size 
B1 ~1.1 kb 
B4 (small) ~500 bp 
B4 (large) ~600 bp 
D3 ~600 bp 
D4 ~600 bp 
 
Table 7.6. Fragments of unexpected size, indicating the presence of 
bacterial DNA. 
Fragments from B4 were of poor quality and fragments of D3 and D4 gave no 
homology to phage DNA and were therefore rejected. Fragment B1 however, 
gave both ΦCD27 sequence and sequence homologous to C. difficile 630 (in 
the absence of C. difficile 12727 sequence data) as illustrated in Fig. 7.11. 
These results show that ΦCD27 integrates at a position identical to base pair 
3379694 in the genome of C. difficile 630. 
CTTTATTACATATATTATTTCCAGAAAAGTAAAAAGCCACTCTGGCAGGAGTGACTTTGAGC
TTGATGTAAAAATCAAGTTTAATAAAAAACGACATTAATATTTAGTTAATGAAACTTCACTC
TAGGCTAATAGATTGTAGTTTCTTTTTTTGTTTTTGATACGAATTTACATCTTTATTATATC
GCATTTTGAGAAAAAATAAAACTATGAATATTAGAAATATATTTTATTTTATCTCTAAGTAT
ATATATTATTAGCCACCTAAAAAACTTTCATAAAAACAAAAAGAACAATATCTTTTTGGCAA
CTGGCTGGCATAATTTATAAGAATTTTATAAATCTTAGTCTGCGTCACTAATTTTCTCTAGT
TTTGCCGATTTAGTTTTGTTATACAACTAAAATAATACAATAGAATTAGTTAATGTTCAACA
AGGTTGTTTGAAAATTAAATAAATTTATAGGTATGAATAGTATTTATTCCTAAAAAGGAACA
GAGTATTTAAAGGTCAAGGTAAGTTAGAATAGTATTGTGAACTAACATTTGATTATGCGAAA
TTCTATGAAACAGGAACCCTGTGACTTTAGTCATGGGAGGTTCAGTGTATATCGCGTATTTC
AATTGTTATAAGTATTTTATTTATTTGGACTAACTAATAATAGCCAAGTGGATGTGGTAAAA
CTACATTACTTAGAATAATAGCAGGTCTTGAAGATGTAAATAGTGGAACTATAATTCTCCAG
GATAAAGATATTACAAATTTAGAGCCATCAAAGAGAGGTTTTGGTATAGTATTTCAATCATA
TGCATTATTTCCGAATATGACTGCTTATAACAATATAGCTTTTCCACTAAAAGAGAGAAAAG
TTTCAAAAGAAAAAATAGATAATAAAGTTAAGGAAGTACTTGAAACAGTTGGATTGACTAAT
GAAGCTCATAAATACCCTAAAGCATTATCAGGTGGACAACAACAGAGGATTGCAATAGCAAG
AGCATTAGCTCTTGAACCAAAGTTTTTACTTTTAGATGAACCAATGTCTGCATTAGATGCAA
AGGTTAGACACAAGCTTGGCGTAATCATGGTCATAG 
 
Figure 7.11. Sequence product of fragment B1 (NCTC 12727 digested 
with HindIII). Red type shows sequence matching ΦCD27 genome, blue 
sequence shows sequence matching to C. difficile 630 DNA. The HindIII 
site is underlined. Black sequence represents vector (pUC19) DNA. 
In order to confirm this integration site of ΦCD27 in 12727 (and all ΦCD27 
lysogens), primers up- and down-stream of the integration site were designed: 
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 INTGRTN_ORF41_F: 5’-AGT CCC TAT AGC TTT GCG TCA C-3’ (Tm 
63.3°C) 
 INTGRTN_CD630_R: 5’-TGC ATC TAA TGC AGA CAT TGG-3’ (Tm 
63.6°C) 
 
The primers gave a product of 717 bp in size (as shown in Fig. 7.12) only from 
the lysogens. The PCR products were subcloned and sequenced. This 
confirmed the same integration site in all 4 lysogens. 
 
 
Figure 7.12. PCR products using primers to confirm integration site of 
ΦCD27 (INTGRTN_ORF41_F and INTGRTN_CD630_R). Hyperladder I (1), 
11204 (2), 11204LYS (3), 11205 (4), 11205LYS (5). 11207 (6), 11207LYS (7), 
11209 (8) and 11209LYS (9). 
 
7.6. Discussion 
Differential toxin production in wild type and lysogenic C. difficile strains was 
successfully determined, and showed reduced levels for 3 of the 4 lysogenic 
counterparts, and stronger production for 1 relative to the wild-types. 
Differential expression of toxin genes and toxin regulator genes was also 
assessed, and was found to be discordant from the phenotypic profiles. 
Despite stark reductions in toxin production in lysogens relative to wild-types 
as measured by EIA (in agreement with previous reports of levels of up to 
50% lower (Govind et al., 2009)), the trends in tcdA and tcdR expression were 
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only very slightly lower in the lysogen of 11205 relative to the wild type.  A 
decrease in tcdA expression for 11207LYS was also observed even though 
phenotypic toxin expression was significantly higher in this lysogen relative to 
the wild-type and expression in 11209LYS was higher relative to the wild-type 
despite comparatively less toxin production phenotypically. Other studies 
have reported increases and decreases in phenotypic toxin A and B 
production with no corresponding change in the transcription of the implicated 
gene (Goh et al., 2005). This observation could imply effects on the release of 
toxin rather than being directly involved in the regulation of toxin gene 
transcription, but in these cases it does not appear to be due to changes in 
tcdE expression.  
The results of cDNA PCR must be interpreted with caution since gene 
expression in bacteria is greatly affected by the growth rate and nutritional 
status (Lodish et al., 2000). Despite every effort to control the conditions prior 
to RNA extraction, subtle variations between cultures may have given rise to 
the differences observed. In addition to this, visual estimation of band intensity 
is a rather crude method of analysis and replicate experiments were not 
carried out to assess the degree of variation between tests. Also, previous 
studies have suggested that secondary structures, which may have formed in 
the extracted RNA, can prevent primer binding and target transcription 
(Braham et al., 2009).  Having said this, the purpose of this investigation was 
to highlight clear differences in expression in advance of EMSA testing with 
the putative phage repressor ORF44, and this method has also been adopted 
by previous studies (Govind et al., 2009). Real-time PCR is an alternative 
method of analysis that could be used to support these results. Expression 
levels may have shown clearer differences (or similarities) at different times 
during the growth phase. The stationary phase was selected as this is the 
time when peak toxin production is expected and therefore differences were 
more likely to be apparent. Extractions from other time points would add 
considerable value to this work since the duration of toxin production may 
have been affected. This observation has been reported previously for the 
highly virulent C. difficile 027 strain (Freeman et al., 2007). While peak toxin 
amounts remained similar to strain 001, the period of toxin production was 
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significantly extended and this feature is thought to explain the severe disease 
seen in infected patients. Also of note is that lysogenic strains required an 
incubation time 1-3 h in excess of their wild-type counterparts to reach the 
same optical density. This observation opposes the findings of previous work, 
showing no difference in the growth rate of lysogens and wild types (Govind et 
al., 2009; Sekulovic et al., 2011). 
In other studies of phage-mediated toxin production, cells of C. difficile were 
lysed prior to measuring the quantity of toxin produced to include intracellular 
amounts (Govind et al., 2009). This approach was not considered here since 
it was initially thought not to impact greatly on the virulence of the pathogen 
(at least until cell death when the pathogen degrades) but data for this may 
have helped to elucidate the effect on mediators of toxin production, for 
example down-regulation of tcdE, which may play a role in toxin export due to 
the homology to phage holins.  
Many strains of C. difficile show variations within PaLoc, namely the tcdC 
region (Spigaglia and Mastrantonio, 2002) and these variations impact on 
strain toxigenicity. A frameshift mutation in tcdC in the highly virulent C. 
difficile 027 is thought to play a role in the hypertoxigenicity of this pathogen 
(Dupuy et al., 2008). Subtle strain-to-strain variations were observed in terms 
of toxin A production and this may in part be explained by sequence 
differences in tcdC that were unfortunately not investigated.  
The putative phage repressor ORF44 was successfully cloned and expressed 
in E. coli. No significant interactions between ORF44 and the promoters of 
tcdA, tcdB, tcdC, tcdE and tcdR were demonstrated by EMSA. Similarly, 
ORF44 showed no affinity to the estimated promoters of CodY, CcpA or 
Spo0A. The results are inconclusive in that the ORF44 protein may interact 
with genes elsewhere in the C. difficile genome that are currently not regarded 
as regulators of toxin production. It may also be that a different repressor may 
be interacting with any of these regions. The protein extract used for these 
experiments appeared relatively pure when visualised by gel electrophoresis 
but it must be considered that contaminating proteins from the cell extracts 
could cause interference with the binding reactions, particularly since the 
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protein could not be visualised on the EMSA gels. Despite absence of 
evidence for dimerisation after denaturing gel electrophoresis, the possibility 
of multimer formation in the protein’s native form, a feature of many DNA-
binding proteins (Jia et al., 2005), cannot be ruled out and could be an 
alternative explanation for its absence from the gel images. This may also 
have impeded the binding interactions with the promoter-containing DNA 
molecules.  
The affinities of the 2 other putative repressor proteins of ΦCD27, ORF45 and 
ORF72, were not determined in this study due to time limitations. Expression 
of ORF45 was negligible in the C. difficile lysogens and ORF72 expression 
was detected only in 11205LYS. Investigation of these proteins using the 
same methods employed for ORF44 may help to elucidate the mechanisms of 
toxin regulation in these lysogens. All three putative repressors ORF44, ORF 
45 and ORF 72, may be involved in the lysogenic switch and may therefore 
still be useful targets in terms of therapeutic manipulation.  
The integration site of ΦCD27 was determined successfully and has been 
shown to be the same in all the lysogenic strains tested and strain 12727, 
from which the phage originally derives. This position is the same as 
prophage 2 of CD630 (Sebaihia et al., 2006). It is in a region containing 
repeat sequences of DNA with no known toxin or regulatory genes within an 
ORF encoding a putative ATP binding protein of an ABC transporter (based 
on alignment to the published C. difficile 630 genome and nucleotide Blast of 
the sequence). This may indicate a detrimental effect on toxin export in the 
lysogenic strains. There is of course the possibility for multiple integration 
sites, as has been described previously for the Stx phage Φ24B (Fogg et al., 
2007). This may cause the disruption of genes with known (and unknown) 
roles in toxin regulation. 
In summary, the phenotypic expression of toxin has been shown to vary 
considerably between wild types and lysogenic strains of C. difficile, in 
agreement with previous work (Govind et al., 2009; Goh et al., 2005). ORF44 
was identified as a putative phage repressor proteins based on its expression 
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in the lysogenic state, but its role in toxin regulation has not yet been 
determined.  
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Chapter 8 – Concluding remarks 
The pace of research into the use of phages to manage bacterial infections in 
humans is increasing, driven by the diminishing efficacy of current antibiotic 
strategies. There are numerous studies demonstrating in vitro and in vivo 
remediation of a host of bacterial infections including Staphylococcus aureus 
(Seth et al., 2013), Campylobacter jejuni (Loc Carillo et al., 2005) and 
Pseudomonas aeruginosa (Vieira et al., 2012). Some phage studies have now 
come as far as phase II clinical trials (Harper et al., 2011). 
There are very few studies that have investigated the control of CDI using 
phage, but all have demonstrated improvements in features of CDI, such as 
increased survival rates in animal models (Govind et al., 2011; Ramesh, et al., 
1999) and reductions in C. difficile toxin production (Meader et al., 2010). The 
in vitro model investigations performed in this study to examine the efficacy of 
phage treatment are the first to evaluate a prophylactic approach using phage 
for the prevention of CDI. Prophylaxis for CDI is feasible since we are aware 
of many of the risk factors that give rise to CDI, such as broad spectrum 
antibiotic therapy (Starr et al., 2003) or proton pump inhibitor use (Loo et al., 
2011). In the preliminary batch fermentation studies it was indicated that this 
strategy may be more effective than a remedial regime and this might also be 
true for other treatments, such as Tolevamer – a C. difficile toxin binding 
protein (1.7.9). The observation that ФCD27 is effective at preventing 
outgrowth of germinating spores (3.5.1) is another argument for prophylactic 
use 
The colon model has previously been shown to give results consistent with 
the inferences of clinical trials (Baines et al., 2009) and bearing this in mind, 
this initial assessment of the performance of phages in the prevention of CDI 
demonstrates some potential for use in humans. ΦCD27 seemed to survive 
well in the simulated gut environments but neither of the models assessed the 
viability and subsequent activity of the phage after oral administration and 
traversal of the (neutralised) acidic barrier of the stomach. 
One of the problems highlighted in both the batch fermentation and colon 
model experiments was the tendency for ΦCD27 to lysogenise with the host, 
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causing numbers of C. difficile to reach levels of an untreated control. In 
conditions where energy is in short supply, bacterial cells have high levels of 
cyclic AMP and this is known to promote lysogeny following phage infection. 
Similarly, plentiful energy supplies are conducive to low levels of cyclic AMP 
and this state promotes the lytic cycle (Kutter and Sulakvelidze, 2005). 
Despite the comprehensive validation of the colon model by MacFarlane et al. 
(1998) the abundance of nutrients at the start of the experiment and gradual 
depletion of nutrients towards the end could affect the lysogenic and lytic 
tendencies of the phage. This may also help to explain the apparent differing 
efficacies of phage treatment in prophylactic and remedial regimens since the 
phage lytic cycle would be favoured earlier at the start of the experiment 
before the media becomes spent. These observations suggest that 
manipulation of the environment via the availability of nutrients in order to 
favour the lytic cycle might be possible but is also likely to have an impact on 
the commensal flora of the gut. Nutrient depletion has been shown to pre-
dispose to C. difficile infection, based on findings from patients fed via naso-
gastric tubes (Iizuka et al., 2004). This observation hints at the possibility that 
in plentiful energy supplies, available in the guts of healthy individuals, 
spontaneous lytic induction of phage may help to maintain normal turnover of 
gut bacteria.  
The failure of prophylactic phage treatment to control C. difficile numbers in 
one of the three colon model replicates led to the finding that lysogenisation of 
ΦCD27 gave rise to reduced levels of toxin production relative to the wild-type 
strain. This finding was later supported by Govind et al. (2009), who 
demonstrated the action of a phage repressor protein, RepR, on the promoter 
region of tcdR to cause a reduction in the expression of toxin A. In a 
reproduction of this work, the putative phage repressor of ΦCD27, ORF44, 
was not demonstrated to function in this way (or have an affinity to any of the 
PaLoc promoter regions), but other putative repressors of ΦCD27 (ORF 45 
and ORF 72) are yet to be investigated. In addition to this mechanism, the 
possibility of multiple integration sites cannot be ruled out, leading to 
disruption of a gene or genes that contribute to the regulation of toxin 
production.  
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The annotation of the ΦCD27 genome (carried out in 2008) was based on 
comparisons between other sequences submitted to NCBI for which functions 
had been experimentally determined or putatively assigned. The rate of 
sequence submission to the NCBI database is over 200,000 every month 
(http://www.ncbi.nlm.nih.gov) and the high value of re-annotating sequences 
several years after the initial searches has previously been demonstrated 
(Stabler et al., 2009). Regular re-annotation of the ΦCD27 genome might 
allow the identification of additional known and putative repressors that have 
since been presented to the database.   
C. difficile’s highly mosaic genome is a testament to its remarkable ability to 
acquire new genetic elements (Sebaihia et al., 2006) and studies of all novel 
therapies should consider the potential for resistance. Throughout the studies 
of ΦCD27 detailed in this manuscript, this feature was difficult to assess since 
C. difficile from the batch fermentations and colon models that were not killed 
by phage treatment were subsequently found to contain ΦCD27 prophage. 
The use of phages that are unable to lysogenise would permit better 
evaluation of resistance emergence. In the evaluation of the antimicrobial 
peptide lacticin 3147 as a potential treatment for CDI (Rea et al., 2007), the 
possibility of using Lactobacillus spp. which are resistant to the agent in 
combination with it to counteract the effect on the commensal Lactobacillus 
spp. was suggested. No data relating to the preservation of the sensitivity of 
C. difficile in these circumstances was presented, but it would be interesting to 
check for instances of transferred resistance.  
There are many other aspects of phage therapy that require attention to fully 
assess its potential, which are beyond the scope of this thesis. The 
preparation of phage stocks for administration is one such area and should be 
taken into account for in vitro and in vivo work-up studies, since treatment and 
purification steps might alter the viability and/or behaviour of the phage. 
Purification of phage according to buoyant density by caesium chloride 
gradient centrifugation is most commonly employed and is effective at 
removing bacterial cell debris and endotoxins (Biswas et al., 2002), thought to 
be associated with many of the treatment failures in early reports of phage 
therapy that used basic methods such as filtration (Gill and Hyman, 2010). 
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One consideration however, is that the antigenic determinants in these more 
primitive preparations may have stimulated the immune system and 
contributed to apparent treatment successes. It remains to be seen if ΦCD27 
efficacy as a therapeutic phage is altered by purification processes such as 
CsCl gradient centrifugation - some researchers have stated the need for 
higher MgCl2 concentrations afterwards in order to maintain the phage’s 
ability to form plaques (Kutter and Sulakvelidze, 2005). 
Attempts were made to disable the lysogenic capacity of ΦCD27 but the 
desired phenotype was not obtained (3.5.2). Similarly, efforts to isolate 
exclusively lytic phages infecting C. difficile from environmental and clinical 
samples were not fruitful (4.5.7). Isolation of phages from environmental 
samples remains an unpredictable technique, which has so far only resulted 
in the isolation of phages with lysogenic capacity. Phages that can integrate 
into the host genome are unlikely to be considered for use as a therapeutic 
agent since their use carries a risk of acquisition of phage-derived virulence 
factors, although no genetic regions encoding known virulence determinants 
have been identified in any of the C. difficile phages characterised to date. 
Despite this, the association between C. difficile virulence and the carriage of 
specific prophages suggests that some genetic determinants of virulence are 
yet to be characterised (Shan et al., 2012). 
Summary 
Given the profound effect of broad-spectrum antimicrobial activity on 
commensal bacteria and the host of detrimental implications that we are now 
realising, specific treatments such as phage therapy should be considered as 
a priority, not just in answer to the problem of antibiotic resistance.  
The models of CDI used in this study clearly demonstrate potential for phage 
therapy and highlight the need to further work to overcome the problems 
encountered, namely disabling the capacity for lysogeny and widening the 
susceptible host range. Genetic manipulation has the potential to alleviate 
these issues but would subject this therapeutic approach to another level of 
scrutiny given the public hostility to such techniques.  
234 
 
This study investigated phage therapy as a sole treatment for the prophylaxis 
of C. difficile, but improved results could be anticipated if it were to be used in 
conjunction with other strategies for prophylaxis and remediation. Phage 
therapy used with probiotics and prebiotics could be enough to selectively 
control the burden of C. difficile cells and the associated toxins, while 
supporting the growth of bacterial groups that offer colonisation resistance 
against C. difficile. Similarly, phage therapy could work synergistically with 
toxin-neutralising agents such as Tolevamer (1.7.9).  
Standardisation of the techniques and governance of phage therapy appears 
to be one of the greatest challenges preventing this approach from moving 
forward. Regulations will most certainly require a certain degree of flexibility to 
allow for the use of phages with differing specificities, in a similar manner to 
the directives in place for seasonal influenza vaccines, which allow for the use 
of different antigenic determinants produced using a standard method (World 
Health Organisation Technical Report Series No. 963, 2011).  
Phages have provided a wealth of information and resources to molecular 
biologists since their discovery. This study contributes to the rapidly growing 
body of data that may one day lead to an established role of phage therapy in 
Western medicine for the treatment of bacterial infections including CDI.  
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 Appendices 
 
Appendix 1: Table of bacterial strains used throughout the thesis.  
 
Genus and species Strain  Source Sensitivity to 
ΦCD27 
Clostridium difficile NCTC 11204  1 S 
Clostridium difficile NCTC 11205  1 S 
Clostridium difficile NCTC 11206  1 R 
Clostridium difficile NCTC 11207  1 S 
Clostridium difficile NCTC 11208  1 R 
Clostridium difficile NCTC 11209  1 S 
Clostridium difficile NCTC 11223  1 R 
Clostridium difficile NCTC 12726 1 R 
Clostridium difficile NCTC 12727 1 R 
Clostridium difficile NCTC 12728 1 R 
Clostridium difficile NCTC 12729 1 R 
Clostridium difficile NCTC 12730 1 R 
Clostridium difficile NCTC 12731 1 R 
Clostridium difficile NCTC 12732 1 R 
Clostridium difficile NCTC 12733 1 R 
Clostridium difficile NCTC 12734 1 R 
Clostridium difficile NCTC 11382  1 R 
Clostridium difficile R23 521 2 R 
Clostridium difficile R23 524 2 R 
Clostridium difficile R23 613* 2 R 
Clostridium difficile R23 614 2 R 
Clostridium difficile R23 621 2 R 
Clostridium difficile R23 635 2 R 
Clostridium difficile R23 639 2 R 
Clostridium difficile R23 642 2 R 
Clostridium difficile R23 720 2 R 
Clostridium difficile R23 727 2 R 
Clostridium difficile R23 732* 2 R 
Clostridium difficile R23 737 2 R 
Clostridium difficile G83/03 2 R 
Clostridium difficile DSMZ 12056 3 R 
Clostridium difficile DSMZ 12057 3 R 
Clostridium difficile NNUH-1 4 R 
Clostridium difficile NNUH-2 4 R 
Clostridium difficile NNUH-3 4 R 
Clostridium difficile NNUH-4 4 R 
Clostridium difficile NNUH-5 4 R 
Clostridium difficile NNUH-7 4 R 
Clostridium difficile NNUH-8 4 R 
Clostridium difficile PIG-ENV 5 R 
Clostridium sporogenes BL81-04 6 R 
Clostridium sporogenes BL84-18 6 R 
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Clostridium sporogenes BL84-17 6 R 
Clostridium sporogenes BL02-01 6 R 
Clostridium sordellii ATCC 13356 7 R 
Clostridium sordellii NCTC 13356 1 R 
Clostridium bifermentans C22-10 6 R 
Escherichia coli K12 8 R 
Micrococcus luteus FI10640 8 R 
 
Table A1: Bacterial strains used throughout the thesis. Sources 1) 
National Collection of Type Cultures, Central Public Health Laboratory, 
London, U.K; 2) kindly provided by Dr. Jonathan Brazier, Anaerobe 
Reference Unit, Dept. of Medical Microbiology and PHLS, University 
Hospital of Wales, Cardiff (*ribotype 027); 3), Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ), GmbH Inhoffenstrasse 7 B, 
38124 Braunschweig, Germany; 4) clinical faecal samples; 5) 
environmental isolates; 6) kindly provided by Dr. Clare Aldus; 7) 
American Type Culture Collection, Virginia, U.S.A. and 8) kindly 
provided by Dr. Diane Hatziioanou. S, shows sensitivity to infection by 
bacteriophage ΦCD27; R, insensitive to ΦCD27.  
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Appendix 2: Local and Regional Ethics Committee (LREC) letter 
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Appendix 3: Colon model results continued; The effect of phage therapy 
on the growth of Bifidobacterium spp., total anaerobes, Gram-positive 
cocci and total Clostridium spp. 
 
 
 
 
 
Figure A.1. Bifidobacterium spp. recovered from the (a) control and the 
(b) phage-treated ascending sections of the colon model.       = replicate 
1       = replicate 2 and           = replicate 3 
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Figure A.2. Bifidobacterium spp. recovered from the (a) control and the 
(b) phage-treated transverse sections of the colon model.        = replicate 
1        = replicate 2 and        = replicate 3 
 
 
 
Figure A.3. Bifidobacterium spp. recovered from the (a) control and the 
(b) phage-treated descending sections of the colon model.       = 
replicate 1        = replicate 2 and        = replicate 3 
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Figure A.4. Total anaerobes recovered from the (a) control and the (b) 
phage-treated ascending sections of the colon model.         = replicate 1        
= replicate 2 and        = replicate 3 
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Figure A.5. Total anaerobes recovered from the (a) control and the (b) 
phage-treated transverse sections of the colon model.         = replicate 1        
= replicate 2 and        = replicate 3 
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Figure A.6. Total anaerobes recovered from the (a) control and the (b) 
phage-treated descending sections of the colon model.         = replicate 1        
= replicate 2 and        = replicate 3 
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Figure A.7. Gram positive cocci recovered from the (a) control and the 
(b) phage-treated ascending sections of the colon model.        = replicate 
1        = replicate 2 and        = replicate 3 
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Figure A.8. Gram positive cocci recovered from the (a) control and the 
(b) phage-treated transverse sections of the colon model.        = replicate 
1        = replicate 2 and        = replicate 3 
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Figure A.9. Gram positive cocci recovered from the (a) control and the 
(b) phage-treated descending sections of the colon model.       = 
replicate 1        = replicate 2 and        = replicate 3 
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Figure A.10. Total Clostridium spp. recovered from the (a) control and 
the (b) phage-treated ascending sections of the colon model.    = 
replicate 1        = replicate 2 and        = replicate 3 
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Figure A.11. Total Clostridium spp. recovered from the (a) control and 
the (b) phage-treated transverse sections of the colon model.    = 
replicate 1        = replicate 2 and        = replicate 3 
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Figure A.12.  Total Clostridium spp. recovered from the (a) control and 
the (b) phage-treated descending sections of the colon model.      = 
replicate 1        = replicate 2 and        = replicate 3 
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